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Voor mijn vader Hans 
 
Een neef van Bekker is onlangs gepromoveerd tot Dr. in de Economie
op een proefschrift: ‘Pen en gat in de meubelmakerij’. 
Ik ben er heen gegaan. 
In de vestibule hing een rooster van de colleges. Ik heb niet gezien 
hoeveel professoren er waren, maar ik denk wel vijftig.  
De promovendus zei iets en toen stond er een jong mensch op, een 
eindje voor me en sprak nog al lang. Ik keek naar z’n ooren. Daarna 
sprak de promovendus ook nog al lang. Ik kon het niet verstaan en 
als ik ’t had verstaan had ik ’t niet kunnen volgen. Aan de rechterkant 
van den promovendus stond een jongmensch, zoo maar, en aan z’n 
linkerkant zat er een, zoo maar. 
De jongeman die zoo lang gesproken had sprak weer en de 
promovendus gaf weer antwoord. Daarna spraken nog twee van de 
professoren, een zelfs twee maal en de promovendus antwoordde 
telkens. Het is wonderlijk hoeveel iemand weten kan over niets. 
 
uit::  Alma Mater (1947) van Nescio  
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Introduction 
 
 
Tuberculosis (TB), an infection caused by the bacterium Mycobacterium tuberculosis, 
remains a major and growing health problem throughout the world. In 1997, an 
estimated eight million people, mostly in their productive age, developed active TB 
worldwide [1]. In the same year almost two million people died of TB, accounting for 
one quarter of avoidable adult deaths in developing countries. The growing incidence 
of TB has renewed the interest of policy makers, clinicians and scientists, who may 
approach the problem form different angles. We may distinguish a pathophysiological 
and an operational approach. 
The pathophysiological approach is aimed at understanding the pathogenesis of 
TB. The lifetime risk of developing active TB (in the absence of HIV) after infection is 
only 5-10%. In addition, among patients with active TB, disease localisation and 
severity is highly variable. The interindividual differences in outcome after infection 
with M. tuberculosis are determined by factors related to the microorganism as well 
as to the human host (Figure 1). Increased knowledge about such factors and their 
role in susceptibility to, and course of TB may contribute to the development of more 
effective vaccines and new therapeutic strategies. 
cytokine production 
M. tuberculosis 
infection 
active TB
outcome
host genetics 
malnutrition 
co-morbidity 
MTB virulence 
vaccination 
Figure 1. A pathophysiological approach to TB
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The operational approach has a very different starting point. Management of TB 
is complicated by problems related to diagnosis and treatment (Figure 2). Such 
problems may differ between countries and health settings. Clinical, bacteriological 
and other (e.g. logistic) research may provide (partial) solutions to such problems. 
This will improve patient care and may reduce the burden of TB. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Outline 
 
The first half of this thesis (chapters 2-6) was written from a pathophysiological point 
of view and includes investigations into host defense in TB. The second half 
(chapters 7-11) uses an operational approach and consists of bacteriological and 
clinical studies in TB. Much of the research from both parts (chapters 4,6,8-11) was 
conducted in Indonesia. 
active TB 
outcome 
inadequate treatment 
drug resistance 
delayed diagnosis 
non-compliance 
patient drop-out 
treatment failure
disease relapse 
low case-detection
co-morbidity 
drug-toxicity 
Figure 2. An operational approach to TB. 
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Traditionally, our acquired T-cell immunity is thought responsible for protective 
immunity in TB. Recent immunological and genetic studies support the long-standing 
notion that innate host defense mechanisms also contribute to protection. In chapter 
2 the current knowledge of the innate host defense in TB is reviewed. As is clear 
from this review, cytokines play an important role in the regulation of our 
immunological response to M. tuberculosis. Chapters 3-5 are specifically related to 
cytokine production in TB. Cytokine production in humans can be measured in vivo, 
in the circulation or at the tissue level, and  ex vivo, usually by stimulation of isolated 
white blood cells. In chapter 3 we ask the question whether whole blood cultures can 
be used as a simple alternative for assessment of the cytokine response in TB 
patients. Chapter 4 addresses a popular concept in mycobacterial infections: the 
Th1-Th2 paradigm. Cell-mediated immunity is considered to be responsible for 
eradication of mycobacteria, but also for damage of host tissues. In this respect, 
animal models suggest that Th1-type cytokines are protective, and Th2-type 
cytokines are harmful. In this chapter the question is asked whether an imbalance 
between production of gamma-interferon (a Th1-type cytokine) and interleukin-4 (a 
Th2-type cytokine) exists in human TB, and whether this causes or aggrevates tissue 
damage. Cytokines are important for protection in TB, but they also account for 
unwanted effects of the host response such as fever, cachexia and tissue necrosis. 
In chapter 5 the question is asked whether pentoxifylline and thalidomide, two drugs 
that have been used in attempts to reduce these detrimental effects of the host 
response in mycobacterial infections, show synergistic effects for in-vitro modulation 
of cytokine production.  
Severe weight loss (wasting) is a prominent feature of TB, and is probably one 
of the determinants of disease severity and outcome. However, our understanding of 
the exact interplay between nutritional status and host defense mechanisms in TB 
remains incomplete. In chapter 6, the role of leptin, an adipocyte product involved in 
regulation of body weight and cellular immunity, is investigated in TB patients in 
Indonesia. The question is asked whether leptin may contribute to TB-associated 
wasting itself, or to its effects on host response and disease outcome in TB. 
   
The part of this thesis dealing with operational research includes bacteriological and 
clinical studies. Chapter 7 explores a diagnostic pitfall which may be encountered in 
patients with suspected TB. Under a microscope, Mycobacterium tuberculosis, which 
causes TB, cannot be distinguished from nontuberculous (atypical) mycobacteria, 
many of which are harmless. In this chapter, the question is asked what the 
significance and clinical implications are of finding nontuberculous mycobacteria in 
patients with suspected TB in a Dutch TB-clinic.  
Chapters 8-11 are based on studies conducted in Indonesia. This country has 
the third highest TB case load worldwide, but little is known about clinical aspects of 
this epidemic such as the quality of diagnosis and treatment, HIV-infection and drug 
   introduction 
 11 
 
resistance of M. tuberculosis isolates. In Chapter 8 some of these questions are 
addressed in a prospective cohort study in a TB-clinic in a poor area of Jakarta. This 
first evaluation raised further questions (chapters 9-11). In countries endemic for TB, 
diagnostic performance may suffer from the burden of patients. In chapter 9, the 
question is asked whether a simple intervention can increase the yield of sputum 
microscopy for diagnosis of TB in this setting. In chapter 10 the question is asked 
whether M. tuberculosis “Beijing” genotype, which is emerging worldwide, and which 
is associated with multidrug resistant TB, is present among Indonesian TB patients. 
Chapters 11 focusses on therapy. Plasma concentrations of antituberculous drugs 
may be relevant for drug toxicity and cure rates. The question is asked whether 
patients under TB-treatment in Jakarta have therapeutic concentrations of rifampicin, 
a key drug for treatment of TB. Chapter 12 contains a summary of the answers to 
these questions and a general discussion of this thesis. 
 
The separation of host response and clinical practice in this thesis is somewhat 
artifical. During my PhD-project, the above mentioned pathophysiological and 
operational approach have cross-fertilized and strengthened each other. Cytokine 
studies in this thesis directly led to the clinical and bacteriological studies conducted. 
In turn, good clinical practice was needed for the patient-related immunological 
research. In addition, careful observation of patients, especially in Indonesia, has 
initiated further pathophysiological research. Therefore, while this thesis is internally 
diverse and ramified, I hope to be able to convince the reader of its main thrust: the 
combination of pathophysiological and operational research is natural, and helpful in 
the battle against TB.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global 
burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO 
Global Surveillance and Monitoring Project. JAMA 1999; 282:677-686. 
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Abstract 
 
 
The different manifestations of infection with M. tuberculosis (MTB) reflect the 
balance between the bacillus and host defense mechanisms. Traditionally, protective 
immunity to tuberculosis has been ascribed to T-cell mediated immunity with a crucial 
role for CD4+ T-cells. Recent immunological and genetic studies support the long-
standing notion that innate immunity is also relevant in tuberculosis. In this review, 
emphasis will be on these natural, innate host defense mechanisms, referring to 
experimental data (e.g. studies in gene-knock out mice), and epidemiological, 
immunological and genetic studies in human tuberculosis. The first step in the innate 
host defense is cellular uptake of MTB, which involves different cellular receptors and 
humoral factors. Toll-like receptors seem to play a crucial role in immune recognition 
of MTB, which is the next step. The subsequent inflammatory response is regulated 
by production of pro- and anti-inflammatory cytokines and chemokines. Different 
natural effector mechanisms for killing of MTB have now been identified. Finally, the 
innate host response is necessary for induction of adaptive immunity to MTB. These 
basic mechanisms augment our understanding of disease pathogenesis and clinical 
course, and will help designing adjunctive treatment strategies. 
  innate immunity to TB 
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Introduction 
 
One-third of the world population is infected with Mycobacterium tuberculosis (MTB), 
but only 5 to 10% has a lifetime risk of developing active tuberculosis, either within 
one or two years after infection (primary tuberculosis), or thereafter (postprimary 
tuberculosis, Figure 1). When active tuberculosis develops, disease localization, 
severity and outcome are highly variable. Miliary tuberculosis, characterized by the 
hematogenous dissemination of large numbers of mycobacteria throughout the body, 
is the most serious disease manifestation. On the other end of the clinical spectrum, 
tuberculous pleuritis is usually self-limiting. Tuberculosis may develop anywhere in 
the body, but usually presents as pulmonary infection, ranging from mild infiltration to 
chronic, cavitary and severely destructive disease. The different manifestations of 
infection with MTB reflect the balance between the bacillus and host defense 
mechanisms, in which the quality of host defense determines outcome. In this review, 
emphasis will be on the natural, innate host defense mechanisms to MTB. However, 
to enable the reader to place those mechanisms in the context of both innate and 
acquired defense, a complete picture of MTB infection is briefly reviewed first. One 
should be aware that dissecting innate and acquired host defense mechanisms is an 
artificial approach. In real life the two components of the host response are 
complementary and synergistic. 
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inhalation of M.tuberculosis
primary complex
(PPD+) 
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(primary TB) 
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Figure 1.  
After inhalation of M.tuberculosis (MTB) droplet nuclei, several ‘scenarios’ may follow. 
Mycobacteria may be destroyed by alveolar macrophages, in which case no real infection 
will take place. Alternatively, MTB is not immediately killed: a ‘primary complex’ consisting 
of a small infiltrate and a draining lymph node will develop. Small calcifications may be seen 
on radiographic examination and the PPD skin-test, as a marker of a MTB-specific T-cell 
response, becomes positive. Most often, infection is stabilized at this point. In a minority of 
cases active disease now develops (primary TB), either in the lungs or anywhere else after 
hematogenous dissemination of MTB. Months or years afterwards, usually under conditions 
of failing immune surveillance, latent infection may reactivate (post-primary TB). 
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Chronological events in the pathogenesis of tuberculosis  
Based on Lurie’s fundamental studies in rabbits [1], four stages of pulmonary 
tuberculosis have been distinguished [2]. The first stage begins with inhalation of 
tubercle bacilli. Alveolar macrophages (AM) ingest the bacilli and often destroy them. 
At this stage, the destruction of mycobacteria depends on the intrinsic microbicidal 
capacity of host phagocytes, and virulence factors of the ingested mycobactera. 
Mycobacteria that escape the initial intracellular destruction will multiply, and this will 
lead to disruption of the macrophage. When this happens, blood monocytes and 
other inflammatory cells are attracted to the lung (second stage). These monocytes 
will differentiate into macrophages, which again readily ingest but do not destroy the 
mycobacteria. In this symbiotic stage, mycobacteria grow logarithmically, and blood-
derived macrophages accumulate, but little tissue damage occurs. Two to three 
weeks after infection, T-cell immunity develops with antigen-specific T-lymphocytes 
that arrive, proliferate within the early lesions or tubercles, and then activate 
macrophages to kill the intracellular mycobacteria. Subsequent to this phase the 
early logarithmic bacillary growth stops (third stage). Central solid necrosis in these 
primary lesions inhibits extracellular growth of mycobacteria. As a result, infection 
may become stationary or dormant.  Disease may progress and hematogenous 
dissemination may take place after primary infection, as well as months or years 
afterwards (postprimary tuberculosis), under conditions of failing immune 
surveillance. Liquified caseous foci provide excellent conditions for extracellular 
growth of MTB. Cavity formation may lead to rupture of nearby bronchi, allowing the 
bacilli to spread through the airways to other parts of the lung and the outside 
environment. In summary, after entry in the human lung, MTB has a series of 
encounters with different host defense mechanisms. The final outcome of infection 
with MTB depends on the balance between outgrowth and killing of MTB, and the 
extent of tissue necrosis, fibrosis and regeneration.  
  
Protection against tuberculosis; acquired T-cell mediated immunity 
Elimination of MTB infection mainly depends on the success of the interaction 
between infected macrophages and T-lymphocytes. Primary as well as acquired 
immunodeficiencies, especially HIV-infection, have dramatically shown the 
importance of cellular immunity in tuberculosis. CD4+ T-cells exert their protective 
effect by the production of cytokines, primarily interferon-γ (IFNγ), after stimulation 
with mycobacterial antigens. Other T-cell subsets, like CD8+ T-cells, are likely to 
contribute as well, by secreting cytokines and lysing infected cells [3,4]. The T-cell 
response is mostly antigen-specific, and attention has focused on the identification of 
immunodominant antigens, which might be used for the development of effective 
vaccines [5]. The acquired T-cell response develops in the context of the major 
histocompatibility complex (MHC), and polymorphism of MHC may contribute to 
differences in disease susceptibility or outcome [6-8]. 
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Functional diversity of T lymphocytes may also be relevant. In 1986, it was 
reported that murine helper T (Th) lymphocytes could be divided into two subsets: 
Th1 clones were characterized by the production of IFNγ, and Th2 clones by the 
production of interleukin (IL)-4 [9]. Both subsets develop from naive T-cells, whose 
differentiation is influenced by the environment: IL-12, produced by activated 
macrophages and dendritic cells, is the principal Th1-inducing cytokine, while IL-4 
promotes induction of Th2 cells [10]. More cytokines and different cellular subsets 
have been included in this Th1-Th2 concept [11], which is thought to be relevant in 
many disease entities [12]. In mycobacterial infection, Th1-type cytokines seem 
essential for protective immunity. Indeed, IFNγ gene knockout mice are highly 
susceptible to MTB [13], and individuals lacking receptors for IFNγ suffer from 
recurrent, sometimes lethal mycobacterial infections [14-16]. Th2-type cytokines 
inhibit the in-vitro production of IFNγ [12,17], as well as the activation of 
macrophages [18], and may therefore weaken host defense[19]. We and others have 
shown an increase in Th2-type cytokines in tuberculosis patients [20-24]. However, 
this is not a consistent finding [25-28] and the relevance of the Th1-Th2 concept in 
disease susceptibility or presentation remains uncertain. 
 
Protection against tuberculosis; evidence for innate immunity     
Phagocytic cells play a key role in the initiation and direction of adaptive T-cell 
immunity by presentation of mycobacterial antigens, and expression of co-stimulatory 
signals and cytokines. In addition, innate defense mechanisms of phagocytic cells 
may be important, as highlighted in Lurie’s fundamental studies with resistant and 
susceptible inbred rabbits [1]. Seven days after primary infection through inhalation of 
tubercle bacilli, the lungs of susceptible rabbits contained 20- to 30-fold more viable 
mycobacteria than resistant rabbits [2]. Obviously, this difference during early 
infection cannot be attributed to T-cell immunity. More recently it was found that 
acquired T-cell immunity in vaccinated mice effectively protects them from 
disseminated tuberculosis, but does not prevent the initial pulmonary infection 
[29,30].  
In human disease, the same holds true. Acquired T-cell immunity after 
vaccination with BCG is more effective against disseminated infection than against 
pulmonary disease [31]. Similarly, naturally acquired T-cell immunity does not 
prevent exogenous re-infection of the lung [32]. Thus, local, T-cell independent host 
defense mechanisms clearly are involved in protection against pulmonary infection. 
More epidemiological data support a role for innate immunity in human tuberculosis. 
For example, in racially integrated nursing homes, infection, as measured by 
tuberculin skin-tests conversion, occurred twice as often in black as in white 
individuals who were equally exposed to active tuberculosis [33]. Apparently, innate 
host defense mechanisms at this early stage were less efficient in black residents. In 
accordance with this, macrophages from Afro-Americans demonstrate a relative 
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permissiveness for intracellular growth of virulent mycobacteria [34]. Support for the 
relevance of T-cell independent, intrinsic bactericidal activity of macrophages is also 
found in genetic studies which have shown associations between tuberculosis and 
functional gene-polymorphism for various macrophage products [35-38]. There is 
more evidence, both from clinical and experimental studies, to support the relevance 
of innate immunity in tuberculosis. In the following paragraphs, the various 
components and processes that make up the innate host response to MTB will be 
discussed in more detail.  
 
 
Phagocytosis of M. Tuberculosis 
 
Alveolar resident macrophages are the primary cell type involved in the initial 
uptake of MTB. After this first encounter, dendritic cells, and monocyte-derived 
macrophages also take part in the phagocytic process [39,40]. Endocytosis of MTB 
involves different receptors on the phagocytic cell (Figure 2), which either bind to 
non-opsonized MTB or recognize opsonins on the surface of MTB. As an example of 
the latter mechanism, mycobacteria can invade host macrophages after opsonisation 
with complement factor C3, followed by binding and uptake through complement 
receptors (CR) 1, CR3 and CR4 [41-43]. The relative importance of the various 
receptors for complement factor C3 is apparent from experiments in vitro, in which in 
the absence of CR3, phagocytosis of MTB by human macrophages and monocytes 
is reduced by approximately 70 to 80% [41,44]. For opsonisation with C3, the split 
product C3b should first be generated by activation of the complement system. MTB 
also utilizes part of the classical pathway of complement activation by direct binding 
to C2a, even in the absence of C4b; in this way the C3b necessary for binding to 
CR1 is formed [45]. This mechanism facilitates mycobacterial uptake in environments 
low in opsonins such as the lung. Nevertheless, non-opsonized MTB can bind directly 
to CR3 [46] and CR4 [47]. However, the best-characterised receptor for non-opsonin-
mediated phagocytosis of MTB is the macrophage mannose receptor (MR), which 
recognises terminal mannose residues on mycobacteria [41,48]. When uptake by 
CRs and MR is blocked, macrophages may also internalize MTB through the type A 
scavenger receptor [49]. Fcγ-receptors, which facilitate phagocytosis of particles 
coated with antibodies of the IgG class, seem to play little role in tuberculosis [50]. 
Enhanced binding of MTB to epithelial cells or alveolar macrophages may 
represent a risk factor for developing clinical tuberculosis. Collectins, a structurally 
related group of proteins including surfactant proteins, mannose binding lectins and 
C1q, seem to be important in this respect. Surfactant protein A (Sp-A) facilitates the 
uptake of MTB [51], either through binding to the macrophages [52], type II 
pneumocytes [53,54], or neutrophils [55]. Interestingly, it has been reported that HIV-
infected individuals have increased levels of Sp-A in the lungs, and this results in a 
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threefold greater attachment of MTB to alveolar macrophages [56]. In contrast, 
another surfactant protein, Sp-D, has been found to block the uptake of pathogenic 
strains of MTB in macrophages [57]. It may therefore be hypothesized that the 
relative concentrations of different surfactant proteins correlate with the risk of 
infection. 
Another member of the collectin family, the plasma factor mannose binding 
lectin (MBL), may also be involved in the uptake of mycobacteria by phagocytic cells. 
MBL recognises carbohydrate configurations on a wide variety of pathogens [58], 
and induces phagocytosis directly through a yet undefined receptor, or indirectly by 
activation of the complement system [59]. Genetic polymorphisms of the MBL-gene 
account for significant variability of serum MBL concentrations in different populations 
[60]. One study has reported elevated serum concentrations of MBL in TB patients 
[61], and genetic polymorphisms associated with increased production of MBL have 
been reported to be a relative disadvantage in mycobacterial infections [62]. 
Although MTB has a tropism for phagocytic cells, it may also interact with non-
professional phagocytic cells, such as alveolar epithelial cells [53]. This binding may 
involve fibronectin, a glycoprotein found in plasma and on the outer surface of many 
cell types [63]. Similar to M. leprae [64], MTB may bind to epithelial cells since the 
bacterium produces and secretes the 30-31 kDa antigen 85 complex, a fibronectin-
binding protein family [65]. In addition, a 28 kDa heparin-binding adhesin, produced 
by MTB, will bind to sulfated glycoconjugates on host cells [66].  
Thus, there are multiple mechanisms for the uptake of MTB, involving a number 
of different host cell receptors. Most of these interactions have been demonstrated in 
vitro and their relative importance in vivo remains to be shown. Distinct routes of 
entry of MTB may lead to differences in signal transduction, immune activation and 
intracellular survival of MTB. For example, Fcγ-receptor mediated phagocytosis is 
directly linked to an inflammatory response, and binding to CR is not [43]. Survival of 
MTB after binding to CR1 is better than after binding to CR3 or CR4 [67]. Also, 
phagocytosis of Sp-A opsonised mycobacteria by alveolar macrophages suppresses 
reactive nitrogen intermediates [51], one of the putative effector mechanisms 
involved in the killing of mycobacteria [68-70]. Likewise, virulent strains of MTB are 
phagocytosed through macrophage MR, while attenuated strains are not [41], 
suggesting that this route of entrance is advantageous to the mycobacterium. Indeed, 
phagocytosis through MR does not trigger O2- production [71], and MTB exerts an 
antiinflammtory signal through MR [72]. In vivo, the possible role of these events in 
immune evasion by MTB remains to be determined. Of interest, strong linkage was 
found with several markers on chromosome 10p13 [73], where the MR gene is 
located, in a recent genome scan of 245 families with leprosy in India [74]. 
  innate immunity to TB 
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Figure 2.  
Phagocytosis and immune recognition of M. tuberculosis 
Various receptors have been identified for phagocyosis of M. tuberculosis (MTB) by 
macrophaes and dendritic cells: complement receptors are primarily responsible for uptake 
of opsonized MTB; mannose receptors and scavenger receptors for uptake of non-opsonized 
MTB. Toll-like receptors (TLRs) play a central role in immune recognition of MTB. In the 
context of CD14, TLR2 binds lipoarabinomannan (LAM), TLR4 binds to mycobacterial 
lipoproteins, and possibly, TLR9 binds to MTB DNA. After binding to TLRs, common 
signalling pathways lead to cell-activation and cytokine production. TLRs are not only 
expressed at the cell surface, but also in phagosomes, Therefore, immune activation may 
occur with or without phagocytosis. On the other hand, phagocytosis alone probably does not 
lead to immune activation without the involvement of TLRs.  
IRAK = IL-1receptor associated kinase; MyD88 = myeloid differentiation protein 88; NFkB = nuclear 
factor kappa beta 
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Recognition of M. Tuberculosis; the role of toll-like receptors 
 
Besides phagocytosis, recognition of MTB or mycobacterial products is a crucial 
step in an effective host response. Immune recognition of the major mycobacterial 
cell wall component, lipoarabinomannan (LAM), appears to resemble that of gram-
negative bacterial lipopolysaccharide (LPS) [75]. Several circulating factors and 
receptors are involved. Plasma LPS-binding protein (LBP) enhances macrophage 
responses to LPS and LAM by transferring these microbial products to the cell 
surface receptor CD14 [76]. Similarly, soluble CD14 confers responsiveness to both 
LAM and LPS in CD14-negative cells [77]. Of interest, serum concentrations of CD14 
and LBP were elevated in patients with active tuberculosis [78].  
Toll-like receptors (TLRs) are phylogenetically conserved mediators of innate 
immunity which are essential for microbial recognition on macrophages and dendritic 
cells [79-81]. Members of the TLR family are transmembrane proteins containing 
repeated leucin-rich motifs in their extracellular domains, similar to other pattern-
recognizing proteins of the innate immune system. The cytoplasmic domain of TLR is 
homologous to the signaling domain of IL-1 receptor, and links to IRAK (IL-1 receptor 
associated kinase), a serine kinase that activates transcription factors like NFkB to 
signal the production of cytokines [82]. To date, at least 10 TLRs have been 
identified; of those TLR2, TLR4 and TLR9 seem responsible for the cellular 
responses to peptidoglycan and bacterial lipopeptides [83], endotoxin of gram-
negative bacteria [44], and bacterial DNA [84] respectively.  
TLRs are also involved in cellular recognition of mycobacteria (Figure 2). 
Through TLRs, MTB lysate or soluble mycobacterial cell wall-associated lipoproteins 
induce production of interleukin-12 (IL-12), a strong proinflammatory cytokine [85]. 
MyD88, a common signaling component that links all TLRs to IRAK [82] was found 
essential for MTB-induced macrophage activation [86]. A mutation of TLR2 
specifically inhibited MTB-induced TNFα production; this inhibition was incomplete, 
thereby suggesting that beside TLR2, other TLRs may be involved [86]. In a 
transfection model using Chinese hamster ovary (CHO) cells (that are relatively 
deficient of TLR), expression of TLR2 or TLR4 conferred responsiveness to both 
virulent and attenuated MTB [87]. TLR2, and not TLR4, was necessary for signaling 
of the mycobacterial lipopolysaccharide LAM [86,87] and a 19-kDA MTB lipoprotein 
[85,88], while an undefined heat-labile cell-associated mycobacterial factor was found 
to be the ligand for TLR4 [87,89]. Interestingly, mycobacterial infection and 
proinflammatory cytokines increase surface expression of TLR2 [90]. Besides TLR2 
and TLR4, other TLR’s may be involved in immune recognition of MTB: 
heterodimerization of TLR2 with TLR6 or TLR1 is necessary for signal tranduction 
[91,92], and TLR9 binds CpG dinucleotides in bacterial DNA [84,93].  
From several lines of evidence it has become clear that phagocytosis does not 
lead to immune activation in the absence of functional TLRs (Figure 2). Even though 
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TLR2 is recruited to phagosomes during phagocytosis [94], cytokine production was 
abrogated by the expression of a mutant TLR2, but particle binding and 
internalization were unaffected. Furthermore, the expression of CD14 and TLRs did 
not alter uptake of MTB in in-vitro studies. Apparently, TLRs play an important role in 
innate recognition of mycobacteria and this also holds for humans. Interestingly, a 
recent study showed that TLR2 activation directly leads to killing of intracelullar MTB 
in alveolar macrophages in vitro [95]. It may be anticipated that genetic 
polymorphism, or perhaps mutations, in the relevant TLR or the downstream 
signaling proteins will affect the performance of the innate host response to 
mycobacteria. 
 
 
Cytokine production driven by M. Tuberculosis 
 
 
Proinflammatory cytokines 
Recognition of MTB by phagocytic cells leads to cell-activation and production 
of cytokines which in itself induce further activation and cytokine production in a 
complex process of regulation and cross-regulation. This cytokine network plays a 
crucial role in the inflammatory response and the outcome of mycobacterial infections 
(Figure 3). Several proinflammatory cytokines will be discussed.  
TNFα. Stimulation of monocytes, macrophages [96] and dendritic cells [39] with 
mycobacteria or mycobacterial products induces the production of tumor necrosis 
factor-α (TNFα), a prototype proinflammatory cytokine. TNFα plays a key role in 
granuloma formation [97,98], induces macrophage-activation and has 
immunoregulatory properties [99,100]. In mice, TNFα is also important for 
containment of latent infection in granuloma [101]. In TB patients, TNFα production is 
present at the site of disease [27,102,103]. Systemic spill over of TNFα may account 
for unwanted inflammatory effects like fever and wasting. Clinical deterioration early 
in treatment is associated with a selective increase [104], and quick recovery with a 
rapid decrease of plasma TNFα [105]. To limit the deleterious effects of TNFα [26], 
s[106]ystemic production of TNFα is downregulated [107-109], and soluble TNFα-
receptors which block TNFα-activity are increased [110]. Gene knock out (KO) mice 
which are unable to make TNFα, [111-113] or the TNFα-receptor p55 [97,114], 
display an increased susceptibility for mycobacteria. In line with this, the use of 
potent monoclonal anti-TNFα-antibodies in Crohn’s disease and rheumatoid arthritis 
has been associated with increased reactivation of tuberculosis (including miliary and 
extrapulmonary disease) [115]. In human tuberculosis, no TNFα-gene mutations 
have been found and no positive association has yet been established between 
gene-polymorphism for TNFα and disease susceptibility [6,116].  
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IL-1β. A second proinflammatory cytokine involved in the host response to MTB 
is interleukin-1β (IL-1β). Like TNFα, IL-1β is mainly produced by monocytes, 
macrophages and dendritic cells [117,118]. In TB-patients, IL-1β is expressed in 
excess [119], and at the site of disease [102,120]. Studies in mice suggest an 
important role of IL-1β in TB: IL-1α and β double KO mice [121] and IL-1 receptor 
type I deficient mice (which do not respond to IL-1), display an increased 
mycobacterial outgrowth, and also defective granuloma formation after infection with 
MTB [122]. In addition, among 90 Hindu TB-patients in London, haplotypes for IL-1β 
and IL-1 receptor antagonist (IL-1Ra, a naturally occuring antagonist of IL-1) were 
unevenly distributed: a “proinflammatory haplotype”, reflected in an increased ratio of 
IL-1β / IL-1Ra production, was significantly more common in TB pleurisy than in other 
types of TB [35]. Because TB pleurisy is a usually self-resolving type of primary TB, 
one may hypothesize that an increased ratio of IL-1β / IL-1Ra protects against a 
more severe presentation of TB. 
IL-6. This cytokine which has both pro- and anti-inflammatory properties [123] is 
produced early during mycobacterial infection and at the site of infection 
[102,124,125]. IL-6 may be harmful in mycobacterial infections as it inhibits the 
production of TNFα and IL-1β [126] and promotes in-vitro growth of M. avium [127]. 
Other reports support a protective role for IL-6: IL-6 deficient mice display increased 
susceptibility to infection with MTB [128], which seems related to a deficient 
production of IFNγ early in the infection, before adaptive T-cell immunity has fully 
developed [129]. 
IL-12. IL-12 is a key player in host defense to MTB. IL-12 is produced mainly by 
phagocytic cells, and phagocytosis of MTB seems necessary for its production 
[130,131]. IL-12 has a crucial role in the induction of IFNγ production [132]. In TB, IL-
12 has been detected in lung infiltrates [103,133], in pleurisy [134], in granulomas 
[120] and in lymphadenitis [25]. The expression of IL-12 receptors is also increased 
at the site of disease [135]. The protective role of IL-12 can be inferred from the 
observation that IL-12 KO mice are highly susceptible to mycobacterial infections 
[136-138]. In humans suffering from recurrent non-tuberculous mycobacterial 
infections, deleterious genetic mutations in the genes encoding IL-12p40, and IL-12R 
have been identified [139-142]. These patients display a reduced capacity to produce 
IFNγ [143]. Recently, a IL-12R-defect has also been identified in a patient with 
abdominal TB [144]. Apparently, IL-12 is a regulatory cytokine which connects the 
innate and adaptive host response to mycobacteria [132,145,146], and which exerts 
its protective effects mainly through the induction of IFNγ [136].  
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 Figure 3.  
The inflammatory response of phagocytic cells upon activation with M. tuberculosis. 
Immune recognition of M. tuberculosis (MTB) by macrophages and dendritic cells is followed by 
an inflammatory response with a crucial role for cytokine production. Initial events in this cellular 
response include non-specific host defense mechanisms, which may lead to early killing or 
containment of infection. In addition, various cellular products, including cytokines and cell-
surface markers, are involved in these processes as depicted in the figure (italics). Not 
represented in this picture are the anti-inflammatory cytokines (see text: ‘anti-inflammatory 
cytokines’). Not represented in this figure are the anti-inflammatory cytokines. 
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 IL-18 and IL-15. In addition to IL-12, two cytokines are important in the IFNγ-
axis. IL-18, a novel proinflammatory cytokine which shares many features with IL-1 
[147], was initially discovered as an IFNγ-inducing factor, synergistic with IL-12 [132]. 
It has since been found that IL-18 also stimulates the production of other 
proinflammatory cytokines, chemokines and transcription factors [148,149]. There is 
evidence for a protective role of IL-18 during mycobacterial infections: IL-18 KO mice 
are highly susceptible to BCG and MTB [150], and in mice infected with M. leprae, 
resistance is correlated with a higher expression of IL-18 [151]. IL-18’s major effect in 
this model seems to be the induction of IFNγ. Indeed in TB pleurisy, parallel 
concentrations of IL-18 and IFNγ were found [152]. Also, MTB-mediated production 
of IL-18 by PBMC is reduced in tuberculosis patients, and this reduction may be 
responsible for reduced IFNγ production [152]. IL-15 resembles IL-2 in its biologic 
activities, stimulating T-cell and NK-cell proliferation and activation [153,154]. Unlike 
IL-2 however, IL-15 is primarily synthesized by monocytes and macrophages. In 
leprosy, IL-15 mRNA was found to be expressed more strongly in immunologically 
resistant tuberculoid leprosy than in unresponsive lepromatous leprosy [155]. As far 
as we know, no report has been published yet about IL-15 in tuberculosis.  
IFNγ. The protective role of IFNγ in tuberculosis is well established [16], 
primarily in the context of antigen-specific T-cell immunity [5]. Mycobacterial antigen-
specific IFNγ-production in vitro can be used as a surrogate marker of infection with 
MTB [156]. In principal, naive (tuberculin skin-test negative) individuals do not show 
PPD-stimulated IFNγ production in vitro [156]. However, in both PPD-positive and 
PPD-negative individuals, MTB-infected monocytes stimulate lymphocytes for the in-
vitro production of IFNγ [107]. We found that PPD (consisting of mycobacterial 
proteins) selectively induces IFNγ production in PPD-positive individuals, while MTB 
sonicate, which contains mycobacterial polyglycans and phospholipids, non-
selectively induced IFNγ production in PPD-positive and PPD-negative individuals 
alike (van Crevel et al, 2000, unpublished data). This MTB sonicate stimulates 
production of monocyte derived cytokines like TNFα and IL-1β [157]. These, as well 
as IL-12 and IL-18, may act as co-stimuli for antigen-independent IFNγ production 
[132,158,159].  
Which cells are responsible for this non-specific production of IFNγ? Firstly, 
before adaptive T-cell immunity has fully developed, natural killer (NK) cells may be 
the main producers of IFNγ, either in response to IL-12 and IL-18 [160], or directly by 
exposure to mycobacterial oligodeoxynucleotides [161]. Second, lung macrophages 
were found to produce IFNγ in MTB-infected mice [138]. This remarkable observation 
needs confirmation. Third, T-cells bearing limited T-cell receptor diversity including γδ 
T-cells and CD1-restricted T-cells may produce IFNγ during early infection. T-cells 
expressing γδ T-cell receptors (γδ T-cells) may directly recognize small mycobacterial 
proteins [162] and non-protein ligands [163-165], in the absence of antigen 
presenting molecules. In mice, a single priming with MTB substantially increases the 
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number of γδ T-cells, but not the number of αβ T-cells (CD4+ and CD8+ T-cells) in 
draining lymph nodes [162]. In mice infected with MTB, γδ T-cells accumulate at the 
site of disease [166], and seem necessary for early containment of mycobacterial 
infections [167,168]. Like γδ T-cells, CD1-restricted T-cells do not react with 
mycobacterial protein antigens in the context of MHC class I or class II molecules. 
Instead, these T-cells react with mycobacterial lipid and glycolipid antigens bound to 
CD1 on antigen presenting cells [169-172]. CD1 molecules have close structural 
resemblance to MHC class I, but are relatively non-polymorphic. In mycobacterial 
infections, several different T-cell subsets have been found to interact with CD1, 
including CD4- CD8- (double negative) T-cells, CD4 + or CD8+ single positive T-cells 
and γδ T-cells [173-175]. CD1-restricted T-cells display cytotoxic activity and are able 
to produce IFNγ [176]. 
 
Anti-inflammatory cytokines 
The proinflammatory response that is initiated by MTB is antagonized by anti-
inflammatory mechanisms. Soluble cytokine receptors (e.g. s TNFα-receptors I and 
II) prevent binding of cytokines to cellular receptors, thereby blocking further 
signaling. As already mentioned, IL-1β is counteracted by a specific antagonist, IL-
1Ra. In addition, three anti-inflammatory cytokines, IL-4, IL-10 and TGFβ, may inhibit 
the production or the effects of proinflammatory cytokines in tuberculosis.  
IL-10. IL-10 is produced by macrophages after phagocytosis of MTB [177], and 
after binding of mycobacterial LAM [117]. T-lymphocytes, including MTB-reactive T-
cells, are also capable of producing IL-10 [178-180]. In patients with tuberculosis, 
expression of IL-10 mRNA has been demonstrated in circulating mononuclear cells, 
and at the site of disease in pleural fluid, and alveolar lavage [27,179]. Ex-vivo 
production of IL-10 was shown to be upregulated in tuberculosis by some 
investigators [181,182], but this was not found by others [25]. IL-10 antagonizes the 
proinflammatory cytokine response by downregulation of production of IFNγ, TNFα 
and IL-12 [182-184]. Since the latter cytokines – as discussed under the previous 
heading – are essential for protective immunity in tuberculosis, IL-10 would be 
expected to interfere with host defense against MTB. Indeed, IL-10 transgenic mice 
with mycobacterial infection develop a larger bacterial burden [185]. In line with this, 
IL-10 deficient mice showed a lower bacterial burden early after infection in one 
report [186], albeit normal resistance in two other reports [187,188]. In human 
tuberculosis, IL-10 production was higher in anergic patients, both before and after 
successful treatment, suggesting that MTB-induced IL-10 production suppresses an 
effective immune response [180].  
TGFβ. Transforming growth factor-beta (TGFβ) also seems to counteract 
protective immunity in tuberculosis. Mycobacterial products induce production of 
TGFβ by monocytes and dendritic cells [189]. Interestingly, LAM from virulent 
mycobacteria selectively induces TGFβ-production [117]. Like IL-10, TGFβ is 
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produced in excess during tuberculosis and is expressed at the site of disease 
[189,190]. TGFβ suppresses cell-mediated immunity: in T-cells, TGFβ inhibits 
proliferation and IFNγ production; in macrophages it antagonizes antigen 
presentation, proinflammatory cytokine production and cellular activation [191]. In 
addition, TGFβ may be involved in tissue damage and fibrosis during tuberculosis, as 
it promotes the production and deposition of macrophage collagenases [191] and 
collagen matrix [192]. Naturally occurring inhibitors of TGFβ abrogate the 
suppressive effects of TGFβ on mononuclear cells from tuberculosis patients, and in 
macrophages infected with MTB [193]. Within the anti-inflammatory response TGFβ 
and IL-10 seem to synergize: TGFβ selectively induces IL-10 production, and both 
cytokines show synergism in the suppression of IFNγ production [194]. TGFβ may 
also interact with IL-4. Paradoxically, in the presence of both cytokines, T-cells may 
be directed towards a protective Th1-type profile [195]. 
IL-4. The deleterious effects of IL-4 in intracellular infections (including 
tuberculosis) has been ascribed to its suppression of IFNγ production [12,17] and 
macrophage activation [18,19]. In mice infected with MTB, progressive disease [196] 
and reactivation of latent infection [197] are both associated with increased 
production of IL-4. Similarly, over-expression of IL-4 intensified tissue damage in 
experimental infection [198]. Conversely, inhibition of IL-4 production did not seem to 
be promote cellular immunity: IL-4 -/- mice displayed normal instead of increased 
susceptibility to mycobacteria in two studies suggesting that IL-4 may be 
consequence rather than cause of TB development [187,188]. In contrast, a recent 
study on IL-4 KO mice showed increased granuloma size and mycobacterial 
outgrowth after airborn infection [199]. Compared with control mice, production of 
proinflammatory cytokines was increased in these animals and accompanied by 
excessive tissue damage. In human TB patients, we and others have detected 
increased production of IL-4 in TB patients, especially those with cavitary disease 
[20,22,119,200]. However, this is not a consistent finding [25-28], and it still remains 
to be determined whether IL-4 causes or merely reflects disease activity in human 
TB. Thus, the role of IL-4 in TB susceptibility is not yet entirely resolved. 
Production of soluble cytokine receptors and anti-inflammatory cytokines may 
help to regulate the inflammatory response during tuberculosis. An unrestrained 
proinflammatory response may lead to excessive tissue damage (as in IL-4 KO 
mice), while a predominance of anti-inflammatory effects may favor outgrowth of 
MTB. MTB may evade protective immune mechanisms of the host by selective 
induction of anti-inflammatory cytokines. In addition, individuals genetically 
predisposed to higher production of these cytokines may display increased innate 
susceptibility to MTB. To date, such genetic predisposition has not yet been reported 
in humans.  
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Chemokines 
Chemotactic cytokines (chemokines) are largely responsible for recruitment of 
inflammatory cells to the site of infection. About 40 chemokines and 16 chemokine 
receptors have now been identified [201]. A number of chemokines have been 
investigated in tuberculosis. First, several reports have addressed the role of 
interleukin-8 (IL-8), which attracts neutrophils, T-lymphocytes and possibly 
monocytes. Upon phagocytosis of MTB [202], or stimulation with LAM, macrophages 
produce IL-8 [202,203]. This production is substantially blocked by neutralization of 
TNFα and IL-1β indicating that IL-8 production is largely under control of these 
cytokines [202]. Pulmonary epithelial cells also produce IL-8 in response to MTB 
[204]. In TB patients, IL-8 has been found in broncheoalveolar lavage fluid [205,206], 
lymph nodes [120], and plasma [109,203]. Patients who died from tuberculosis 
showed higher concentrations of IL-8 [109]. Interestingly, upon antituberculous 
treatment, concentrations of IL-8 remain elevated in alveolar lavage fluid [206] and 
serum [109] for months. This finding is puzzling, first of all because it is unclear what 
drives such prolonged production. Secondly, because IL-8 is a potent neutrophil 
attractant and a neutrophilic response is not prominent in established TB.  
A second major chemokine is monocyte chemoattractant protein-1 (MCP-1), 
which is produced by, and acts on monocytes and macrophages. MTB preferentially 
induces production of MCP-1 by monocytes [207]. In murine models, deficiency of 
MCP-1 inhibited granuloma formation [208]. Also, C-C chemokine receptor 2 deficient 
mice, which fail to respond to MCP-1, display reduced granuloma formation and 
suppressed Th1-type cytokine production [209], and die early after infection with 
MTB [210]. In alveolar lavage fluid [206], serum [203] and pleural fluid [211] from TB 
patients, concentrations of MCP-1 were found elevated. A third chemokine is 
RANTES, which is produced by a wide variety of cells, and which shows 
promiscuous binding to multiple chemokine receptors. In murine models, expression 
of RANTES was associated with development of M. bovis induced pulmonary 
granulomas [212]. In human patients, RANTES has been detected in alveolar lavage 
fluid [206]. Apart from IL-8, MCP-1 and RANTES, other chemokines may be involved 
in cell trafficking in tuberculosis [213]. Inhibition of chemokine production may lead to 
an insufficient local tissue response. However, due to the redundancy of the 
chemokine system, the contribution of individual chemokines is difficult to evaluate. 
As far as we are aware, no clear-cut defects of chemokine production have been 
identified up to now in patients with mycobacterial infectious diseases.  
 
 
Effector mechanisms for killing of M. Tuberculosis 
 
Macrophages are the main effector cells involved in killing of MTB. To become 
active against mycobacteria, macrophages need to be activated. In vitro models of 
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macrophage activation for the killing of MTB seem rather artificial, and therefore the 
exact conditions for optimal activation remain unknown. However, it is clear that 
lymphocyte products, mainly IFNγ, and proinflammatory cytokines like TNFα are 
important. In addition, vitamin D seems involved in macrophage activation. 
The active metabolite of vitamin D, 1,25-dihydroxyvitamin D, helps 
macrophages to suppress growth of MTB [214-216]. Serum concentrations of vitamin 
D have reported to be lower in tuberculosis patients in some populations [217], but 
not in others [218]. A recent study among Gujarati Hindus, a mainly vegetarian 
immigrant population in London, showed that vitamin D deficiency was a risk factor 
for tuberculosis [36]. When considered in combination with vitamin D deficiency, 
three polymorfisms of the vitamin D receptor were also associated with disease 
susceptibility in this population. For another variant of the vitamin D receptor (tt 
genotype), 6% of tuberculosis patients in The Gambia proved homozygous 
compared with 12% of control subjects [37], suggesting that this polymorphism 
protects against active tuberculosis. It should be noted however, that no functional 
changes, which might affect macrophage activation, have yet been described for any 
of the vitamin D receptor polymorfisms associated with disease.  
Putative mechanisms involved in killing of MTB within the phagolysosomes of 
activated macrophages include the production of reactive oxygen or nitrogen 
intermediates. The study of these mechanisms has been hampered by differences 
between mice (the most important animal model used for mycobacterial infections) 
and man. However, when we restrict ourselves to data derived from human cells or 
patients, controversy remains. In vitro, mycobacteria seem resistant to killing by 
reactive oxygen intermediates (ROI) such as superoxide and hydrogen peroxide [70]. 
A possible explanation lies in the fact that several mycobacterial products, including 
sulfatides and LAM, are able to scavenge ROI [219-221]. In vivo, it was found that 
p47 (phox -/- ) mice, which lack a functional p47 unit of NADPH-oxidase needed for 
superoxide production, suffer from increased early outgrowth of mycobacteria in 
experimental infection [222]. Therefore, this supports a role for ROI in the killing of 
MTB. On the other hand, patients with chronic granulomatous disease (CGD), who 
have defective production of ROI, do not seem to display increased susceptibility to 
tuberculosis [223].  
The role of reactive nitrogen intermediates (RNI) in tuberculosis also remains a 
matter of debate. In vitro, human alveolar macrophages infected with M. bovis BCG 
display increased inducible nitric oxide synthase (iNOS) mRNA [69], and inhibition of 
iNOS is followed by increased bacterial outgrowth [69]. In tuberculosis patients, 
alveolar macrophages show increased production of iNOS as well [224]. However, 
whether iNOS gene expression leads to in vivo NO production remains uncertain as 
in humans post-translational modification of iNOS may be necessary for functional 
activity [225]. Therefore, the exact contribution of RNI in human tuberculosis remains 
to be elucidated.  
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Sustained intracellular growth of MTB may depend on its ability to avoid 
destruction by lysosomal enzymes, ROI and RNI. When phagocytosed by 
macrophages, bacteria typically enter specialized phagosomes that undergo 
progressive acidification followed by fusion with lysosomes. However, MTB delays or 
inhibits fusion of phagosomes and lysosomes [50,226]. In addition, MTB prevents 
phagosomal maturation and acidification of phagosomes, thereby blocking the 
digestive activity of acidic hydrolases [227,228].  
Nramp1, which encodes for natural-resistance-associated macrophage protein 
(Nramp), is an interesting gene involved in macrophage activation and mycobacterial 
killing [229]. The protein is an integral membrane protein, which belongs to a family of 
metal ion transporters. These metal ions, particularly Fe2+, are involved in 
macrophage activation and generation of toxic antimicrobial radicals [230]. Following 
phagocytosis, Nramp1 becomes part of the phagosome. Nramp1 mutant mice 
display reduced phagosomal maturation and acidification [231]. Surprisingly, 
mycobacterial outgrowth is unaffected in these animals [232]. In humans, functional 
polymorphism in the promotor region of Nramp1, associated with reduced gene 
expression, was found to be associated with susceptibility to tuberculosis in studies 
from West Africa [38,233]. Thus, genetic variation in Nramp1 may affect the outcome 
of infection with MTB. However, to prove the significance of this gene in human 
tuberculosis further epidemiological and mechanistic studies are needed. 
Apoptosis may constitute another effector mechanism for the infected host to 
limit outgrowth of MTB [234,235]. Apoptosis of phagocytic cells may prevent 
dissemination of infection. In addition, apoptosis of infected cells reduces viability of 
intracellular mycobacteria, while necrosis of infected cells does not [236,237]. TNFα 
is required for induction of apoptosis in response to infection with MTB [235]. 
Interestingly, pathogenic MTB strains induced significant less host cell apoptosis than 
related attenuated strains [235]. This difference was explained by selective induction 
and release of neutralizing soluble TNFα-receptors by pathogenic strains [238]. 
Release of TNFα-receptors in turn was regulated by IL-10 production [238]. Thus, 
pathogenic strains of MTB may selectively induce IL-10 leading to decreased TNFα 
activity and reduced apoptosis of infected cells. Independent of cytokine production, 
lipoarabinomannan (LAM) may prevent in-vitro apoptosis of MTB-infected cells in a 
Ca2+ dependent mechanism [239]. In addition, increased expression of Fas-ligand in 
infected macrophages may also contribute to decreased macrophage apoptosis 
[240].  
We briefly want to mention the role of other cell-types. Although the precise 
mechanisms remain to be elucidated, human neutrophils may contribute to killing of 
MTB [241,242]. However, patients with disorders of neutrophil activity do not show 
increased susceptibility to tuberculosis. Of more clinical relevance may be the 
contribution of cytotoxic T-cells [243]. Of special interest, granules of cytotoxic T-cells 
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and NK-cells contain granulysin, a molecule that directly alters the mycobacterial 
membrane integrity and thereby kills MTB [244].  
 
 
Initiation of adaptive immunity to M. Tuberculosis 
 
It is clear that innate and adaptive immunity are closely connected. 
Macrophages and dendritic cells, the primary cell types involved in the innate 
immune response to mycobacteria, play a crucial role in the initiation of adaptive 
immunity. Although an in-depth overview of the mechanisms involved in the adaptive 
host response to mycobacteria is beyond the scope of this review, we will briefly 
summarize this subject. In principal, three processes contribute to the initiation of 
adaptive immunity: antigen presentation, co-stimulation and cytokine production. 
Patients with active tuberculosis may suffer from anergy or T-cell unresponsiveness 
[182]. This may be caused by intrinsic defects or dynamic inhibition of one of these 
three processes. 
Antigen presentation. Presentation of mycobacterial antigens by macrophages 
and dendritic cells involves distinctive mechanisms. First, MHC class II molecules 
present mycobacterial proteins to antigen-specific CD4+ T-cells. These antigens 
must be processed in phagolysosomal compartments in professional antigen 
presenting cells. Second, MHC class I molecules, expressed on all nucleated cells, 
are able to present mycobacterial proteins to antigen-specific CD8+ T-cells. This 
mechanism allows for the presentation of cytosolic antigens, which may be important 
as certain mycobacterial antigens may somehow escape the phagosome [245]. The 
importance of MHC I mediated antigen presentation has been shown in murine 
models [246] and tuberculosis patients [4,247]. Third, non-polymorphic MHC-I like 
type I CD1 (a,b,c) molecules, which are expressed on macrophages and dendritic 
cells, are able to present mycobacterial lipoproteins to CD1-restricted T-cells. This 
mechanism of antigen presentation enables the activation of a larger fraction of T-
cells at an earlier point in infection, before antigen specificity has developed. A fourth 
pathway may involve non-polymorphic MHC-Ib molecules [248]. 
The expression of particular class I and class II MHC alleles in an individual 
determines the ability of that individual to respond to particular (mycobacterial) 
antigens and epitopes. Certain allelic human leucocyte antigens (HLA) variants have 
been associated with tuberculosis [6,249]. HLA-polymorphism may explain the 
vulnerability of certain isolated populations like Amazonian Indians which have only 
recently been exposed to tuberculosis [250]. There is a large body of evidence for 
similar mechanisms in leprosy. The expression of antigen presenting molecules is 
also a dynamic process, which is regulated by cytokines. While proinflammatory 
cytokines, primarily IFNγ, stimulate expression of MHC, anti-inflammatory cytokines 
inhibit its expression. Mycobacteria may modulate the antigen presentation function, 
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but different results have been obtained in vitro with macrophages and dendritic cells. 
Mycobacteria may downregulate expression of antigen presenting molecules in 
macrophages, most likely through the production of anti-inflammatory cytokines 
[251,252]. On the other hand, MHC expression on dendritic cells is upregulated 
following MTB infection [39,253].  
Co-stimulation. It is well known that antigen presentation only leads to T-cell 
stimulation in the presence of particular co-stimulatory signals. The most well-known 
co-stimulatory signals for T-cell stimulation are B-7.1 (CD80) and B-7.2 (CD86). 
These molecules are expressed on macrophages and dendritic cells and bind to 
CD28 and to CTLA-4 on T-cells. Interestingly, in vitro infection of monocytes with 
MTB leads to diminished expression of B-7.1 [254]. On the other hand, MTB infection 
of dendritic cells induces expression of B7.1, CD40 and ICAM-1 [39]. In the absence 
of proper co-stimulatory signals, antigen presentation may lead to increased 
apoptosis of T-cells [255,256]. 
Cytokine production. Several cytokines produced by activated macrophages 
and dendritic cells are essential for stimulation of T-lymphocytes. Macrophages and 
dendritic produce the type-1 cytokines IL-12, IL-18 and IL-23 [257]. In patients with 
recurrent or fatal nontuberculous mycobacterial infections, functional genetic 
mutations have been found in the genes encoding IL-12p40 [140,141], IL-12Rβ1 
[139,143], IFNγ-receptor 1 [14,15,258] and IFNγ-receptor 2 [259], all of which are 
involved in IFNγ receptor signaling in macrophages and dendritic cells. Clearly the 
capacity of these cells to produce or react to Th1-type cytokines is necessary for 
proper T-cell stimulation (Figure 4). In addition, proinflammatory cytokines like IL-1 
[260] and TNFα [100] have important T-cell stimulatory properties. Reduced 
production of type-1 or proinflammatory cytokines may delay or decrease T-cell 
stimulation and the initiation of antigen specific T-cell immunity. In this respect, the 
production of anti-inflammatory cytokines may be relevant as well. For instance, in 
anergic tuberculosis patients it was recently shown that IL-10 production is 
constitutively present, and that T-cell receptor-mediated stimulation results in 
defective signal transduction [180]. TGFβ may have a similar antagonistic role 
[191,193]. 
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 Figure 4.   
Cytokines and cytokine receptors involved in type I immunity in tuberculosis.  
A major effector mechanism of cell-mediated immunity in tuberculosis is the activation of 
MTB-infected macrophages by IFNγ. IFNγ is produced by NK-cells and different T-cell 
subsets, and its production is regulated by TNFα, IL-1β, IL-12, IL-18 and possibly IL-15, 
all released from activated macrophages and dendritic cells. 
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Concluding remarks 
 
The interplay between MTB and the human host determines the outcome after 
infection. With respect to the human host, both innate and adaptive defense 
mechanisms are involved. After uptake of MTB in alveolar macrophages, several 
possible scenarios may be envisaged. MTB may be destroyed immediately, in which 
case no adaptive T-cell response is developed. When infection is established 
however, a focal nonspecific inflammatory response follows. This response is 
regulated by a network of pro- and anti-inflammatory cytokines and chemokines. 
Most of the mediators at this point are derived from macrophages or dendritic cells, 
but IFNγ has several cellular sources including NK-cells, γδ-T-cells and CD1-
restricted T-cells. This initial response determines the local outgrowth of MTB 
(sometimes dissemination) or containment of infection. Phagocytic cells also play a 
key role in antigen-presentation and initiation of T-cell immunity that follows. At many 
stages in the host response, MTB has developed mechanisms to circumvent or 
antagonize protective immunity. 
The interindividual differences in outcome after infection with MTB may in part 
be explained by the efficiency of various innate host defense mechanisms. 
Phagocytosis, immune recognition, cytokine production and effector mechanisms 
may all contribute to innate immunity. In this respect, different gene-polymorphisms 
have been found which are associated with increased susceptibility and severity of 
tuberculosis. Some of these polymorphisms are functional, but for many of these no 
functional (immunologic) changes have been demonstrated yet, and these 
associations therefore need further confirmation and investigation.   
What remains to be determined is to what extent the encounters between MTB 
and the human host can be modulated. In many settings the most cost-effective way 
to improve disease outcome is to increase patients access to health care facilities, 
and to strengthen the quality of diagnosis and antimycobacterial treatment. However, 
in many parts of the world the spread of multidrug resistant TB seriously threatens 
the success of antibiotic treatment. Therefore, more effective vaccines and new 
therapeutic strategies (like immunotherapy) are desperately needed. It is expected 
that increased understanding of disease pathogenesis will help the design of such 
adjunctive treatment, which will undoubtedly benefit the outcome of individual 
patients and limit the spread of MTB around the world. 
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Abstract                                                                                                                                       
 
 
As a simple method for field studies to assess the cytokine-status of patients with 
tuberculosis (TB), the use of whole blood instead of isolated cells has advantages, 
especially since the risk of contamination is minimal. Therefore, cytokine production 
in whole blood cultures was determined using non-specific and disease-specific 
stimuli. Heparinized blood from healthy volunteers was either incubated in closed 
vacutainer tubes or in tissue culture wells after dilution in culture medium.  Dose-
response and kinetics were investigated for the production of TNFα, IL-1β, IL-1ra, IL-
10 and IFNγ. Patients with TB and healthy individuals were examined for IFNγ 
production in whole blood. In the absence of a stimulus, the production of cytokines is 
negligible in whole blood cultures. LPS induces the production of TNFα, IL-1β, IL-1ra 
and IL-10; PHA induces the production of IFNγ and IL-10. Live BCG induces the 
production of proïnflammatory cytokines, irrespective of tuberculin skin status. In 
contrast, PPD and MTB-culture filtrate induce production of IFNγ in skin-test positive 
and not in skin-test negative healthy subjects. Five out of 13 patients with TB had a 
low antigen-specific IFNγ production, suggestive of a minimal or absent specific T-cell 
response. For most purposes, cultures in closed vacutainer tubes are optimal. If one 
wishes to focus on T-cell cytokines or if only small volumes of blood are available, 
dilution of whole blood in culture medium before incubation in tissue culture wells 
may be preferable.  
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Introduction 
 
The host defense in tuberculosis involves both mononuclear phagocytes and 
lymphocytes [1,2]. Mononuclear phagocytes are able to produce both 
proïnflammatory cytokines, e.g. tumor necrosis factor-α (TNFα), interleukin-1β (IL-1β) 
and interleukin-12 (IL-12) and antiinflammatory cytokines, e.g. interleukin-1 receptor 
antagonist (IL-1ra), interleukin-10 (IL-10) and transforming growth factor-β (TGFβ). 
Similarly, after stimulation, T-lymphocytes produce so-called Th1-type cytokines, e.g. 
interferon-γ (IFNγ) and interleukin-2 (IL-2) or Th2-type cytokines, interleukin-4 (IL-4) 
and interleukin-10 (IL-10) [3]. The delicate balance between pro- and anti-
inflammatory cytokines is considered to influence the outcome of disease [4]. For this 
reason the study of cytokine profiles in patients with tuberculosis may provide 
valuable information leading to a better understanding of host defense mechanisms 
against Mycobacterium tuberculosis. 
Cytokine production in humans can be studied in vivo, in the circulation and at 
the tissue level, and ex vivo by stimulation of isolated cells. Concentrations of 
circulating cytokines are often low or undetectable and do not reflect local cytokine 
production [5,6]. Measurement of cytokines at the tissue level meets with practical 
problems in humans and studying ex-vivo cytokine production is associated with 
other difficulties. In general, isolated white blood cells or cultured cell lines are used. 
The isolation of cells is cumbersome and cannot be done easily outside the setting of 
a research laboratory. In addition, the isolation procedure itself may lead to activation 
of cells [7]. Furthermore, artefacts may arise because of unintentional selection of 
cells, and because isolated cells, deprived from neighbouring cells and serum 
components may not retain their in vivo characteristics. In this respect, the study of 
whole blood ex vivo has both practical and theoretical advantages.  
Several systems for ex vivo cytokine production in whole blood have been 
devised. Broadly, two methods exist. In the first, undiluted whole blood is stimulated 
and incubated in syringes or closed sampling tubes [8]. In the second method, whole 
blood is diluted in culture medium before incubation in tissue culture wells [9]. Aiming 
for a method that permits measurement of both monocyte- and T-cell-derived 
cytokines, we evaluated ex-vivo cytokine production in undiluted and diluted whole 
blood. Lipopolysaccharide (LPS), as a stimulus for monocytes, and phytohaem-
agglutinin (PHA), which non-specifically stimulates T-lymphocytes, were used, as 
well as the disease-specific stimuli Mycobacterium bovis BCG, M.tuberculosis culture 
filtrate and tuberculin (PPD). Experiments were performed to determine dose-
response and kinetics with the blood of healthy volunteers. In addition antigen-
specific stimulation of whole blood with PPD was used to try and distinguish 
tuberculin skin-test positive individuals from control subjects. 
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Methods 
 
Ex-vivo stimulation of whole blood.  
In all experiments, blood samples were taken from healthy individuals between 8 and 
9 a.m. unless stated otherwise. Dry vacutainer tubes to which sterile sodium heparin 
was added and different commercially available glass (Becton and Dickinson, Leiden, 
the Netherlands) or plastic (Greiner, Leiden, the Netherlands) vacutainer tubes 
containing lithium heparin, sodium heparin or ammonium heparin were used in a pilot 
experiment to test for background stimulation by heparin, which appeared to be 
present to variable degrees. All further experiments were performed using 2-mL glass 
tubes (Becton and Dickinson) containing lithium heparin. The following stimuli were 
used; lipopolysaccharide (E.coli serotype 055:b5; Sigma, Zwijndrecht, the 
Netherlands), phytohaemagglutinin (PHA-P, Sigma), bovine tuberculin PPD (ID-DLO, 
Lelystad, the Netherlands), live M.bovis BCG (Danish 1331, RIVM, Bilthoven, the 
Netherlands) and MTB culture-filtrate (a kind gift from Dr.A.H.J. Kolk, Royal Tropical 
Institute, Amsterdam, the Netherlands). Stimuli were dissolved in phosphate-buffered 
saline and added shortly after blood sampling with a 1 mL syringe and a 0.6 mm 
needle through the rubber stopper of the sampling tubes, which remained closed 
during this procedure. After the indicated times of incubation at 370 C, tubes were 
centrifuged at 2250 x g for 10 min. and the supernatants were centrifuged again at 
15000 g for 5 min. to obtain platelet-poor plasma. Aliquots were stored at -20o C until 
assay.  
Alternatively, 200 µl of heparinized blood were diluted 1:4 in culture medium (RPMI 
1640 containing 100 IU penicillin/mL) in 24 well tissue culture plates (Costar, 
Badhoevedorp, the Netherlands). After addition of the above-mentioned stimuli and 
incubation (370 C, 5% CO2), supernatants were removed and centrifuged at 15000 x 
g for 5 min before storage at -20 0C.  
 
Cytokine measurement.  
In all samples the concentration of TNFα, IL-1β and IL-1ra was measured by specific 
radioimmunoassay (detection levels respectively 40, 40 and 80 pg/mL) as described 
[10]. Concentrations of IFNγ and IL-10 were measured by ELISA according to the 
guidelines of the manufacturer (Pelikine, CLB, Amsterdam, the Netherlands).  
 
Dose response and kinetics of ex-vivo cytokine production.  
Blood from 5 healthy volunteers was stimulated for ex-vivo cytokine production in 
both systems with various concentrations of the stimuli and a single incubation period 
of 24 h. Final concentrations ranged from 1 pg to 100 ng/ mL LPS; 1 to 100 µg/ mL 
PHA, PPD, MTB-culture filtrate or MTB-sonicate and 105 - 108 M.bovis BCG CFU/ 
mL. The kinetics of the production of different cytokines in whole blood and diluted 
whole blood were assessed. Using a single blood sampling tube or tissue culture well 
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per time point, blood from 4 healthy volunteers was incubated for 1,2,4,8,24,48 and 
72 h with final concentrations of 1 ng of LPS /mL, 5 µg of PHA /mL or 10 µg of PPD 
/mL. 
 
Variation of cytokine response in whole blood; correlation with cell count 
Inter- and intra-individual variations of cytokine production in whole blood were 
assessed. Based on the results of the dose-response and kinetic experiments, 
standardised conditions for cytokine production were chosen; whole blood was 
stimulated in vacutainer tubes with 10 ng of LPS/mL or 10 µg PHA/ mL during a six-
hour incubation period. For the assessment of inter-individual variation in cytokine 
production, blood from 20 healthy volunteers was sampled and stimulated between 
8.00 and 9.00 a.m. Absolute monocyte and lymphocyte counts and the percentage of 
T-lymphocytes, as determined by standard flowcytometry, were correlated with 
cytokine production. Intra-individual variation of ex vivo cytokine production was 
assessed in ten healthy volunteers. For day-to-day variation of ex vivo cytokine 
production, whole blood from 10 individuals was sampled on three separate days 
between 8.00 and 9.00 a.m. For diurnal variation of cytokine production blood from 
10 individuals was sampled on one single day at 9 a.m., 12 p.m. and 16 p.m. 
 
Antigen-specific stimulation with PPD; comparison of patients and controls. 
IFNγ production after stimulation with 10 µg/mL PPD was assessed in 13 patients 
with active pulmonary tuberculosis, 13 tuberculin-positive and 13 tuberculin-negative 
control subjects. 
 
 
Results 
 
Spontaneous cytokine production in whole blood 
Before stimulation as well as after incubation without stimuli, TNFα, IL-1β, IFNγ and 
IL-10 were not detected. In contrast, IL-1ra was produced in vacutainer tubes without 
stimulation after 8 h incubation and in tissue culture wells after 4 h. In whole blood 
from 4 volunteers, the concentrations of spontaneously produced IL-1ra at 24 h were 
1.19 ± 0.3 ng/mL in tubes and 1.16 ± 0.46 ng/mL in culture wells compared with 9.35 
± 1.71 ng/mL and 2.95 ± 0.46 ng/mL respectively after 24 h of LPS-stimulation.  
 
Stimulation of whole blood with LPS  
LPS is a potent stimulus for the production of TNFα, IL-1β, IL-1ra and IL-10 in whole 
blood cultures. In undiluted whole blood, production of cytokines continues to rise 
with increasing concentrations of LPS (Figure 1). In contrast, in blood diluted in 
medium, the production of TNFα, IL-1β and IL-1ra reaches a maximum at 1 ng of 
LPS/ mL, whereas the production of IL-10 rises with increasing concentrations of 
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LPS. When corrected for the dilution in culture medium, the production of IL-10 in 
diluted samples is approximately 15-fold higher than in undiluted blood (Figure 1). 
Experiments to determine the kinetics of cytokine production in whole blood 
cultures showed a similar pattern in all subjects. In undiluted whole blood, stimulation 
with LPS (1 ng/mL) led to maximal concentrations of TNFα and IL-10 at 4 and 8 h, 
respectively, while IL-1β and IL-1ra continued to rise with time. In contrast, similar 
stimulation of diluted whole blood in tissue culture wells led to maximal 
concentrations of TNFα and IL-1β at 8 h, and of IL-10 at 24 h. Using short incubation 
periods, LPS induced higher concentrations of cytokines in undiluted whole blood. 
After 4 h of incubation of with LPS (1 ng/mL), the concentration of TNFα and IL-10 in 
undiluted blood was 3.2 ± 1.2 ng/mL and 168 ± 154 pg/mL respectively, compared 
with 1.1 ± 0.5 ng of TNFα/mL and 6 ± 1 pg of IL-10/mL in diluted whole blood. 
 
Stimulation of whole blood with PHA 
In whole blood, PHA induces a dose-dependent increase of IFNγ, IL-10, IL-1ra and 
TNFα (Figure 1). IL-1β was not detected in PHA-stimulated samples. Using PHA, the 
production of IL-10 in diluted whole blood was higher than in undiluted blood, 
whereas the opposite was true for IFNγ, TNFα and IL-1ra. After PHA-stimulation, 
absolute cytokine concentrations showed high inter-individual variation. However, the 
patterns of production with time were similar in all subjects tested. Stimulation of 
undiluted blood in a vacutainer tube with PHA (5 µg/mL) induced maximal 
concentrations of IFNγ, TNFα and IL-10 at 8 h of incubation, after which 
concentrations started to fall. Similar stimulation of diluted whole blood in tissue 
culture wells induced a continued rise in the concentrations of cytokines with time. 
Short periods of incubation (up to 8 h) led to similar concentrations of IFNγ and IL-10 
in the two systems used. 
 
 
Table 1.  
Ex-vivo cytokine production in undiluted whole blood from 20 healthy volunteers 
cytokine before stimulation LPS-stimulated PHA-stimulated no stimulus 
TNFα 0.05       ± 0.01 8.44     ± 2.55 nd 0.25    ± 0.22 
IL-1β 0.04       ± 0.01 7.7       ± 4.2 nd 0.04    ± 0.01 
IL-10  < 5 320      ± 235 127      ± 103 nd 
IFNγ 0.008     ± 0.002 nd 7.38    ± 8.94 0.011    ± 0.010 
IL-1ra 0.15       ± 0.06 10.05   ± 2.14 nd 0.88    ± 0.20 
For ex-vivo cytokine production, whole blood was incubated in closed vacutainer tubes at 370 
C for 6 h with or without the addition of 10 ng LPS /mL respectively 10 µg PHA /mL. TNFα, 
IL-1β, IL-1ra and IFNγ (ng/mL) and IL-10 (pg/mL) were measured in culture supernatants. 
The data are given as mean ± SD. nd = not done. 
  whole blood cytokine production 
  57
Figure 1.  Ex-vivo cytokine production after stimulation with increasing concentrations of LPS 
or PHA and incubation for 24 h. Cytokine production in vacutainer tubes with undiluted whole 
blood  (         )  and in tissue culture wells with whole blood in RPMI (1:4)  (         ) are shown 
as the mean (SD) in samples from 5 healthy subjects. 
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Variation of cytokine response in whole blood; correlation with cell count 
Interindividual and intra-individual variation of cytokine production was assessed in 
twenty healthy subjects using undiluted whole blood. Because stimulation of 
undiluted blood led to maximal concentrations of TNFα after 4 h of incubation and to 
maximal concentrations of IL-10 and IFNγ after 8 h, a common incubation period of 
six h was chosen. The amount of blood drawn into 2 mL vacutainer tubes showed 
very little variability (2.21 ± 0.078 g). The mean concentrations of TNFα, IL-1β, IL-
1ra, IL-10 and IFNγ produced ex-vivo in healthy volunteers are shown in Table 1. 
Inter-individual variation, defined as the standard deviation divided by the mean, 
ranged from 21% (IL-1ra) to 122% (IFNγ) (Table 2). Intra-individual variation of 
cytokine production, defined as mean variation (SD/mean) in 10 healthy volunteers, 
is also represented in Table 2. Intra-individual variation was smaller than inter-
individual variation. Diurnal variation was larger than day-to-day variation for all 
cytokines tested, except for IFNγ (Table 2). Concentrations of IFNγ after stimulation 
of blood from a single individual were more variable than concentrations of the other 
cytokines tested. IL-1ra showed very little intra-individual variation. Inter-assay 
variation was small and not different for the various cytokines measured (Table 2). 
LPS-induced production of TNFα (r2 = 0.31; P = 0.017) and IL-1β (r2 = 0.44 ; P = 
0.002), significantly correlated with the absolute number of monocytes in the 20 
healthy subjects tested. Production of IL-1ra, IL-10 and IFNγ did not correlate with the 
absolute T-lymphocyte or monocyte count (data not shown), although a slight and 
insignificant correlation was found between the number of CD8-positive cells and the 
production of IFNγ (r2 = 0.19; P = 0.06).  
 
 
 
Table 2. 
Inter- and intra-individual variation of ex-vivo cytokine production in whole blood  
 
stimulus cytokine inter-individual 
variation (n=20)*
day to day 
variation (n=10)*
diurnal 
variation (n=10)* 
inter-assay 
variation (**) 
LPS TNFα 30 %           12 % 13 % 12,6 %     (37) 
 IL-1β 55 %           23 % 32 %         12,1 %     (40) 
 IL-10 73 %           17 % 25 %          12,7 %     (17) 
 IL-1ra 21 %           5 % 8 %          13,9 %     (37) 
PHA IFNγ 122 %  47 % 32 %  13,6 %     (26) 
 IL-10 73 %  16 % 35 %  12,7 %     (17) 
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To determine the variation in ex-vivo cytokine production, undiluted whole blood was 
incubated in closed vacutainer tubes at 370 C for 6 h after the addition of 10 ng LPS /mL 
respectively 10 µg PHA /mL. Blood from 20 healthy volunteers was sampled and stimulated 
on the same day between 8.00 and 9.00 a.m. (inter-individual variation). Three different 
blood samples from 10 healthy subjects were drawn and stimulated on three separate days 
between 8.00 and 9.00 a.m (day-to-day variation) and on the same day at 8.00 a.m., noon 
and 16.00 p.m respectively (diurnal variation). Interindividual variation is SD/mean of 20 
individuals (x 100%). Day-to-day and diurnal variation represents the average of variation 
(SD/mean x 100%) in 10 individuals.  * = number of patients; ** = number of assays done. 
Antigen-specific stimulation with BCG, PPD and MTB-culture filtrate 
(BCG). No detectable concentrations of cytokines were found after stimulation 
of whole blood with 105 or 106 live BCG CFU/mL. Using 107 or 108 BCG CFU/ mL, 
stimulation of undiluted whole blood led to a dose-dependent production of IFNγ at 24 
h of incubation, irrespective of the tuberculin-skin-test of the donor. In four 
individuals, the mean concentration in plasma after incubation with 108 BCG CFU/mL 
was 4.9 ng/mL, with a maximal concentration of 9.6 ng/mL in one BCG-immunized 
individual. Small and variable amounts of TNFα (1.55 ± 2.01 ng/mL) were detected, 
independent of PPD-status. The concentrations of IL-1β and IL-10 were under or just 
above their limits of detection after BCG-stimulation.  
(PPD). PPD induced a dose-dependent increase of IFNγ in the whole blood of 
two skin-test positive but not of three skin-test negative individuals. In undiluted 
whole blood, maximal concentrations of 962 and 2000 pg IFNγ /mL were reached 
after 24 h of incubation with 100µg PPD/mL. In diluted whole blood, maximal 
concentrations of 136 and 633 pg/mL were found after stimulation with 10 µg 
PPD/mL blood. Using 100 µg PPD /mL, small quantities of TNFα (mean 0.4 ng/mL) 
were found, irrespective of the skin-test status. No IL-1β or IL-10 was found after 
stimulation with PPD. Experiments were performed to determine the kinetics of 
antigen-specific cytokine production. In three tuberculin-skin-test positive individuals, 
maximal concentrations of IFNγ (195 -1346 pg/mL) were found after 24 h of 
incubation of whole blood with PPD, while in diluted whole blood the concentrations 
continued to rise with longer periods of incubation (106 - 3880 pg/mL at 72 h of 
incubation).  
(MTB-culture filtrate).  Irrespective of tuberculin-skin-test status, MTB-culture 
filtrate induced a dose-dependent increase of TNFα in whole blood from three 
individuals. In undiluted blood, 100 µg of MTB-culture filtrate/ mL blood led to a 
maximal concentration of TNFα (mean 8.6 ± 3.0 ng/mL) after 4 h of incubation. In 
addition, an IFNγ response was found in three tuberculin-skin-test positive 
individuals. Maximal concentrations (1850-5250 pg/mL) were found after 24 h of 
incubation of diluted whole blood with 100 µg MTB-culture filtrate / mL. 
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Antigen-specific stimulation with PPD; comparison of patients and controls. 
Antigen-specific stimulation with PPD (10µg/mL) was used to compare IFNγ 
production in patients with active tuberculosis and healthy controls (Figure 2). After a 
24-hour incubation period the mean concentration of IFNγ in 13 patients was 769 
pg/mL (range 15-3350) compared with 980 pg/mL (range 90-5676) in 13 tuberculin-
skin-test-positive individuals and 18 pg/mL (range 4-50) in 13 tuberculin-skin-test 
negative control subjects. Five out of 13 patients with active tuberculosis had an 
almost absent antigen-specific production of IFNγ. 
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Figure 2 
Production of IFNγ (log pg/mL) in whole blood from 13 patients with active pulmonary TB, 13 
PPD-positive and 13 PPD-negative control subjects. Undiluted whole blood was stimulated 
with 10 µg /ml of PPD and incubated for 24 hr. The horizontal bar represents the median for 
each group. 
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Discussion 
 
In this paper we describe the development of a clinically useful whole blood cytokine 
test to assess the ex-vivo production of various cytokines in TB-patients and healthy 
volunteers. A whole blood culture system using closed vacutainer tubes appeared to 
be most suitable for field studies, since it is easy to perform with a very small risk of 
contamination under semi-sterile conditions. Spontaneous production of cytokines in 
these systems is low, with the exception of IL-1ra. Low-dose LPS induces the 
production of TNFα, IL-1β and IL-1ra, cytokines that are probably mainly produced by 
monocytes. PHA induces the production of IFNγ by T-lymphocytes. IL-10, which is 
produced by both monocytes and lymphocytes, is induced by both LPS and PHA. 
BCG induces the production of proïnflammatory cytokines. PPD and MTB-culture 
filtrates induce the production of IFNγ in skin-test positive individuals but not in skin-
test negative controls. In addition MTB-culture filtrate induces production of TNFα, 
irrespective of tuberculin-skin-test status.  
 
To the best of our knowledge, the use of whole blood cultures for cytokine production 
in research involving TB-patients has only been reported by Friedland et al. [11,12]. 
No disease specific stimuli were mentioned in their reports and the production of 
IFNγ, a pivotal cytokine in host defense against MTB, was not reported. In other 
areas of cytokine research whole blood cultures are increasingly used. However, 
since its first description in 1982 [9], the use of whole blood cultures for cytokine 
studies has been poorly standardized. There has been much variation in the stimuli 
and exact conditions used for incubation [13-16]. The present study was aimed at 
optimizing a whole blood cytokine test for the study of TB-patients. Ex-vivo cytokine 
production was assessed in two ways; either by culturing whole blood diluted in 
medium in tissue culture wells or by stimulating undiluted blood in closed vacutainer 
tubes. The latter has proven to be a simple and reliable method for ex vivo production 
of cytokines under primitive conditions [10,17,18]. The dilution of blood and 
incubation in tissue culture wells facilitates the use of much smaller volumes of blood 
and longer incubation periods, both of which may be advantageous for the detection 
of cytokines with a lower production rate (e.g. IL-10). However, stimulation in tissue 
culture wells requires sterile conditions, and the manipulation of cells may lead to 
their spontaneous activation. In earlier experiments stationary and agitated samples 
showed similar results. 
 
The characteristics of whole blood cytokine assays determine both its drawbacks and 
advantages. Even with optimal standardization many cellular and humoral variables 
cannot be controlled. Plasma components such as cortisol [19], lipids [20] or soluble 
cytokine receptors [21] may influence results by enhancing or inhibiting cell-
stimulation and inactivating or capturing secreted cytokines. However, all these 
chapter 3                                                                                                                             
 62
effects reflect in vivo conditions, whereas artefacts are created by separating cells 
and eliminating plasma components. Person to person variation in cytokine 
production is well known. The extent of variation found in this whole blood assay, 
clearly not the same for all cytokines tested, determines the significance of 
differences found between subjects. Diurnal variation underlines the importance of 
maximal standardization of cytokine assays.  
  
Aiming for a disease-specific whole blood cytokine test to be used in TB-patients, 
three specific stimuli were evaluated. Live BCG induced the production of 
proïnflammatory cytokines, irrespective of tuberculin-skin-status. In contrast, PPD 
and MTB-culture filtrate induced production of IFNγ in skin-test-positive individuals 
only. In addition MTB-culture filtrate also induced the production of TNFα, 
irrespective of tuberculin-skin-test status. Circulating memory T-cells probably 
account for the antigen-specific production of IFNγ in immunized individuals. Antigen-
specific stimulation may therefore be used as an alternative to the tuberculin skin 
test. This approach prevents sensitization and abolishes the need for a return visit. In 
addition, the sensitivity and specificity of in vitro testing may be higher [22,23]. Apart 
from its diagnostic value, antigen- specific stimulation may help to assess the 
prevalence and underlying mechanisms of anergy in latent infection and active 
tuberculosis [24-27]. In this study, antigen-specific ex-vivo production of IFNγ was 
very high in some patients but almost absent in others. Longitudinal studies are 
needed to see if this difference, which is suggestive of specific T-cell 
unresponsiveness, correlates with a different disease outcomes. 
  
In conclusion, a simple whole blood test has been developed for non-specific and 
disease specific ex-vivo production of monocyte and T-cell derived cytokines. For 
most purposes, stimulation and incubation of heparinized blood in closed tubes has 
major advantages in terms of simplicity, risk of contamination and minimal in vitro 
manipulation. When focusing on T-cell cytokines, the addition of culture medium may 
be used to provide a more sensitive test using very small volumes of blood.  
The characteristics of whole blood cultures wil permit the study of cytokine networks 
in both physiological and pathophysiological conditions. Since the outcome of 
mycobacterial infections is under the influence of pro- and anti-inflammatory 
cytokines produced by monocytes and T-lymphocytes, the assessment of non-
specific and disease-specific cytokine production in whole blood from patients with 
active tuberculosis or latent infection may increase our knowledge about 
pathogenesis and help to direct and monitor possible immunotherapy.  
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Abstract 
 
 
In tuberculosis, cellular immunity is considered to be responsible for eradication of 
infection but also for damage of host tissues. In animal models, the balance between 
Th1-type cytokines, especially interferon-γ (IFN-γ), and Th2-type cytokines, primarily 
interleukin-4 (IL-4), seems crucial for these effects. Reports on Th1-type and Th2-
type cytokines in human tuberculosis are conflicting, and little is known about their 
role in tissue damage. To address these issues, flow cytometric assessment of 
cytokine responses was performed in HIV-seronegative patients with active 
tuberculosis and healthy controls. Patients and controls showed no significant 
difference in expression of IFN-γ. However, patients demonstrated a striking increase 
in production of IL-4, in CD4+ as well as CD8+ T-cells. Most remarkably, the 
expression of IL-4 was especially elevated in patients with cavitary tuberculosis. The 
Th2-type response with increased production of IL-4 in patients with tuberculosis may 
antagonize host defense and lead to tissue necrosis. 
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Introduction 
 
In tuberculosis, cell-mediated immunity (CMI) is responsible for eradication of 
mycobacteria. The major effector mechanism of CMI is thought to be the activation of 
infected macrophages by Th1-type cytokines, particularly IFN-γ. The protective 
effects of Th1-type cytokines may be antagonized by Th2-type cytokines, primarily 
IL-4 [1]. Like in leprosy the balance between Th1-type and Th2-type cytokine 
responses in tuberculosis may influence mycobacterial growth as well as 
immunopathology.  
 
In human tuberculosis, studies on the patterns of T-cell cytokines have met with 
conflicting results  [1-5]. Uncertainty also remains about the cellular source of the 
various cytokines in tuberculosis. CD4+ T-cells have long been regarded as the major 
immune regulatory cells. CD8+ T-cells were viewed as CD4-dependent, IFN-γ 
secreting cytotoxic cells, whose main function was the MHC class I-restricted lysis of 
infected host cells. Therefore, most studies on T-cell cytokine profiles have 
concentrated on CD4+ T-cells, although expression of IL-4 has also been 
demonstrated in CD8+ T-cells in mycobacterial infections.  
 
In atypical mycobacterial infections in man, a Th1-type response is essential [6]. In 
murine tuberculosis, Th1-type cytokines are necessary for protective immunity [7], 
while increased production of Th2-type cytokines may be responsible for tissue 
damage [8,9].  
 
To further evaluate the Th cytokine response in human tuberculosis, to establish the 
cellular source, as well as the possible role in tissue damage, cytokine production by 
circulating T-lymphocytes of patients with active tuberculosis with and without 
cavitation was investigated by flow cytometry and compared to tuberculin-skintest 
positive controls. 
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Methods 
 
Subjects 
Eighteen HIV-seronegative patients with active pulmonary tuberculosis were included 
at a University Hospital in Jakarta, Indonesia. Eleven were male (61%) and the 
average age was 32.8 years (range 16-66). Most patients had extensive pulmonary 
involvement; 11 had pulmonary cavities, and four had miliary disease. Fourteen 
tuberculin-skin-test positive healthy individuals of similar age and sex were recruited 
as controls.  
 
Cell stimulation and immunofluorescent staining. 
Intracellular cytokines by circulating T-lymphocytes were detected as described [10], 
with minor modifications. Briefly, 1 x 106 peripheral blood mononuclear cells (PBMC), 
isolated by density centrifugation, were stimulated with 25 ng/ml phorbol myristic 
acetate (PMA, Sigma, Zwijndrecht, the Netherlands) and 1 µg/ml ionomycin (Sigma) 
in the presence of 10 µg/ml brefeldin (Sigma), to inhibit protein secretion. Due to the 
low number of antigen-specific T-cells in the circulation, stimulation with PPD did not 
yield a detectable signal (not shown). After 4 hours of incubation cells were fixed and 
permeabilized using Fix and Perm (Caltag, Burlingame, Ca.) according to the 
manufacturer’s guidelines. CD4 cannot be used for phenotypic subsetting after 
stimulation since it is heavily down regulated by PMA [11]. CD3-PE-Cy5 and CD8-PE 
(Dako, Cilostrup, Denmark) were therefore used to define CD8+ T-cells and CD8- T-
cells (mainly CD4+ T-cells), further referred to as CD4+ T-cells. After 
permeabilization, cells were incubated for 20 minutes with anti-IFN-γ-FITC and/or 
anti-IL-4-PE (Pharmingen, San Diego, Ca.). PBMC from several patients and control 
subjects were assayed simultaneously. Interassay variation was less than 15% (not 
shown).  
 
Flow cytometric analysis  
Cells were analyzed for immunofluorescence in a Coulter Epic XL (Coulter, Hialeah, 
Fl.). IL-4+ and IFN-γ + cells were determined in the CD4+ CD3+ and CD8+ CD3+ cell 
population in separate measurements (minimum: 50000 cells). Spontaneous 
expression of cytokines was similarly low in patients and control subjects (mean: 
0.75% for IFN-γ and 0.6% for IL-4). For final analysis, residual expression of 
cytokines was subtracted from expression after maximal stimulation. 
 
Statistical Analysis 
Comparisons between groups were performed using Mann-Whitney-U-test and Chi2-
test. P-values were two-sided and the level of significance was set at P< 0.05. 
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Results 
 
T-cells from TB-patients do not produce more IFN-γ than controls.  
After stimulation of PBMC, IFN-γ was detected in CD8+ and CD4+ T-cells from all 
patients and controls. Within the subset of CD4+ T-lymphocytes, the percentage of 
cells staining positive for IFN-γ was almost identical in the two groups, ranging from 
7.8-29.9% (mean: 12.7%) in patients and 4.7-21.3% (mean: 11.8%) in controls. 
Within CD8+ T-cells, expression of IFN-γ was detected in 29.0% (range 10-65%) of 
stimulated cells from patients, compared with 21.3% (5.7-42%) in controls (P = .16). 
 
Both CD4+ and CD8+ T-cells from TB-patients produce more IL-4 than controls.  
After stimulation of PBMC, T-lymphocytes also expressed IL-4. Both in CD4+ and in 
CD8+ T-cells, production of IL-4 was significantly higher in patients with tuberculosis 
than in healthy controls. The percentage of CD4+ T-cells positive for IL-4 ranged from 
1.5-7.3% in patients (mean: 3.9%) and from 0.4–2.4% (mean: 1.4%) in control 
subjects (P < .001). In CD8+ T-cells expression of IL-4 exhibited a wide range in 
patients (0.4–21.0%; mean 4.7%) and was low or undetectable (range: 0–2.0%; 
mean 0.7%) in control subjects (P < .005). Five patients expressed IL-4 in more than 
5% of CD8+ T-cells. Analysis of a second sample of these 5 individuals yielded 
similarly high expression (6.9-18.7 %).  
 
The ratio of IFN-γ and IL-4 production is decreased in TB-patients. 
The ratio of production of IFN-γ to IL-4 in single individuals has been used as a 
marker for Th1-Th2 balance, with a lower ratio pointing towards a Th2 response [1]. 
For CD4+ cells, this ratio was much lower in patients than in controls (3.9 vs. 9.6;   P 
< .001). The same was true for CD8+ T-cells (21.6 vs. 36.2; P < .05). Figure 1 
depicts the simultaneous detection of IFN-γ and IL-4 in circulating T-cells from a 
representative patient after in-vitro stimulation of PBMC. Unstimulated cells from this 
patient demonstrate spontaneous ex-vivo production of IFN-γ in 0.9% of CD3+ cells 
(Fig.1A). Stimulation of cells induces expression of IFN-γ in 10.1% of T-cells 
(Fig.1B). In the same patient, 0.6% of unstimulated T-cells and 13.0% of stimulated 
T-cells express IL-4. Double staining for IFN-γ and IL-4 in single T-cells was equally 
low in all individuals examined (<1.2%).  
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Figure 1 
Expression of IL-4 and IFN-γ in circulating T-cells from a patient with cavitary pulmonary 
tuberculosis. Flow cytometric assessment of cell-specific cytokine response in unstimulated 
(A) and stimulated (B) PBMC was performed using immunfluorescent antibodies against 
CD3, IFN-γ and IL-4. Depicted is the % of CD3+ cells expressing IFN-γ or IL-4. 
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Expression of IL-4 and IFN-γ in TB patients with pulmonary cavities, patients without 
cavities and PPD-positive healthy controls. Depicted are the % of CD4+ and CD8+ T-cells 
expressing IL-4 (A, B) and IFN-γ (C, D). Each dot represents one individual. Horizontal bar 
is median. Significant differences in production of IL-4 were found between groups (Mann-
Whitney-U-test; *** P < 0.0005; ** P < 0.001; * P < 0.05). No significant differences in 
production of IFN-γ were found. 
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Cavitary tuberculosis is associated with increased IL-4 production  
Next, expression of cytokines was related to clinical characteristics. Extent and 
nature of pulmonary involvement, as exemplified by the presence of cavities on chest 
X-ray, demonstrated a correlation with production of IL-4, but not with IFN-γ (Fig 2). 
The median number of CD8+ T-cells expressing IL-4 was 3.7% in eleven patients with 
pulmonary cavities compared with 1.1% in seven patients without cavities (P < .05). 
In contrast, the number of CD8+ T-cells expressing IFN-γ was almost similar in 
patients with or without pulmonary cavities (27.0% vs. 22.4%; P = .22). As a result, 
the ratio of IFN-γ to IL-4 production in CD8+ T-cells was much lower in cavitary 
disease (median: 7.4 vs. 26.5; P < .05). Within the subset of CD4+ cells, expression 
of IL-4 also tended to be higher in patients with pulmonary cavities (4.5% vs. 3.0%; P 
= .19). Expression of IFN-γ and ratio of IFN-γ to IL-4 in CD4+ was similar in both 
groups. IL-4 was more frequently expressed in CD8+ T-cells than in CD4+ cells in the 
majority (63%) of patients with pulmonary cavities, while this never occurred in 
patients without cavities (P = .01).  
Four patients with miliary disease, all severely ill, exhibited much lower IL-4 
expression, especially in CD8+ T-cells. The percentage of CD8+ T-cells expressing IL-
4 was 0.8 % in miliary and 7 % in cavitary tuberculosis (P < .05), while expression of 
IFN-γ was not significantly different (27.3% vs. 32%, P = 0.6).  
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Discussion 
 
In this study, we demonstrated that patients with pulmonary tuberculosis exhibit a 
markedly increased capacity for IL-4 production in circulating T-lymphocytes. 
Production of IL-4 was not only established in CD4+ T-cells, the primary cytokine-
producing cell in the Th1-Th2 concept, but also in CD8+ T-cells. Interestingly, the 
highest expression of IL-4 in these two cellular subsets occurred in patients with 
pulmonary cavities, suggesting a role for IL-4 in the development of tissue damage.  
 
It is unclear whether increased production of IL-4 causes, or merely reflects severe 
disease. With regard to the first notion, IL-4 may reduce killing of mycobacteria by 
phagocytes through inhibition of IFN-γ production [1]. However, in our study, in-vitro 
production of IFN-γ was not affected. With regard to the second possibility, severely 
ill patients with miliary tuberculosis did not demonstrate increased expression of IL-4, 
suggesting that IL-4 is not just a marker of disease severity as such. Our findings 
suggest that increased production of IL-4 plays a role in tissue necrosis. The 
deleterious role of IL-4 in various infectious diseases, including leprosy and 
leishmaniasis, has been ascribed to its suppression of the protective inflammatory 
response of Th1-type cytokines [1]. However, IL-4 may also induce or intensify tissue 
damage; only when primed for production of IL-4, mice infected with saprophytic 
mycobacteria develop peribronchial and intersititial necrosis when [8]. Likewise, 
overexpression of IL-4 in PPD-sensitized mice increased the size and cellularity of 
PPD-induced granulomas [9]. Thus, these reports point to involvement of IL-4 in 
tissue damage in mycobacterial infections in mice, and our observations extend this 
conclusion to human tuberculosis. 
 
Another interesting finding is the expression of IL-4 in CD8+ T-cells, which are usually 
viewed as CD4+-dependent, IFN-γ-secreting cytotoxic cells. Until now, the role of 
CD8+ T-cells in human tuberculosis remains controversial. Specific CD8+ T-cell 
clones, which recognize M. tuberculosis infected cells and react with high expression 
of IFN-γ, have been obtained from patients [12]. Other reports have challenged a 
protective role of CD8+ T-cells. Killing of M. tuberculosis by human macrophages is 
dependent on CD4+-cells, but independent of CD8+-cells [13]. High umbers of CD8+ 
cells in alveolar lavage of TB-patients correlated with delayed resolution of disease 
[14]. It is conceivable that CD8+ T-cells exert their counterproductive role through 
secretion of IL-4.  
 
The Th2-type response found in this study of human tuberculosis is in agreement 
with previous reports [2,3]. In culture supernatants, IL-4 may not be detectable [4,5], 
since production of IL-4 splice variants, or binding of secreted IL-4 to soluble or 
cellular receptors interferes with this assay [15]. To circumvent this problem and to 
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allow for cell specific analysis of Th status in tuberculosis, we used flow cytometric 
detection of intracellular cytokine expression, which is unaffected by natural release 
of cytokine inhibitors or receptors [10]. 
 
As protective immunity in tuberculosis depends on a cellular host response, with an 
important role for CD4+ T-helper cells, the Th1-Th2 concept has long thought to be 
important in the outcome after infection with M. tuberculosis. In agreement with 
several other intracellular infections, a Th1-type response would be beneficial, while 
a Th2-type response would be ineffective or even harmful in tuberculosis. An 
essential role for Th1-type cytokines has been established in murine tuberculosis [7] 
and in nontuberculous mycobacterial infections in man [6]. Assessment of Th1- and 
Th2-type cytokine patterns after experimental murine infection has demonstrated 
high production of IFN-γ in early infection versus increased production of IL-4 during 
the chronic phase of infection that was characterized by progressive fibrosis and 
necrosis [8].  
 
The finding of a correlation between a systemic Th2-type cytokine response and 
tissue necrosis in patients with pulmonary tuberculosis is instrumental in explaining 
the divergent manifestations of mycobacterial disease in humans. Increased 
understanding of the role of cytokines in determining the delicate balance between 
protective immunity and immunopathology in tuberculosis may help the design of 
successful immunotherapy. 
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Abstract 
 
 
Pentoxifylline and thalidomide have been used to downregulate production of 
TNFα in several disease entities including mycobacterial infections and 
autoimmune disorders. These drugs inhibit the production of TNFα by different 
mechanisms, but little is known about possible synergism and modulation of other 
cytokines. Pentoxifylline and thalidomide inhibited the in-vitro stimulated 
production of TNFα, IL-1β and IFNγ in blood mononuclear cells. No significant 
modulation of antiinflammatory cytokines was found. When used together, these 
agents demonstrated additive inhibition, but no synergism. Modulation of cytokine 
response was similar when different stimuli were used, including M.tuberculosis 
in tuberculin-positive individuals.  
Therefore, the balance between efficacy and toxicity may be more favourable 
when pentoxifylline and thalidomide are used together instead of either drug 
alone. Clinical studies are needed to establish this advantage when anti-cytokine 
strategies are considered. 
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Introduction 
 
Tumour necrosis factor-α (TNFα) is essential to host immunity, but excessive 
production of TNFα and other proinflammatory cytokines may have deleterious 
effects in acute and chronic inflammatory conditions. TNFα activity has been 
implicated as a central mediator in the pathogenesis of a wide range of human 
diseases including autoimmune disorders, cancer cachexia and endotoxic shock [1]. 
In human tuberculosis, clinical deterioration after initiation of therapy is accompanied 
by an increase in TNFα production [2]. Similarly, effective treatment of leprosy may 
be followed by the development of erythema nodosum leprosum, a toxic syndrome 
associated with excess production of TNFα [3,4]. Therefore, TNFα may be an 
important target for pharmacological intervention.  
Pentoxifylline, a phosphodiesterase inhibitor licensed for the treatment of 
claudication, and thalidomide, which has been used as an antiemetic and sedative 
drug in the past, both inhibit the production of TNFα [5]. These substances have 
been examined as immunosuppressive or immunomodulatory agents in a number of 
disease entities including aphtous ulcera during HIV-infection, Behcet’s disease, 
Still’s disease, rheumatoid arthritis and graft versus host disease. With regard to 
mycobacterial infections, pentoxifylline and thalidomide have been used successfully 
in erythema nodosum leprosum [3,6]. Similarly, thalidomide accelerated weight gain 
and inhibited TNFα production [7] in active tuberculosis, while pentoxifylline showed 
moderate beneficial effects in HIV-seropositive pulmonary tuberculosis [8]. 
Pentoxifylline inhibits the transcription of TNFα mRNA in vitro [5], while 
thalidomide lowers the production of TNFα by enhancing TNFα mRNA degredation 
[9]. Since pentoxifylline and thalidomide have different mechanisms of action, 
combined therapy may lead to synergism, and thus be advantageous in terms of 
effectiveness and toxicity. Indeed, in patients with refractory rheumatoid arthritis [10], 
and in a patient with Still’s disease [11], the use of both agents together had a more 
potent clinical effect than pentoxifylline or thalidomide alone. Synergism of 
pentoxifylline and thalidomide in the inhibition of LPS-induced production of TNFα by 
isolated monocytes in vitro was claimed in a previous report [9]. Contradictory reports 
have been published on the effect of these drugs on antiinflammatory cytokines, 
which may antagonise the effects of proinflammatory cytokines [12-14].  
We investigated the effect of pentoxifylline and thalidomide, alone and in 
various combinations, on proinflammatory cytokines, primarily TNFα, interleukin-1β 
(IL-1β) and interferon-γ (IFNγ), and on antiinflammatory cytokines like IL-1-receptor 
antagonist (IL-1ra) and interleukin-10 (IL-10), using in-vitro stimulation of human 
PBMC with different stimuli. 
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Methods 
 
Stimulation of human peripheral blood mononuclear cells (PBMC) 
Blood from 8 healthy individuals was used in these experiments. In experiments 
using antigen-specific stimulation with M. tuberculosis, blood from 4 tuberculin-
positive individuals was used. Isolation of peripheral blood mononuclear cells 
(PBMC) was performed as described [15], with minor modifications. Briefly, venous 
blood was drawn in to 10 mL tubes containing 0.2 mg of EDTA (Monoject, ’s-
Hertogenbosch, the Netherlands). The PBMC fraction was obtained by density 
centrifugation of blood (diluted 1:1 in pyrogen free saline) over Ficoll-Paque 
(Pharmacia Biotech AB, Sweden). PBMC were washed twice in saline, and 
resuspended in culture medium (RPMI 1640 Dutch modification, ICN Biomedicals, 
Inc., Costa Mesa) supplemented with heat inactivated human serum 5%, 
gentamicine 1%, L-glutamine 1% and pyruvate 1%). The cells were counted in a 
Coulter counter (Coulter Electronics, Mijdrecht, The Netherlands) and the number 
was adjusted to 5x106 cells/mL. 5x105 PBMC/ well were incubated in 96-well tissue 
culture plates (Greiner, Alphen a/d Rijn, The Netherlands) and stimulated with 1 
ng/mL lipopolysaccharide (E.Coli 055:B5, Sigma, St Louis, MO.), 1 µg/mL 
phytoheaemoagglutinin (PHA-P, Sigma) or 1 µg/mL M. tuberculosis sonicate (kindly 
provided by Dr. A.H.J. Kolk, Royal Tropical Institute, Amsterdam, The Netherlands). 
PBMC were cultured in the presence or absence of 1,10 or 100 µg/mL of 
pentoxifylline (Hoechst Pharma) and/or thalidomide (Penn Pharmaceuticals, UK). 
Thalidomide was dissolved in DMSO at a concentration of 25 mg/mL (2.5 % w/v). In 
preliminary experiments, DMSO was found to potentiate LPS-induced production of 
cytokines. Therefore, a similar final concentration of DMSO was used in all cultures 
performed. After 24 hours of incubation (TNFα, IL-1β, IL-1ra, IL-10) or 72 hours of 
incubation (INFγ), the supernatants were collected and stored at –70o C until 
analysis. 
 
Cytokine measurements 
In all samples the concentrations of TNFα, IL-1β, and IL-1ra were measured by 
specific radioimmunoassays (detection level: 40 pg/mL) as described [16]. 
Concentrations of IFNγ and IL-10 were measured by ELISA (detection level: 4 pg) 
according to the manufacturer (Pelikine, CLB, Amsterdam, the Netherlands). 
 
Statistics 
Comparisons between related culture samples were performed using the Wilcoxon-
signed-rank-test (SPSS 6.3 software). For assessment of possible synergism 
between pentoxifylline and thalidomide, multilevel regression analysis was performed 
(SAS 6.12, SAS institute, Cary, NC). P-values were two-sided and the level of 
significance was set at p < 0.05. 
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Results    
 
Cytokine production; separate use of pentoxifylline and thalidomide.  
Unstimulated PBMC did not produce significant quantities of cytokines. Likewise, 
pentoxifylline or thalidomide did not induce cytokine production by unstimulated 
human PBMC (not shown). After stimulation with 1 ng of LPS, culture supernatants 
contained high concentrations of TNFα (mean: 2.2 + 0.5 ng/mL) and IL-1β (mean: 
15.0 + 6.6 ng/mL). Both pentoxifylline and thalidomide inhibited the LPS-induced 
production of TNFα in a dose-dependent fashion (Figure 1A). At 1 µg/mL, 
thalidomide was more potent than pentoxifylline (P < 0.05). Maximal inhibition with 
thalidomide was already present at 10 µg/mL. With the highest concentration used, 
maximal inhibition of LPS-induced production of TNFα was 74% for pentoxifylline 
compared with 31% for thalidomide (P < 0.05). Production of IL-1β was also inhibited 
by pentoxifylline and thalidomide (Fig.1B). However, maximal inhibition of IL-1β was 
50% for thalidomide compared with 19% for pentoxifylline (P < 0.05). Maximal effects 
were found with 10 µg/mL of both drugs. IL-1ra production was not modulated 
significantly by either drug (Figure 1C). 
After stimulation of PBMC with PHA (1µg/mL), high concentrations of IFNγ (mean: 
8995 + 6220 pg/mL) were found in culture supernatants. Both pentoxifylline and 
thalidomide inhibited the PHA-induced production of IFNγ (Figure 2A). Pentoxifylline 
demonstrated a dose-dependent effect with maximal inhibition of 84%. Similar to its 
effect on LPS-induced production of TNFα, thalidomide demonstrated its maximal 
inhibitory effect at 10 µg/mL, and was less potent than pentoxifylline at 100 µg/mL (P 
< 0.01). In addition to IFNγ, PHA induced production of IL-10 by PBMC (mean: 912 + 
195 pg/mL). Only pentoxifylline had a significant, although modest effect on the 
production of IL-10 (Figure 2B). With 1 and 10 µg/mL of pentoxifylline, 17% inhibition 
of IL-10 production was found, while at higher concentrations individuals showed 
more variable responses.
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Figure 1.  
The effect of thalidomide (closed circles) and pentoxifylline (open squares) on LPS-
induced TNFα, IL-1β and IL-1ra production by human PBMC. * p < 0.05 vs. baseline. 
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Figure 2.  
The effect of thalidomide (closed circles) and pentoxifylline (open squares) on PHA-
induced IFNγ and IL-10 production by human PBMC. * p < 0.05 vs. baseline. 
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Modulation of M. tuberculosis (MTB) induced cytokine production was also 
investigated. In these experiments, MTB led to the production of TNFα (2990 + 1660 
pg/mL) and IL-1β (8740 + 2030 pg/mL), as well as to a variable production of IFNγ 
(median 8350 pg/mL; range 310 – 29000), and modest production of IL-10 (mean 43 
+ 18 pg/mL). Similar to their effect on LPS-induced cytokine production, pentoxifylline 
and thalidomide inhibited MTB-induced production of TNFα (Figure 3A), and IL-1β 
(data not shown). Thalidomide showed a trend towards a more potent inhibition when 
used after stimulation with MTB than after stimulation with LPS. However, this 
difference was not significant. Production of IFNγ after antigen-specific stimulation 
with MTB was also inhibited by pentoxifylline and thalidomide (Figure 3B). Again, the 
inhibitory effect of thalidomide appeared to be more pronounced after stimulation with 
MTB than after stimulation with PHA (76% vs. 35% inhibition; P < 0.05). With regard 
to the production of IL-10, we found small and variable effects of pentoxifylline and 
thalidomide (Figure 3C). Pentoxifylline had no significant inibitory effect, while 
thalidomide at the highest concentration significantly inhibited production of IL-10 (37 
+ 16 %). 
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Figure 3.  
The effect of thalidomide (closed circles) and pentoxifylline (open squares) on MTB
sonicate-induced TNFα, IFNγ and IL-10 production by human PBMC. * P < 0.05 vs. 
baseline. 
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cytokine production; combined use of pentoxifylline and thalidomide. 
In the same experiments, pentoxifylline and thalidomide were used together to 
evaluate possible synergism of inhibition of cytokine response. Pentoxifylline and 
thalidomide had additive effects on LPS-induced production of TNFα (Fig. 4A). No 
synergistic, as opposed to mere additive effects, exist between the two drugs for the 
inhibition of TNFα, as demonstrated by multilevel regression analysis (P  > 0.05). The 
moderate inhibitory effect of pentoxifylline on the production of IL-1β did not 
significantly add to the effect of thalidomide alone (not shown). No significant 
inhibition of the production of IL-1ra was found with combined use of pentoxifylline 
and thalidomide, even at the highest concentrations. Inhibition of PHA-induced 
production of IFNγ was more pronounced with the combination of pentoxifylline and 
thalidomide (Figure 4B). However, this inhibition was additive and not synergistic (P  
> 0.05).  IL-10 was not inhibited by the combination of pentoxifylline and thalidomide.  
When PBMC were stimulated with M. tuberculosis sonicate, the combination of 
pentoxifylline and thalidomide had additive inhibitory effects on the production of 
TNFα and IFNγ, similar to the additive effect of these drugs after stimulation with LPS 
or PHA (not shown). Production of antiinflammatory cytokines was not inhibited by 
the combination of pentoxifylline and thalidomide. 
 
 
Discussion 
 
The results presented in this study show that after stimulation of PBMC with LPS, 
both pentoxifylline and thalidomide inhibited the production of TNFα and IL-1β. 
Pentoxifylline more strongly inhibited TNFα, while thalidomide more strongly inhibited 
IL-1β. After stimulation with PHA, both agents diminished secretion of IFNγ. No 
significant modulation of antiinflammatory cytokines IL-10 and IL-1ra was found. 
When used together, pentoxifylline and thalidomide had an additive inhibitory effect 
on the release of TNFα and IFNγ. Similar results were achieved when disease-
specific stimulation with M. tuberculosis sonicate was used. 
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The combined effect of thalidomide (TLD) and pentoxifylline (PTX) on the LPS-induced 
production of TNFα (A), and on the PHA-induced production of IFNγ (B).  
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Using either pentoxifylline or thalidomide, the ex-vivo production of proinflammatory 
cytokines has been examined under various conditions. The results of the present 
study demonstrate inhibition of TNFα and of IL-1β by pentoxifylline after stimulation 
with LPS. This is in line with other studies showing that pentoxifylline downregulates 
not only TNFα, but also IL-1β [12,14,17], and IL-12 [14]. In this study, as reported 
before [9,18], thalidomide inhibited production of TNFα, irrespective of the stimulus 
used. Thalidomide was also found to inhibit IL-1β, which is in accordance with a 
study demonstrating that potent thalidomide analogues downregulated IL-1β in 
PBMC [19]. However, according to another report, in which lymphocytes were 
removed, thalidomide did not affect IL-1β [18]. This suggests that lymphocytes are 
required for the inhibitory effect of thalidomide on IL-1β.  
 
Both pentoxifylline and thalidomide have been used in mycobacterial infections. In 
tuberculosis, excess production of TNFα and other proinflammatory cytokines is 
thought to be involved in detrimental tissue necrosis, and to be responsible for the 
weight loss, fever and other constitional symptoms. Indeed, thalidomide increased 
the body weight of patients with active tuberculosis [7], and pentoxifylline moderately 
ameliorated anemia and general performance in HIV-positive patients with 
tuberculosis [8]. During treatment of leprosy, erythema nodosum leprosum, a toxic 
syndrome with systemic manifestations and painful nodules related to former leprosy 
lesions, can be treated with thalidomide [3] or pentoxifylline [6].  
 
Because of its application in mycobacterial infections, we investigated the modulation 
of M.tuberculosis (MTB) induced cytokine production by thalidomide and 
pentoxifylline. After specific stimulation of PBMC with MTB, there is a predominant 
production of proinflammatory cytokines, which was, similar to LPS-mediated 
cytokine production, inhibited by pentoxifylline and thalidomide. Interestingly, the 
effect of thalidomide appeared stronger after stimulation with MTB. These effects 
during mycobacterial stimulation are in accordance with earlier investigations of 
either pentoxifylline [6,8] or thalidomide [7,18]. 
 
Traditionally, immunomodulation by pentoxifylline and thalidomide has been 
attributed to effects on monocytes. Both drugs may also act by other mechanisms, 
one of which may be the modulation of T-cell response. Our experiments indicate 
that the production of IFNγ is inhibited by pentoxifylline and thalidomide, both after 
unspecific stimulation with PHA, and antigen-specific stimulation with mycobacterial 
antigens. This is in agreement with earlier reports of in-vitro inhibition of IFNγ by 
pentoxifylline [17,20] and thalidomide [21]. In contrast, other investigators have found 
stimulatory effects of thalidomide on IFNγ production when purified T-cell populations 
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were used [19,22]. Thalidomide has inhibitory effects on monocytes which were 
absent in these experiments. Pentoxifylline and thalidomide may also affect the 
production of antiinflammatory cytokines. In our experiments, neither drug modulated 
the in-vitro production of the natural antagonist of IL-1β, IL-1ra, which has not been 
described previously. Pentoxifylline slightly inhibited IL-10, while thalidomide had no 
significant effect. In contrast to our findings, a recent publication reports the 
upregulation of IL-10 by thalidomide and thalidomide-analogues [19]. However, LPS 
and not PHA was used as a stimulus in that report, suggesting that the effect on 
monocytes and lymphocytes may be different. With regard to pentoxifylline, equivocal 
results have been reported about possible in-vitro modulation of IL-10 [12-14]. In 
whole blood, LPS- induced production of IL-10 was increased with low concentrations 
of pentoxifylline, and inhibited with higher concentrations [12]. In another report, 
modulatory effects of pentoxifylline were related to the stimulus used; LPS-induced 
production was inhibited, while S. pneumoniae-induced IL-10 production was 
potentiated with pentoxifylline [17]. Clearly, no uniform conclusion can be drawn 
about the modulation of IL-10 by pentoxifylline and thalidomide. 
 
Since pentoxifylline and thalidomide exert their effects through different mechanisms, 
the combined use of these substances might be more potent. In vitro, based on 
experiments using thalidomide with a single dose of pentoxifylline, a synergistic effect 
was reported [9]. From our experiments with combinations of pentoxifylline and 
thalidomide in a range of concentrations, it can be concluded that pentoxifylline and 
thalidomide have additive effects on cytokine production, but that no synergism 
exists. Combined lower doses of each drug achieving a similar effect may perhaps be 
safer in clinical practice.  
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Abstract 
 
 
Tuberculosis patients often suffer from severe weight loss, which is considered to be 
immunosuppressive and a major determinant of severity and outcome of disease. 
Because leptin is involved in weight regulation and cellular immunity, its possible role 
in tuberculosis-associated wasting was investigated. In an urban clinic in Indonesia, 
plasma leptin concentrations, indicators of adipocyte mass, appetite, C-reactive 
protein (CRP), tuberculin reactivity and cytokine response were measured in 
tuberculosis patients and healthy controls. Plasma leptin concentrations were lower 
in patients than in controls (615 vs. 2550 ng/L; P<0.001). Multivariate regression 
analysis showed that body fat mass and inflammation were two independent factors 
determining plasma leptin concentrations; there was a positive correlation between 
fat and leptin, whereas, unexpectedly, leptin was inversely associated with CRP and 
TNFα-production. Concentrations of both CRP and leptin were independently 
associated with loss of appetite. Our results do not support the concept that weight 
loss in tuberculosis is caused by enhanced production of leptin. Rather, loss of body 
fat leads to low plasma leptin concentrations, and prolonged inflammation may 
further suppress leptin production. Because leptin is important for cell-mediated 
immunity, low leptin production during active tuberculosis may contribute to 
increased disease severity, especially in cachectic patients. 
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Introduction 
 
Wasting has long been recognized as a prominent feature of tuberculosis, and 
is probably one of the determinants of the disease severity and outcome [1]. 
However, uncertainty surrounds cause as well as effect of a poor nutritional status in 
tuberculosis patients. The cause, or pathogenesis of tuberculosis-associated wasting 
is incompletely understood, although it is likely that inflammatory mediators such as 
tumor necrosis factor-α (TNFα) do play a role [2]. Similarly, a poor nutritional status is 
known to suppress cellular immunity, which is essential against M. tuberculosis, but 
the precise mechanism remains uncertain [3,4].  
Leptin, the 16-kDa product of the ob-gene, may be involved in this cross-
regulation between nutritional status and the immune response in tuberculosis. 
Leptin is produced by adipocytes, and binds to specific receptors in the 
hypothalamus, from where it suppresses appetite [5]. Concentrations of circulating 
leptin are proportional to fat mass [6], are reduced in starvation [7,8], and are 
increased by inflammatory mediators [9]. Administration of leptin to leptin-deficient 
ob/ob mice reduces food intake and increases energy expenditure [10]. Experimental 
evidence has shown a number of other possible functions of leptin, including immune 
regulation. Leptin stimulates the proinflammatory response [11] and promotes 
proliferation, differentiation and activation of hematopoietic cells [12]. In mice, the 
reduction of leptin concentrations induced by starvation enhances sensitivity to 
endotoxic shock [13]. Falling leptin concentrations also appear to be responsible for 
reduced T-cell function during starvation [14].  
On the basis of the above, plasma leptin concentrations in tuberculosis may be 
the result of two antagonistic mechanisms. Whereas tuberculosis-associated loss of 
body fat mass may lead to reduced production of leptin [15], the host inflammatory 
response may increase leptin production [9]. If, as an overall result, plasma leptin 
concentrations are increased in tuberculosis patients, then this might theoretically 
suppress appetite and food intake and be one of the mechanisms underlying weight 
loss. However, if plasma leptin concentrations are decreased in tuberculosis, then 
this might suppress cellular immunity and aggravate disease outcome. Therefore, the 
aim of this study was to measure plasma leptin concentrations in tuberculosis 
patients, and to explore determinants of leptin such as nutritional status and the 
inflammatory response. The study was conducted in Indonesia, where malnutrition is 
highly prevalent among tuberculosis patients [3]. 
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Methods 
 
Subjects 
In an outpatient tuberculosis clinic in Jakarta, Indonesia, 60 consecutively 
selected patients with pulmonary tuberculosis were evaluated before and after 2 
months of standard antituberculous treatment with isoniazide, rifampicin, 
pyrazinamide and ethambutol. Diagnosis was based on clinical presentation and 
radiology, and confirmed by sputum microscopy  and culture for M. tuberculosis. In a 
subgroup of 20 (untreated) patients, tuberculin reactivity was measured. Thirty 
healthy individuals resident in the same neighborhood as the patients were selected 
for comparison. These controls had no history or signs of active pulmonary 
tuberculosis, and had no abnormalities on chest X-ray examination. Informed 
consent was obtained from all patients and control subjects, and the study was 
approved by the ethical committee of the Faculty of Medicine, University of 
Indonesia, Jakarta.  
 
Anthropometric measurements 
Patients and control subjects were weighed barefoot with minimum clothing 
using an electronic weighing scale (SECA-770). Body weight was recorded to the 
nearest 0.1 kg. Height was measured to the nearest 0.1 cm using a microtoise. Total 
body fat was estimated from the average of two duplicate measurements of skinfold 
thickness at four sites (biceps, triceps, subscapular and suprailiac region) [16]. Food 
intake was estimated from two 24-h recalls using World Food vs 2.0 (University of 
California, Berkeley, CA). 
 
Laboratory methods  
Plasma leptin concentrations were measured by capture ELISA according to 
guidelines of the manufacturer (Quantikine DLP00, R&D, Minneapolis, MN). Plasma 
C-reactive protein concentrations (CRP) were measured by standard turbidimetry. In 
a subgroup of 20 patients, ex-vivo production of cytokines was assessed in whole 
blood as previously described [17]. Briefly, whole blood was incubated in closed 
vacutainer tubes at 37 °C without stimulation or with lipopolysaccharide (LPS; final 
concentration 10 µg/L), phytohemoagglutinin (PHA; 10 mg/L) or PPD (10 mg/L). 
Supernatants were harvested after incubation for 6 h (LPS and PHA) or 24 h (PPD). 
Concentrations of TNFα, interleukin-1β (IL-1β) and interleukin-1 receptor antagonist 
(IL-1Ra) were measured by specific radio-immunoassay [18], and concentrations of 
IFNγ and interleukin-6 (IL-6) were measured by ELISA (Pelikine, CLB, Amsterdam, 
The Netherlands). All relevant comparisons were made within single assays. The 
intraassay CV was 3% for leptin, 6% for IFNγ, and < 10% for TNFα, IL-1β and IL-1ra. 
Day to day variation of whole blood ex-vivo cytokine production in humans is 12% for 
TNFα, 23% for IL-1β, 5% for IL-1ra and 47% for IFNγ [17]. 
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Statistical analyses 
Data were analyzed using SPSS version 7.5.2 for Windows (SPSS Inc., 
Chicago, IL). Patients and controls were compared regarding their plasma leptin 
concentrations, body weight, body mass index (calculated as weight/height2, kg/m2), 
body fat mass, sex and age, using Students t-test or Mann-Whitney test as 
appropriate. The relationship between plasma leptin concentrations and body fat 
mass, and between plasma concentrations of leptin and CRP was analyzed by 
univariate regression. Multivariate regression models were used to assess if data 
were consistent with our hypothesis that a tuberculosis-associated change in plasma 
leptin concentration is mediated through changes in body fat mass and CRP. Hence, 
log (plasma leptin concentration) was modeled with body fat mass and CRP as main 
terms. A term for tuberculosis was retained to account for possible mechanisms 
through which it might influence plasma leptin concentration independently from body 
fat and CRP. The geometric mean changes in plasma leptin concentration, food 
intake, and the mean change in body weight, body fat mass and CRP after 2 mo of 
antituberculous treatment were evaluated by one-sample t-tests. Multivariate logistic 
regression analysis was used to evaluate plasma leptin concentrations and 
inflammation as determinants of reported appetite (normal or below normal) in 
tuberculosis patients at baseline. CRP was used as a marker of the inflammatory 
response, which was considered as a possible confounder in the relation of plasma 
leptin concentration with appetite. 
 
 
Results 
 
Plasma leptin concentrations are lower in tuberculosis patients than in controls  
The subjects included in this study were mostly young adults and more often 
male (Table 1). Patients with tuberculosis presented with a 2- to 6-month history of 
respiratory symptoms (100%), fever (60%), night sweats (68%), fatigue (83%) and 
weight loss (80%). None of the investigated patients was HIV-positive. Reported 
weight loss ranged from 0 - 25 kg (median, 5 kg). Patients with untreated 
tuberculosis had substantially lower weight, BMI and body fat mass than controls 
(Table 1). BMI in patients was reduced by 16% compared with controls, and body fat 
mass percentage (%) by 45%. Patients had a geometric mean (95% CI) plasma 
leptin concentration of 617 (469-810) ng/L, compared with 2539 (1548-4168) ng/L in 
healthy control subjects (P < 0.001; Figure 1a). This difference corresponded with a 
76% reduction in patients. Patients were somewhat older than controls, but no 
association was found between age and plasma leptin concentration among either 
controls or patients. Women had substantially higher plasma leptin concentrations 
than men (geometric mean 1938 ng/L compared with 575 ng/L; ratio 3.4, 95% CI 2.0-
5.6), but the sex ratio was similar among patients and controls (Table 1). Both in 
male and female subjects, plasma leptin concentrations were significantly reduced in 
tuberculosis patients (Figure 1b). 
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Figure 1. 
Plasma leptin concentrations in tuberculosis patients and healthy controls 
Log-transformed plasma leptin concentrations of 60 tuberculosis patients (black dots) and 30 
healthy controls (open dots) are depicted in figure 1a. Geometric mean plasma leptin 
concentrations are significantly lower in patients versus control subjects (P<0.001 according to 
Students T-test). Figure 1b demonstrates the log-transformed plasma leptin concentrations 
according to sex. Plasma leptin concentrations are significantly higher in females (P<0.001), but 
both in males and females, plasma leptin is significanlty reduced in tuberculosis patients. 
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Figure 2. 
Plasma leptin concentration and body fat mass in tuberculosis patients and healthy controls. 
Fig 2a shows the log transformed plasma leptin concentrations and percent body fat in 
tuberculosis patients (open circles) and healthy controls (closed squares). The lines represent 
linear regression analysis for patients (r = 0.78; P<0.001) and controls (r = 0.53; P=0.002).  
Fig 2b shows the estimates ([Y] = 10 2.1078 + 0.0484 [X] for tuberculosis patients; [Y] = 102.5669
+ 0.0414 [X] for healthy controls) based on a multivariate regression model with terms for 
tuberculosis, body fat mass and their product term. They indicate that tuberculosis affects plasma
leptin concentrations directly, and through loss of body fat mass. The thin curve ([Y] = 102.3750 +
0.0424 [X]) is based on univariate regression to model plasma leptin concentration as a function 
of body fat mass in tuberculosis patients who have completed 2 mo of treatment (n=38). This 
curve indicates that plasma leptin concentrations show a partial recovery during treatment, which 
cannot be explained by an increase in fat mass. 
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Body fat mass and inflammation are associated with plasma leptin concentrations. 
Univariate analysis showed that plasma leptin concentration increased 
proportionally with body fat mass (Figure 2a). For every 10 units increment in fat 
percentage, plasma leptin concentration increased 3.1-fold (95% CI: 2.4-3.9) and 
2.6-fold (95% CI: 1.4-4.7) in patients and control subjects, respectively. Median CRP 
was 52 mg/L (interquartile range: 19-95 mg/L) in tuberculosis patients and 2 mg/L (1-
3 mg/L) in controls (P<0.001). Among patients, plasma leptin concentrations were 
reduced by 33% (95% CI: 15-46%) for every 50 mg/L increment in CRP. In control 
subjects, there was insufficient variation in CRP to assess its relation with plasma 
leptin concentration.  
Figure 2b shows the results of a multivariate regression model to assess the 
role of body fat mass and possible other mechanisms whereby tuberculosis may 
affect plasma leptin concentration. This figure shows that patients with untreated 
tuberculosis have lower plasma leptin concentrations than expected for body fat 
mass. Table 2 gives a comparison of two regression models to assess the role of 
body fat mass, CRP and possible other mechanisms whereby tuberculosis may affect 
plasma leptin concentrations. Multivariate regression analysis showed no evidence 
for effect modification or confounding by age and sex in these associations. 
Univariate regression (Model 1) gave a crude assessment of the association between 
tuberculosis and plasma leptin concentration. Multivariate regression, with addition of 
CRP and body fat mass (Model 2), reduced this association (from 76% to 35%) and 
shows that plasma leptin concentration was positively associated with body fat and 
inversely associated with CRP. The estimated proportion of variability in plasma 
leptin concentration explained (multiple R2) in Model 2 was 0.64. Taken together, 
these findings are consistent with our hypothesis that tuberculosis-associated 
reductions in plasma leptin concentrations are mediated independently through a 
decreased percentage of body fat, inflammation and possibly other, unidentified 
mechanisms. 
 
Plasma leptin concentrations increase during antituberculous treatment 
The effect of antituberculous treatment on plasma leptin concentrations, 
appetite, nutritional status and acute phase proteins was evaluated in 38 patients for 
whom blood test results were available after 2 mo of treatment. These patients 
reported a clear improvement of symptoms within 1-3 weeks after start of treatment. 
Plasma leptin concentrations were substantially higher following treatment (geometric 
mean difference: 409 ng/L; 95% CI: 219-676 ng/L; P<0.001), corresponding to an 
increase of 64% relative to baseline (Figure 2b). There was no evidence that 
selection bias caused by missing data substantially affected the estimated effect of 
treatment on the change in plasma leptin concentration (not shown). Loss of appetite 
was reported by 27 patients (71%) before treatment, and by none following 
treatment. After 2 months of treatment, patients had a higher energy intake (mean 
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difference: 375 kJ), body weight (mean difference: 1.6 kg; 95% CI: 0.9-2.3 kg, 
P<0.001), and body fat mass (%) (mean difference: 1.6%, 95% CI: 0.6-2.5 %, 
P=0.003), and lower CRP (mean difference: 50 mg/L; 95% CI: 26-74 mg/L; P=0.001). 
 
Plasma leptin and cytokine response  
The relationship between plasma leptin concentrations and the ex-vivo 
production of proinflammatory cytokines was investigated in 19 tuberculosis patients 
for whom data were available. Linear regression analysis showed an inverse 
correlation between spontaneous ex-vivo production of TNFα and plasma leptin 
concentrations before treatment. Plasma leptin concentrations reduced by 42% (95% 
CI: 12%-62%) for every 0.1 ng/mL increment in plasma TNFα concentration. LPS-
mediated production of TNFα, as well as the production of IL-1β, IL-1Ra, and IL-6 
were not significantly associated with plasma leptin concentrations before treatment. 
Following treatment, there was a substantial decrease of plasma concentrations of 
IL-6, and ex-vivo production of IL-1β, IL-6 and TNFα (not shown). However, we could 
not directly demonstrate a significant association between changes in leptin 
concentrations and changes in cytokine production. 
To investigate the relationship between plasma leptin concentrations and T-cell 
immunity, tuberculin skin tests and production of IFNγ were evaluated in untreated 
patients. The size of skin reactions to PPD showed a positive but statistically non-
significant correlation with plasma leptin concentrations (P=0.30). A similar result was 
found for plasma leptin concentrations and PPD-induced ex-vivo production of IFNγ 
(P=0.38). Ex-vivo production of IFNγ increased following treatment (mean difference: 
188 pg/mL; 95% CI: -7 to 539 ng/L). However, no significant relationship could be 
shown between change in plasma leptin concentrations and IFNγ production (P 
=0.39). 
 
Determinants of appetite  
Both inflammation and plasma leptin concentration were associated with loss of 
appetite in tuberculosis patients. Every 50 mg/L-increment in CRP was associated 
with a 1.4-fold increase (95% CI: 0.8-2.6) in the odds of reporting loss of appetite. 
When adjusted for CRP, every 1000 ng/L increment in plasma leptin concentration 
was associated with a 1.7-fold increase (95% CI: 0.7-4.3) in the odds of reporting 
loss of appetite. 
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Discussion 
 
Tuberculosis often leads to severe weight loss (wasting), probably through the 
production of inflammatory mediators [2]. Wasting, in turn, affects the inflammatory 
response, suppresses cellular immunity and aggravates the outcome of tuberculosis 
[19]. In these complex relations between tuberculosis, nutritional status and the host 
immune response, leptin is a possible mediator. In this study, plasma leptin 
concentrations were significantly suppressed in tuberculosis patients in Indonesia. 
Body fat mass was strongly correlated with plasma leptin concentrations, both in 
patients and controls. Unexpectedly, in tuberculosis patients, plasma CRP and in-
vitro production of TNFα showed an inverse correlation with plasma leptin 
concentrations. Results of multivariate regression analysis support the hypothesis 
that tuberculosis-associated reductions of plasma leptin were mediated 
independently by weight loss and inflammation. Although previous data have shown 
that leptin stimulates cell-mediated immunity, we were unable to demonstrate a 
statistically significant correlation of plasma leptin concentrations with tuberculin 
reactivity or IFNγ production.  
To our knowledge, there is one previous study on plasma leptin concentrations 
in tuberculosis patients [20]. In that report, leptin concentrations, as determined by 
radio-immunoassay, were much higher than in ours. The (Turkish) patients in that 
report had a much higher body mass index, but it seems surprising to us that after 
treatment they had three-fold higher leptin concentrations than control subjects. Also, 
the control subjects had increased plasma TNFα values, an unexpected finding in 
healthy individuals. 
Loss of body fat mass could not entirely explain the observed low plasma leptin 
concentrations in tuberculosis patients in our study. Body fat mass is the most 
important determinant of plasma leptin concentrations, but starvation, hormones 
(including insulin and cortisol), as well as inflammatory mediators are able to 
modulate leptin production [21]. Animal studies have shown that LPS, TNFα and IL-
1β raise leptin concentrations in serum and leptin mRNA in adipose tissue (7). 
Similarly, in cancer patients, recombinant TNFα (22) and IL-1β (23) increased 
plasma leptin. In sepsis patients, leptin levels were found to be elevated [23-25]. To 
our surprise, in our study in tuberculosis, CRP and TNFα production were inversely 
correlated with plasma leptin concentrations. Attenuation of the acute phase 
response and proinflammatory cytokine production during antituberculous treatment 
was accompanied by an impressive increase of plasma leptin concentrations. Of 
course, the acute inflammatory response in the animal and patient studies described 
above is different from the more chronic response in tuberculosis patients. The 
pattern of plasma leptin concentrations in weeks or months prior to diagnosis 
remains unknown, but one may hypothesize that the prolonged inflammatory 
response in tuberculosis downregulates or exhausts leptin production. 
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In this study, multivariate analysis indicated that plasma leptin concentrations 
were associated with loss of appetite in tuberculosis. However, plasma leptin 
concentrations were substantially higher in control subjects (without anorexia), and 
patients regained appetite during treatment, in spite of a substantial increase in 
plasma leptin concentrations. Therefore, anorexia in tuberculosis seems to be 
determined to a much larger degree by inflammatory mediators (e.g. pro-
inflammatory cytokines) than by leptin. Leptin signals the brain to decrease food 
intake, but sofar no evidence has been found that anorexia in AIDS [26,27] and other 
inflammatory disorders is caused by increased leptin levels [28,29]. In fact, it may be 
the other way around: both in laboratory animals [30] and human subjects [8], fasting 
induces falling leptin levels which evoke a number of adaptive responses, including 
suppression of metabolic rate [7]. Similarly, in tuberculosis, decreased energy-intake 
may reduce leptin production. We did not measure energy-intake, but it is likely to be 
lower among tuberculosis patients than healthy controls. 
Suppressed production of leptin may be detrimental for host defense against 
infections. In septic shock, mortality was found to be associated with decreased 
plasma leptin levels [22]. In an animal model, the absence [13], or starvation-induced 
down-regulation of leptin increased susceptibility to endotoxic shock, and leptin 
partially reversed this effect [13]. In addition, leptin reversed starvation-induced T-cell 
suppression- [14]. Host defense against tuberculosis depends on cell-mediated 
immunity, with a crucial role for Th1-type cytokines, primarily IFNγ [31]. Therefore, it 
may be hypothesized that decreased leptin production during active tuberculosis 
contributes to T-cell unresponsiveness. Indeed, in our patient group both plasma 
leptin and ex-vivo IFNγ production were low and increased upon successful 
antituberculous treatment. We did not find a significant correlation between these two 
variables, which might be due either to the limited number of patients analyzed for 
cytokine production, or to substantial intra- and inter-individual variation of ex-vivo 
cytokine production [17]. We were also unable to show a statistical association 
between leptin and tuberculin reactivity, but skin testing, which was only done before 
treatment, is a rather crude measurement.  
Based on our data and results from previous studies we hypothesize that in 
untreated tuberculosis, loss of body fat, reduced energy-intake and the host immune 
response reduce leptin production (Figure 3). As leptin is important for cell-mediated 
immunity, suppressed leptin concentrations may contribute to a worse outcome of 
tuberculosis, especially in cachectic patients. In theory, administration of leptin might 
benefit tuberculosis patients, but this is not feasible in a country like Indonesia. 
Supplementation of micronutrients such as vitamin E [32] or zinc, which are known to 
increase leptin production [33], might be a cost-effective alternative. Of interest, zinc 
has the additional advantage of stimulating appetite [34].
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Figure 3. 
Hypothesised role of leptin in human tuberculosis. 
 
The inflammatory response in tuberculosis may suppress leptin production directly (A), 
and through loss of body fat mass (B) and decreased energy intake (C). Suppressed 
leptin production may contribute to decreased cell-mediated immunity (CMI). In addition, 
wasting (cachexia) may contribute to a worse disease outcome through other, undefined 
mechanisms. 
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Abstract 
 
 
The presence of non-tuberculous mycobacteria (NTM) in sputum or bronchial 
washings may cause diagnostic problems, which affect clinical management. In a 
retrospective analysis of 135 patients in a Dutch tuberculosis center, patients with 
NTM isolates were thoroughly investigated. Colonization or contamination by NTM 
was differentiated from true lung disease. 25 HIV-seronegative and two HIV-
seropositive patients with NTM were identified. In only 14 (52%), NTM were a likely 
cause of disease. In 15 (55%), their presence led to preliminary diagnosis and 
treatment of tuberculosis. Unnecessary or inappropriate treatment was instituted in 
17 (63%) of patients with NTM. Also, in two patients, NTM in sputum led to delay in 
diagnosing malignant disease. In this series, NTM in sputum or bronchial washings 
poorly reflected disease, and often led to diagnostic and therapeutic errors. Although 
it is common knowledge that the presence of NTM should be considered in smear-
positive patients, this apparently is a diagnostic pitfall in clinical practice. Reliable 
DNA-based techniques and better communication between physicians and 
microbiologists may improve management of suspected mycobacterial infections. 
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Introduction 
 
Mycobacterial species not belonging to Mycobacterium tuberculosis complex and M. 
leprae are designated ‘atypical‘ or non-tuberculous mycobacteria (NTM) [1]. Human 
transmission of these bacteria, which are ubiquitous in soil and water, is rare [2]. The 
pathogenicity of non-M. tuberculosis complex species varies. M. avium, M. kansasii 
and M. malmoensae are considered the most pathogenic, particularly in patients with 
pre-existent lung disease, past tuberculosis, systemic immunosuppression or the 
acquired immuno deficiency syndrome (AIDS) [3]. Incidentally, NTM may cause 
pulmonary disease in immunocompetent individuals [1,4]. In addition, NTM may also 
colonize the lungs without causing disease [2]. Due to their ubiquitous nature, 
coincidental isolation or contamination of diagnostic samples may also occur [5-7].  
 
On direct microscopic examination, NTM are acid-fast bacilli (AFB), which cannot be 
distinguished from M. tuberculosis. Therefore, pulmonary tuberculosis may falsely be 
suspected [6]. When NTM are cultured from pulmonary specimens, non-tuberculous 
mycobacterial disease still must be differentiated from contamination or colonization. 
Thus, detection of AFB in pulmonary specimens or the isolation of NTM may pose a 
diagnostic problem to the clinician who has to decide whether treatment is indicated 
or not. In recent years this issue has become even more important as NTM are 
detected in sputum or bronchial washings with increasing frequency.  
 
The present study evaluates the clinical impact of the detection of NTM in pulmonary 
specimen. To this end we studied in detail the medical records of all 27 patients with 
NTM in pulmonary specimen in a group of 135 consecutive patients referred to our 
tuberculosis center with presumed pulmonary tuberculosis. 
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Patients and methods 
 
Setting 
The study was performed in the University Lung Center Dekkerswald of Nijmegen 
University, one of the two Dutch tuberculosis centers for prolonged in-hospital 
treatment of tuberculosis patients. Nearly all patients in this center are referred from 
other hospitals, principally because of diagnostic problems, severe or complicated 
disease, or treatment problems like drug-resistance, drug-toxicity or non-compliance.  
 
Study design 
The medical records of all consecutive 135 patients referred from January 1995 to 
December 1998 with presumed or confirmed pulmonary tuberculosis were studied 
retrospectively. From this sample, we further evaluated 90 patients in whom 
mycobacteria had been identified by direct microscopy or culture of sputum or 
bronchial washings, either before or after referral to our tuberculosis center. The 
following characteristics were collected: demographic data; the presence of risk 
factors for NTM disease (pre-existent lung disease, immunosuppressive medication, 
HIV-infection or other immunocompromising diseases); signs and symptoms like 
cough, hemoptysis, weight loss, fever and duration of symptoms; chest X-rays; 
bacteriological results; treatment; and outcome.  
Patients who had NTM isolated from a pulmonary specimen were compared 
with patients with proven M. tuberculosis pulmonary infection. The consequences of 
finding NTM were evaluated in all patients individually. For the diagnosis of non-
tuberculous lung disease, the diagnostic criteria of the American Thoracic Society 
(ATS) were used [8]. 
 
Microbiology 
In 76 patients the initial diagnostic procedure and the initiation of therapy had been 
performed in the referring hospital. In these cases the microbiological results of this 
hospital were used. The diagnostic procedure in the tuberculosis center comprised of 
a direct examination for acid-fast bacilli (AFB) in a fluorochrome- and Ziehl-Neelsen 
stained smear, and of cultures on conventional solid media (Löwenstein and 
Colestos) and liquid media (BACTEC). In all patients sputum examinations were 
repeated at weekly intervals. All isolates, either obtained in the referring hospital or 
the tuberculosis center were sent to the Dutch National Institute of Public Health and 
Environment (RIVM) in Bilthoven, the Netherlands, for identification, DNA 
fingerprinting and determination of drug susceptibility [9]. 
 
Statistics. 
Groups were compared statistically by using a Chi-square test or a non-parametric 
Mann-Whitney-U test. A P-value < 0.05 was considered significant. 
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Results 
 
Microbiology  
Among the 90 patients evaluated, NTM was isolated from sputum or bronchial 
washings in 22 and M. tuberculosis (MTB) in 63. In four patients, not further included 
in the comparison between the NTM- and the MTB-group, both NTM and MTB were 
cultured. The isolated NTM were M. avium (n = 11), M. malmoense (n = 3), M. 
kansasi (n = 2), M. terrae (n = 2), M. gordonae (n = 1), and M. xenopi (n = 1). Fast 
growing NTM (M. peregrinum or M. chelonae) were found in two patients. In five 
cases species identification was incomplete; culture and PCR for MTB or M. avium 
were negative.  
PCR for MTB on sputum or bronchial washings was performed in nine patients 
with NTM. In agreement with the results from culture and conventional species 
differentiation, seven were negative for MTB. In two patients, PCR appeared to be 
false positive for MTB: in one patient MTB was never cultured while all other 
specimens were positive for M. avium, in the other the chest-X-ray abnormalities 
disappeared after treatment with a short course of amoxicillin-clavulanic acid.  
 
Patient characteristics 
Patients with NTM were significantly older (mean age 76 vs. 37 years) than patients 
with tuberculosis and originated less often from countries with a high prevalence of 
tuberculosis (13% vs 63%; P < 0.05). (Table 1). As compared to the patients with 
pulmonary tuberculosis, NTM-patients sligthly more often suffered from chronic 
obstructive pulmonary disease (26 vs. 11%, n.s.), and were more often on 
immunosuppressive medication (30 vs 5%; P < 0.05). 44% of patients with NTM had 
completed treatment for tuberculosis in the past. However, in more than half (52%) of 
the NTM-patients not any of the known risk factors for NTM-infection were present. 
Fever was present in a minority of NTM patients (26% vs. 51%, P < 0.05). No 
significant differences were found with respect to the presence of cough or 
hemoptysis. Solitary nodular lesions on the chest X-ray were found in four patients 
(18%) with NTM isolates as compared to none in patients with MTB (P < 0.05). 
However, cavitary disease was observed slightly more frequently in MTB (44%) as 
compared to patients with NTM (35%) (n.s.). The percentage of patients with AFB on 
direct examination of pulmonary specimen (the smear-positive rate) was similar for 
NTM and MTB, but in patients with NTM, AFB were more often found in bronchial 
washings only (43% vs. 11%; P < 0.05). 
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Table 1 
Characteristics of 86 patients with M. tuberculosis (MTB) or non-tuberculous mycobacteria  
(NTM) in sputum or bronchial washings1. 
 
 MTB (n=63)  NTM (n=23) 
Average age (years) 37 * 62 
male  71 %  74 % 
Originating from TB-endemic areas   63 % * 13 % 
HIV-positive 4 %  0 
Immunosuppressive medication  5 % * 30 % 
pre-existing lung disease 11 %  26 % 
fever (>38.5 o C)  51 % * 26 % 
Cough 77 %  78 % 
Hemoptysis 30 %  22 % 
Pulmonary cavities 44 %  35 % 
Solitary nodule on chest X-ray  0 % * 18 % 
positive for acid-fast-bacilli 
- in bronchial washings only  
79 % 
11 % 
 
* 
70 % 
43 % 
1 The 4 patients in whom both M. tuberculosis (MTB) and non-tuberculous mycobacteria 
(NTM) were present, are not included in this Table. * significant difference; p < .05.  
 
 
 
True infection with NTM versus contamination or colonization 
Based on the ATS-criteria [8], the presence of NTM was unlikely to reflect true non-
tuberculous lung disease in 11 (48%) of the 23 patients with NTM. Three patients 
were presumably temporarily colonized with NTM, as they had M. avium, M. 
peregrinum or M. malmoense in more than one specimen, but did not fulfill ATS-
criteria and failed to show progressive disease during follow-up in the absence of 
treatment.  
Contamination of specimens with NTM seemed most likely in eight patients, all 
with one single positive specimen. Five of them had been referred by the same 
hospital within several months. Bronchial washings in these patients contained AFB, 
for which culture and PCR for MTB and M. avium were negative. Contamination with 
NTM was suspected when AFB were repeatedly detected in the washing machine for 
bronchoscopes. In three additional patients, only one single positive sputum culture 
(M. terrae (2), M. xenopi) was found despite repeated examinations.  
In the four cases hwere NTM together with MTB were isolated from pulmonary 
specimen, NTM reflected true disease in two. Both patients had M. avium disease. In 
these two patients, one HIV-seropositive, acid-fast bacteria reappeared and persisted 
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in sputum during anti-tuberculous treatment. M. avium was cultured, only to 
disappear after ofloxacin and clarithromycin had been added to the treatment 
regimen. In two other cases with NTM (M. malmoense or M. gordonae) and MTB 
isolated from the same patient, contamination of specimens or culture was most 
likely; NTM were isolated only once. 
Patients with true NTM lung disease more often suffered from pre-existing lung 
disease (36% vs. 15%), previous pulmonary tuberculosis (50% vs. 38%), hemoptysis 
(36% vs. 15%) and pulmonary cavities (57% vs. 22%) than NTM-patients, which did 
not fulfill criteria for true pulmonary disease. Use of immunosuppressive medication 
was similar (28% and 30%). M. avium, M. kansasii and M. malmoense were most 
frequently found in patients fulfilling criteria for true pulmonary disease (Table 2). 
Microscopic examination of specimens was positive for AFB in a similar percentage 
of patients, although smear-positive sputum reflected true disease twice as often.  
 
Impact of NTM in pulmonary specimens on diagnosis and treatment. 
The presence of NTM often led to diagnostic and therapeutic errors (Table 2). In 14 
out of 22 patients from whom NTM were cultured, and in all five cases where 
bronchoscopes were thought to have contaminated diagnostic specimens with NTM, 
the initial working diagnosis was different from the the final diagnosis, made with all 
available information. Initially, 15 out of the total of 27 patients with NTM in 
pulmonary specimens (55%) were falsely considered having pulmonary TB. This 
group included 6 patients with true non-tuberculous infections and nine patients in 
whom NTM most likely reflected contamination. All were started on treatment against 
MTB. Acid-fast bacteria reappeared in sputum from two patients with culture-positive 
cavitary tuberculosis after two months of anti-tuberculous therapy. These patients 
were consequently treated for presumed multi-drug-resistant TB until culture 
demonstrated M. avium one, respectively three months later. All together, anti-
tuberculous treatment (median: 6 weeks, range: 3 days – 4 months) was 
unnecessarily instituted in nine patients (33%) and inappropriate drug-regimens 
(median: 8 weeks; range 1 – 3.5 months) were unintentionally prescribed to eight 
patients (29%). Four of these patients developed a rise in serum aspartate 
transaminase (AST) of more than three times the normal upper limit due to the anti-
tuberculous therapy.  
In two patients, a false positive diagnosis of tuberculosis led to a 6 weeks delay 
in the diagnosis and treatment of malignant disease. The first patient, who was under 
immunosuppressive therapy for cryoglobulinemia, presented with infiltrative and 
cavitary abnormalities on a chest X-ray. M. avium was cultured from sputum, but no 
improvement was seen on antimycobacterial therapy. Finally, a lung biopsy was 
diagnostic for adenocarcinoma. The second patient, a 65-year old man using 
prednisone for glomerulonephritis, presented with a solitary cavitary nodule. 
Bronchial washing yielded AFB and anti-tuberculous treatment was started. Culture 
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for mycobacteria remained negative and a lung biopsy, performed six weeks after the 
start of treatment, revealed adenocarcinoma. 
 
 
Table 2. 
Impact of finding non-tuberculous mycobacteria (NTM) in sputum or bronchial washings in 27 
patients 1, as divided in NTM lung disease 2, and colonization or contamination of NTM.  
 
 
  
True NTM lung disease 
 
 
Contamination or 
Colonization  
with NTM 
 
 
    Species determination 
         
        M. avium (9) 
        M. malmoense (2) 
        M. kansasii (2) 
        M. cheloni  
 
M. avium (2) 
M. malmoense 
M. xenopi 
M. peregrinum 
M. terrae (2) 
M. gordonae 
Not specified (5) 3 
 
 
   Diagnostic errors: 
  
      suspected pulmonary TB 6 /14 9 /13 
      suspected MDR-TB 2 /14  
      suspected NTM-disease  2 /13 
      delay of true diagnosis 4 
 
 2 /13 
 
   Therapeutic errors: 
  
      unnecessary treatment 5  9 /13 
      inappropriate regimen 6 
 
8 /14  
 
MDR = multi-drug resistance.  1 including 4 patients, with both MTB and NTM. 2 true lung 
disease due to NTM was diagnosed according to ATS-criteria [8]. 3 no mycobacteria were 
cultured; repeated examination confirmed the presence of AFB, due to contamination of 
bronchoscopes (see text). 4 adenocarcinoma (see text). 5 median: 7 wk. 6 median: 6 wks.  
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Discussion 
 
In this study diagnostic problems related to the presence of NTM in sputum or 
bronchial washings from patients with presumed pulmonary tuberculosis were 
analyzed. In this population with a low prevalence of HIV-infection, NTM, although 
highly prevalent, poorly reflected true disease, and led to delay of true diagnosis and 
even referral to a specialized TB hospital. Often, pulmonary tuberculosis or multi-drug 
resistance were falsely suspected, as a result of which inappropriate or unnecessary 
anti-tuberculous therapy was prescribed. Apparently, despite the fact that it is 
common knowledge that the presence of AFB in pulmonary specimen may reflect 
NTM, this can still be a diagnostic pitfall in clinical practice. 
 
When AFB are present in pulmonary specimens, physicians may have to decide 
about therapy before mycobacterial culture and species determination has been 
performed. The risk of   untreated active tuberculosis must be weighed against the 
consequences of an incorrect diagnosis. In our series, demographic and clinical 
parameters did not prove helpful in differentiating MTB from NTM. Reportedly, the 
presence of diffuse nodular disease on chest X-ray, found in two patients in this 
series, and the occurrence of vanishing infiltrates in elderly women, the so-called 
“Lady Windermere syndrome” are characteristic for NTM-disease [1,11]. However, 
these radiographic abnormalities are not specific. Unlike culture, which may take 
weeks, microscopic examination of AFB does not differentiate MTB from NTM either. 
PCR is able to rapidly differentiate MTB from NTM-isolates, and DNA-fingerprinting 
can identify contamination. However, PCR led to a false-positive diagnosis of 
pulmonary tuberculosis in two patients in this series, as has been demonstrated in 
other settings as well [12,13]. Clearly to date, these techniques, as well as their use 
in clinical practice, may still be improved.  
 
Even when AFB in pulmonary specimen are recognized as NTM, it remains difficult to 
discriminate true disease from colonization or contamination by NTM [14]. Of all M. 
malmoense isolates in the United States between 1993 and 1995, only 10% reflected 
true disease [15]. The new and more sensitive laboratory methods may yield even 
more false-positive cases due to colonization of the patient [1] or contamination of 
diagnostic specimens [5-7]. In our series, the presence of NTM in hospital tap water 
contaminating bronchoscopes led to a false positive diagnosis in five patients [16]. 
The high prevalence of NTM in the present study is in agreement with other reports 
[14,17], although it should be noted that the current study included a selected patient 
group that was referred to a tuberculosis center because of diagnostic or therapeutic 
difficulties.  
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The presence of NTM in our patient group had a substantial impact on clinical 
management. False diagnosis of pulmonary TB due to the presence of NTM led to 
inappropriate or unnecessary treatment in 63% of patients with NTM-isolates. In 
addition, multi-drug resistance was falsely suspected in two patients, and the 
presence of NTM in diagnostic specimens delayed the diagnosis of pulmonary 
malignancies in two patients. Especially when sputum is negative and bronchial 
washings are positive, the odds of isolating NTM rise. Using the ATS-criteria of NTM 
lung disease [8], the significance of finding NTM should be thoroughly evaluated 
before treatment is started. In this respect, careful and repeated bacteriological 
examination, and good communication between physician and microbiologist, are 
crucial.  
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Abstract 
 
 
Indonesia has the third highest tuberculosis caseload worldwide, but little is known 
about important aspects of this re-emerging epidemic, like quality of diagnosis and 
treatment, HIV-infection and drug resistance of MTB isolates. In a TB control clinic in 
Jakarta, we assessed the clinical and microbiological status of a cohort of Indonesian 
patients. In 121 patients with suspected tuberculosis, microscopy of three large-
volume sputum samples was positive in 97 cases (80%). Most patients presented 
with longstanding and extensive disease. HIV-infection was diagnosed in 1%, while 
malnutrition (BMI < 17) was found in 50% of cases. Of 146 non-selected patient 
isolates, 24.7% was resistant to INH and 6.1% to rifampicin. Resistance to at least 
one first-line drug was present in 25.9% of new cases and 39.5% of retreatment 
cases. During treatment, side effects were common, but hepatotoxicity was 
completely absent. 10% of patients defaulted treatment. The death rate was 7%, and 
was strongly related to malnutrition. This study provides a detailed characterization of 
tuberculosis patients in an Indonesian clinic. Sputum microscopy has a high 
diagnostic yield in this endemic setting where most patients present with advanced 
disease. The drug-resistance patterns found threaten the success of first-line 
antituberculous treatment and warrant implementation of more widespread 
susceptibility testing of strains in Indonesia. Because no hepatotoxicity was found, 
patients’ compliance and quality of drug-treatment need further evaluation.   
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Introduction 
 
In 1998 Indonesia had the third highest tuberculosis caseload in the world [1]. 
Unfortunately, according to WHO, only 12.2% of new smear-positive cases were 
detected, and only 54% of smear-positive patients were successfully treated [1]. The 
impaired economic situation in Indonesia most likely contributes to this unfavorable 
situation, but other factors may be important as well. 
 
The first step in identification and treatment of tuberculosis patients is detection of 
acid-fast bacilli in sputum samples. In high prevalence countries, sputum smear 
positive cases have been given the first priority in directly observed treatment, short-
course (DOTS) programs. In recent hospital surveys in Indonesia, sputum was only 
positive for acid-fast bacilli in 25-50% of patients treated for pulmonary tuberculosis 
[2-4]. After a diagnosis is made, a full course of antituberculous drugs needs to be 
taken. DOTS has been shown to improve patients’ adherence to treatment and 
proved very effective in South Sulawesi, an island in the Eastern part of Indonesia 
[5]. However, potential spread of multidrug resistant tuberculosis poses a serious 
threat to the success of DOTS. Indonesia is not included in the worldwide drug 
resistance surveillance [6]. For economic and technical reasons, drug susceptibility 
testing is usually not performed, but limited investigations suggest that multidrug 
resistance may be more than 10% [7]. Other factors may hamper the management of 
tuberculosis in Indonesia. Malnutrition, which is highly prevalent among tuberculosis 
patients in Jakarta [8], affects the outcome of tuberculosis [9]. HIV-infection, which 
increases susceptibility for tuberculosis, is on the increase in Indonesia, but little 
information is available from tuberculosis patients. 
 
From the above it is clear that various diagnostic and therapeutic aspects of 
tuberculosis in Indonesia need further investigation. We conducted an explorative 
study in an outpatient tuberculosis clinic in Central Jakarta. Our findings may apply to 
other low-income urban settings in and outside Indonesia.  
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Methods 
 
patient inclusion, diagnosis and follow-up 
This study was conducted in an outpatient tuberculosis clinic in a densely populated 
area of Jakarta (PPTI, Jl Baladewa). This clinic provides free anti-TB-treatment and 
generally attracts patients from low socio-economic class. The majority of patients 
present themselves spontaneously, but some are referred by health-workers 
elsewhere, mainly for economic reasons. Therefore, patients presenting to this center 
may be a selected group with an increased rate and severity of tuberculosis.  
From December 1998 through March 1999, based on chest X-ray and history, 
121 consecutive patients with suspected tuberculosis were included. Demographic 
data, symptoms and signs, risk factors for tuberculosis, and details about previous 
antituberculous therapy were recorded. In all patients with suspected tuberculosis, 
slides were prepared from three large volume (10-20 ml) sputum samples, Ziehl-
Neelsen stained and examined for the presence of acid-fast bacilli. Shortly before this 
study, large sputum containers (~ 40 ml) had been introduced and patient instruction 
for sputum collection had been intensified in order to try to increase the diagnostic 
yield of sputum microscopy. Chest X-rays were examined by an experienced 
pulmonologist and evaluated for disease extension and the presence of infiltrates, 
cavities, miliary disease, pleural effusion and fibrotic lesions.  
When tuberculosis was confirmed by sputum microscopy or culture of MTB, a 
standard four-drug regimen (INH, rifampicin, pyrazinamide, and ethambutol) was 
prescribed [10]. Patients were provided with free and weekly-supervised treatment. 
During follow-up, physical complaints, body temperature and weight were recorded 
and sputum was examined at weekly intervals. Chest X-rays were repeated after two 
and six months. Standard criteria were used for classification of patients and 
evaluation of therapy [1, 11]. Liver transaminases were measured before and after 
one and two months of treatment, and HIV-seroprevalence was determined in all 
patients. Chest X-rays were re-evaluated independently by three experienced 
clinicians after completion of the study. The study was conducted with informed 
consent from all patients and with permission from the University of Indonesia.  
 
microbiology 
At the time of this study, sputum culture for MTB was not performed in this clinic. For 
this study, sputum samples were stored at 4o C in an equal volume of cetylpyridinium 
0.5%, NaCl 1%, and transported twice-weekly to a reference laboratory for 
tuberculosis. Culture of Mycobacterium tuberculosis (MTB) was performed in 3% 
Ogawa`s medium. Drug susceptibility testing for INH, rifampicin, ethambutol and 
streptomycin was done using a proportional method [12]. More than 90% of strains 
were transported to the Netherlands for susceptibility testing at the National 
Reference Laboratory for Mycobacteriology, Institute of Public Health and the 
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Environment (RIVM), a supranational reference laboratory. Here, serial dilutions of 
five antituberculous drugs on Middlebrook’s medium were used [12]. The minimal 
inhibitory concentration to define drug-resistance were: INH 0,2 mg/L, rifampicin 1 
mg/L, ethambutol 5 mg/L, streptomycin 5 mg/L and pyrazinamide 50 mg/L. To 
confirm drug resistance patterns in this population, 68 additional isolates from non-
selected patients presenting at the same clinic were examined at the supranational 
reference laboratory in the Netherlands. 
 
statistics 
Unless stated otherwise, continuous variables are represented as median 
(interquartile range). Mann-Whitney U test was used for comparison of continuous 
variables, and Pearson chi-squared test for proportions. All reported P values are 
two-sided, and the level of significance was set at P < 0.05. 
   
 
Results 
 
diagnosis 
Based on clinical presentation and chest X-ray, tuberculosis was suspected in 121 
patients. Repeated sputum microscopy identified 97 patients (80%) with smear-
positive tuberculosis. In comparison, before the introduction of larger sputum 
containers and intensified instruction of health personnel and patients in the clinic, 
microscopy was positive in approximately 25% of patients with suspected 
tuberculosis. The diagnosis was established with the first sputum sample in 81 
(84%), with the second sample in an additional 15, and with the third sample in one 
patient. Sputum cultures, performed in 114 individuals, were positive for MTB in 85 
(75%), negative in 28 and contaminated in one. In smear-negative patients, sputum 
cultures were positive for MTB in three cases, bringing the total number of patients 
with sputum smear- or culture-positive tuberculosis at 100, or 83% of all suspected 
cases. Culture remained negative in 12 out of 95 smear-positive patients.  
 
clinical presentation 
Patients with bacteriologically proven tuberculosis were mostly young adults, 
presenting after several months of cough, shortness of breath, chest pain, fever and 
weight loss (Table 1). Symptoms had lasted less than one month in six patients 
(6%), and one year or more in 16 patients (16%). Fifty-one patients (51%) suffered 
from moderate to severe malnutrition (BMI < 17). Chest X-ray examination in 100 
patients revealed pulmonary infiltration in 92%, cavities in 50%, miliary disease in 
5%, pleural effusions in 16%, and old fibrotic lesions in 48%. Bilateral disease was 
present in 74% patients, and 22% showed abnormalities in all lungfields. 
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Table 1.  Patient characteristics (n=100).  
 
 
Men / women (%) 
 
57 / 43 
Age (yr) 29 (23 – 41) 
Duration of symptoms (mo) 3 (2 – 6) 
Cough (%) 100 
Hemoptysis (%) 38 
Dyspnea (%) 77 
Chest Pain (%) 72 
Fever (%) 60 
Night sweats (%) 68 
Reported weight loss (kg) 5 (1.8 – 10) 
Body weight (kg) 43.3 (36.6 – 47.7) 
Body Mass Index (kg/m2) 16.9 (15.3 – 18.7) 
Smoking (%) 35 
Previous anti-TB treatment (%) 
       < 1 yr before presentation 
       full course * 
       insufficient regimen ** 
25 
14 / 25 (56%) 
2 / 25 (8%) 
19 / 25 (76%) 
TB in family or household (%) 12 
Continuous variables are presented as median (interquartile range).  
* 2HRZE,4H3R3 ** too short (< 5 months), or too limited (< 3 drugs);  
see section ‘clinical presentation’ 
 
 
Twenty-five patients had previously been treated for tuberculosis, 14 (56%) 
within 1 year before presentation (Table 1). Only two patients (8%) had been 
prescribed adequate treatment for 6 months (2HRZE, 4H3R3), while 19 (76%) had 
received insufficient treatment. In 14 patients the duration of treatment had been too 
limited (range: 1-5 months). In an additional 5 patients, monotherapy with rifampicin 
(n = 2) or pyrazinamide (n = 1), or treatment with two drugs only (n = 2) had been 
prescribed. In four patients, no data were available about the nature and length of 
previous antituberculous treatment. 
 
HIV-infection 
HIV-infection was found in one patient (1%), who presented with classical symptoms 
of tuberculosis and a chest X-ray showing widespread infiltration and a small cavity in 
the left upper lobe. Sputum microscopy and MTB culture were positive, no drug-
resistance was found, and the response to treatment was unremarkable. 
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drug resistance 
Drug susceptibility testing of patient isolates was performed in two laboratories. At 
the reference laboratory in the Netherlands, 55 out of 78 (70.5%) strains examined 
were fully susceptible, while 23 (29.5%) showed resistance against one or more 
antituberculous drugs. Susceptibility testing of 68 additional patient isolates from the 
same clinic showed similar results. In Table 2, overall resistance and individual 
patterns of all 146 strains are presented. Resistance was found to all first-line drugs 
including pyrazinamide. Nine strains (6.1%) were resistant to at least rifampicin and 
INH (multidrug resistance). At the WHO collaborative laboratory in Indonesia, 
oyrazinamide is not included in susceptibility testing. In addition, in comparison with 
the 78 strains tested at the supranational reference laboratory in the Netherlands, 
resistance to ethambutol (n=4) was missed in three patients, and monoresistance to 
INH (n=9) in one patient. On the other hand, resistance to streptomycin was falsely 
diagnosed in six patients, and multidrug resistant tuberculosis in two. 
Drug resistance (as established in the supranational reference laboratory) was 
higher in retreatment cases than in new cases (39.5% vs 25.9%; P =0.08). Among 
retreatment cases, many were resistant to drugs they had never been treated with 
(data not shown). Out of nine multidrug resistant cases, five had never been treated 
for tuberculosis and one (who was resistant to all five drugs tested) had been 
prescribed a full course of antituberculous drugs in 1991. 
 
 
treatment 
Early in the course of treatment, one patient was referred to hospital with severe 
hemoptysis, and one patient died. The majority of patients however, improved within 
weeks. Fever abated after one or two weeks and most complaints resolved within 
four to six weeks of therapy. After two months, 70 out of 88 patients evaluated (80%) 
had gained a median of 2.5 kg of weight (range: 0.5 - 9), while 16 (18%) had lost 1.1 
kg (range: 0.8 – 2.1). The fasting month may have contributed to weight loss in some 
patients.  
Many patients suffered from mild and transient side effects of the 
antituberculous medication. Among 95 patients evaluated, only four males and one 
female remained without side effects during the first two months of treatment. Out of 
95 patients evaluated, 62 (65%) reported gastrointestinal complaints, while 63 
patients (66%) complained about painful joints, and 67 patients (71%) about itching. 
Blurred vision and color blindness, a possible side effect of ethambutol, was present 
in five patients. One patient developed a peripheral neuropathy. Hepatotoxicity was 
not established: neither jaundice, nor a three-fold rise in liver transaminases was 
found. 
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Table 2. 
Drug resistance of MTB isolates * 
 
 new cases  
(n=108) 
retreatment cases 
(n=38) 
all cases  
(n=146) 
    
Overall resistance    
INH 23 (21.3%) 13 (34.2%) 36 (24.7%) 
rifampicin 5 (4.6%)  4 (10.5%) 9 (6.1%) 
any first-line drug 28 (25.9%) 15 (39.5%) 43 (29.5%) 
    
Resistance patterns #    
HRZES 0 1 1 
HRES 1 0 1 
HRS 2 1 3 
HR 2 2 4 
HES 1 0 1 
HE 1 1 2 
HS 4 1 5 
H 12 7 19 
Z 2 1 3 
S 3 1 4 
fully susceptible 80 23 103 
    
* resistance patterns from 78 isolates from the original patient cohort and 68 additional non-
selected isolates were combined (see: methods). # H= INH, R= rifampicin, Z= pyrazinamide, 
E= ethambutol, S= streptomycin.  
 
 
 
outcome 
The overall cure rate, mostly based on documented sputum conversion, was 75% 
(Table 3). Due to difficult expectoration of sputum, bacteriological evaluation at 6 
months was limited. The proportion of patients that defaulted was 10%. No significant 
differences were found between non-adherent and adherent patients with regards to 
age, sex, disease severity, and distance to the outpatient clinic (data not shown). 
During six months of treatment, seven patients (7%) died (three females, four males; 
age: 18 – 46 years). Four suffered from respiratory failure, two from massive 
hemoptysis, and one patient reportedly died with “high fever”. At presentation, chest 
X-rays had revealed extensive cavitary disease in four, widespread pulmonary 
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infiltrates in two, and a destroyed lung in one patient. Patients who died had a lower 
BMI at presentation than patients who survived (14.7 versus 17.0; P = 0.02). Drug 
resistance had not been detected in any of the patients who died. One patient who 
died had received an incomplete course of antituberculous drugs six months before 
presentation, while six others had never been treated before. All patients who died 
had initially shown a positive response to treatment, and all had gained some weight.  
 
 
 
Table 3. 
Treatment outcome in 100 tuberculosis patients * 
 
Cured / completed treatment  
 
75 
Treatment defaulted 
      < 2 months 
      > 2 months  
10 
          7 
          3 
Incomplete treatment 2 
Treatment failure 3 
Transfer out 3 
Death 
      < 2 months 
      > 2 months 
7 
         1 
         6 
 
* Cured: negative sputum smear on 2 occasions after treatment. Completed treatment: 
negative sputum smear 2 months after start of treatment, with no or only 1 negative sputum 
smear after treatment completion. Treatment defaulted: < 4 mths of treatment. Incomplete 
treatment: between 4 and 5 months of treatment, with negative sputum smear received 2 
months after start of treatment. Treatment failure: > 5 months of treatment, with signs of 
active disease including sputum smear positive results > 5 months after start of treatment. 
Transfer out: transferred to another clinician. Death: death, irrespective of cause.  
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Discussion 
 
This report presents a detailed description of a cohort of Indonesian patients with 
tuberculosis. In the current TB-epidemic in Indonesia, little information is available 
with regard to important clinical aspects like quality of diagnosis and treatment, 
prevalence of HIV-infection, and presence of drug resistant MTB isolates. The size of 
the study population and the fact that it was included at a single outpatient clinic, limit 
the generalizability of the results. However, although our findings may not be 
representative, health workers in Indonesia and elsewhere may face similar 
difficulties while caring for the large number of patients with suspected tuberculosis.  
 
The majority of patients in this cohort presented with classical symptoms of 
pulmonary tuberculosis. Cough was present in all patients, and weight loss was very 
common. Also, hemoptysis and shortness of breath, signifying extensive 
parenchymal involvement, were often present. Ninety-four percent of patients 
presented after more than one month of symptoms. HIV-seroprevalence was low 
(1%), in accordance with another recent survey in the Infectious Disease Hospital in 
Jakarta, in which two out of 99 tuberculosis patients were HIV-positive (Dr. R.H.H. 
Nelwan, personal communication). 
 
Accurate diagnosis is important for control of tuberculosis. Unfortunately, in 
Indonesia antituberculous drugs are often prescribed without bacteriological 
confirmation of tuberculosis. Because of this, some (infectious) patients will remain 
untreated, while others not suffering from tuberculosis will unnecessarily receive 
precious medication. In light of the very large number of patients with suspected 
tuberculosis, any proportion of false positive diagnosis will have serious health 
economic consequences. In this report it was shown that microscopy of two large 
sputum samples was a very strong and cost-effective diagnostic tool, with high 
sensitivity and specificity for tuberculosis. This high diagnostic yield of sputum 
microscopy is a remarkable finding. Obviously, in an endemic setting, patients have a 
high risk of suffering from active tuberculosis. A recent report showed that sputum 
microscopy may be 80% sensitive in patients with a high (> 75%) clinical suspicion of 
tuberculosis [13]. In addition, we believe that introduction of large sputum containers 
and intensified instruction shortly before this study may have led to an increased 
number and better quality of sputum samples collected. Sputum culture rarely 
became positive in smear-negative cases and remained negative in 12% of smear-
positive patients. This may have been due to the decontamination procedure used or 
to the fact that only a single culture was done for every patient.  
 
In this cohort, drug resistance was found against all first-line drugs with 25% of 
isolates resistant to INH, and 6% to rifampicin. Testing of isolates from 68 additional, 
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non-selected patients from the same clinic confirmed these findings. These figures 
are high, but still lower than reported in a hospital survey (Annual Report St Carolus 
Hospital, 1994) and by the WHO-collaborative laboratory: both showed > 30 % 
resistance against INH and > 10 % against rifampicin [7]. Significant differences were 
found between results from the local laboratory and a supranational reference 
laboratory. For technical and economic reasons, culture and drug susceptibility 
testing of MTB isolates is very limited in Indonesia. Proficiency testing or 
supranational supervision is not routine.  
In Indonesia, the majority of patients is treated outside the national program. Of our 
patients, 25% had previously received antituberculous treatment. Most drug 
regimens had been inadequate, which may have contributed to the development of 
drug resistance. However, one out of every four patients not previously treated for 
tuberculosis was infected with a drug resistant strain. Among patients with recurrent 
disease, we were unable to correlate previous treatment regimens with drug 
resistance patterns. Therefore, recurrent disease in this highly endemic setting may 
result from exogenous reinfection rather than from relapse [14].  
 
Several observations were made with regard to treatment. Firstly, even though the 
dosage of antituberculous drugs was not adjusted for body weight in these 
malnourished patients and side-effects were common, hepatotoxicity was absent in 
this study cohort. Insufficient compliance during weekly-supervised treatment 
provides a possible explanation. Alternatively, drug absorption is reduced, 
metabolism is altered, or quality of locally produced drugs is sub-optimal. Further 
investigations are necessary to elucidate this issue. Second, the default rate (10%) in 
this cohort, although much lower than the WHO-reported national average, leaves 
room for improvement. Within this small cohort, we were unable to identify patient 
characteristics related treatment default. Third, with respect to treatment outcome, 
the single most important risk factor for death was malnutrition. Protein-energy 
malnutrition and micronutrient deficiencies, which may both affect host defense 
against tuberculosis, are common among Indonesian tuberculosis patients [8]. 
Supplementation of vitamin A and zinc had beneficial effects in Indonesian patients 
[15].  
 
In summary, this explorative study provides useful information about various clinical 
aspects of tuberculosis in Indonesia. With regard to diagnosis, sputum microscopy is 
a very sensitive and specific diagnostic tool in this endemic setting. This may be due 
to the fact that disease was longstanding, but we think that collection of large and 
good quality sputum samples may help to increase the case-detection rate and to 
limit false-positive diagnosis and unnecessary prescription of antituberculous drugs. 
The observed drug resistance patterns warrant the implementation of more extensive 
and reliable susceptibility testing. HIV-infection is still rare in this setting, but 
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malnutrition is common, and nutritional interventions may benefit treatment outcome. 
Data on previous treatment regimens and the current default rate led us to conclude 
that at least in this urban setting, many Indonesian patients receive insufficient or 
incomplete drug therapy. All together, although our findings may not be 
representative, they highlight some of the problems of clinical management of 
tuberculosis patients in Indonesia.  
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Abstract 
 
 
In many resource-poor settings, low yield of sputum microscopy may contribute to 
insufficient TB case-detection. The number and quality of sputum samples provided 
by the patient may be important in this respect. After introduction of larger sputum 
containers and education of health staff and patients, we observed a sustainable two-
fold increase of the smear-positivity rate in an urban clinic in Indonesia during three 
years follow-up. This effect was confirmed in a randomized controlled study; brief 
counselling by paramedics resulted in a substantial increase in positive samples, 
number of acid-fast bacilli per sputum slide, and patients diagnosed with smear-
positive TB. The effect of education was especially pronounced in female patients. 
Simple interventions like these may increase TB case-detection in Indonesia and 
elsewhere. 
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Microscopic detection of acid-fast bacilli (AFB) in sputum is the mainstay for 
diagnosing pulmonary tuberculosis (TB). According to the textbooks, the sensitivity of 
sputum microscopy for TB is 60-80%. Unfortunately, in resource-poor settings with a 
high burden of TB, case-detection is often much lower [1]. This is probably caused by 
low access to health service and insufficient quality of sputum microscopy. In 
addition, the number and quality of sputum samples provided by the patient may be 
important [2]. We evaluated the effect of education in combination with large sputum 
containers on the yield of sputum microscopy for TB in two urban clinics in Indonesia. 
 
 
In September 1998, an observational study was started to describe the clinical 
and microbiological status of patients in a TB-control clinic in a poverty area of 
Jakarta, Indonesia. Patients in this clinic usually present with longstanding and 
severe disease. However, at that time, many patients with extensive radiographic 
abnormalities remained sputum smear (AFB)-negative. In this resource-poor setting, 
the staining method was used correctly, the microscopist was well trained and the 
microscopes were functioning well. However, we noted that very small containers 
were used for sputum collection and that many patients provided saliva rather than 
sputum. In an effort to increase case detection, larger sputum containers were 
introduced. In addition, health staff from then onwards instructed the patients to 
provide bigger samples of early-morning sputum. Within weeks, the number of AFB-
positive patients increased substantially. Since then, with no further adjustments to 
the diagnostic process, case detection has remained approximately two-fold higher 
than before (see Figure 1).  
 
 
To examine the role of patient education more closely, patients with newly 
suspected tuberculosis were randomly assigned to a control or an intervention group 
in an outpatient TB-clinic of a general hospital in Bandung, Indonesia. Patients in the 
control group followed the routine procedure for sputum collection. Patients in the 
intervention group were addressed individually by a paramedic, who briefly explained 
about the importance of sputum examination and instructed the patient how to 
produce adequate samples. Large clear sputum containers (diameter 5 cm, height 7 
cm) were used in both groups. Microscopy of sputum smears was performed by 
laboratory technicians who were unaware of the patient’s identity or study group. 
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Figure 1.  
AFB (acid-fast bacilli)-positive patients as % of the total number of patients examined in an 
urban TB-clinic in Jakarta, Indonesia (January 1996 – July 2001). Since September 1998, 
larger sputum containers are used, and patients are instructed to provide good-quality 
sputum. Since this time, 1792 out of 8858 patients have been found AFB-positive 
(20.23%), compared with 706 out of 6822 patients (10.34%) in the previous 3-year period 
(P < 0.001) 
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We randomized 110 patients with suspected TB (57 males and 53 females, 35.5 +/- 
17.3 years of age). The control (n=60) and intervention group (n=50) were similar in 
terms of duration of disease, symptoms and chest X-ray abnormalities (data not 
shown). A higher sputum smear-positive TB rate was found in the intervention group 
; 22 patients of the intervention group  (44%) compared with 18 (30%) of patients in 
the control group were AFB positive (NS). Patients provided a total of 268 sputum 
samples; 141 for the control group and 127 for the intervention group. In the 
intervention group, the volume, purulence and leucocyte count of sputum samples 
was significantly higher (data not shown). In addition, the smear-positive rate 
(number of positive samples / number of samples examined) and density of AFB 
were higher (Table 1). Fifty-six out of 127 (44%) samples in the intervention group 
were AFB-positive compared with 40 out of 141 (28%) in the control group (P < 0.01). 
Interestingly, smear-positive rate and effect of education were different between 
males and females. In females, 26% of specimens in the control group were positive, 
versus 58% in the intervention group (P < 0.001). In males this difference was not so 
profound (33% vs. 39%, NS).   
 
The number of patients examined in this controlled study limits its statistical 
power. However, the main conclusion of this trial is very much supported by 
evaluation of 6822 patients before, and 8858 patients after a simple intervention in a 
TB-clinic as presented in Figure 1. Therefore, we conclude that simple means to 
improve volume and quality of sputum samples may result in a substantial and 
sustainable increase of the diagnostic yield of sputum microscopy for TB in a high-
burden setting. Interestingly, the effect of education seems to be much larger in 
females. Previous reports have shown a lower case-detection of TB in females [3]. In 
South East Asia, the estimated female / male ratio is 0.3 [4]. This is probably caused 
by a lower disease prevalence in women [4]. Our study indicates that quality of 
sputum samples may also contribute to this difference and that education may help 
to improve diagnosis in female patients with suspected TB. We hypothesise that for 
socio-cultural reasons, women in Indonesia may be reluctant to provide purulent 
sputum. Implementation of simple and cheap interventions like these may contribute 
to early diagnosis and treatment of TB, which will benefit both the individual patient 
and the community.  
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Table. 1 
Characteristics of sputum samples provided by patients randomly assigned to the routine 
procedure (n=60) or educational intervention (n=50) in a general hospital in Bandung, 
Indonesia. The IUATLD scoring-system was used to quantify the AFB.  
 
 
 Control group 
 
Intervention group 
Number of samples 141 127 
Samples / patient (no.) 2.35 +/-  2.54 +/- 
Density of AFB on sputum smear *   
         0       101  (71.6%)         71   (55.9%) 
         +         29  (20.6%)          26   (20.5%) 
         ++           6    (4.3%)         17   (13.4%) 
         +++           5    (3.5%)         10     (7.8%) 
Any positive *         40  (28.4%)         56   (44.1%) 
* significantly different between groups; P < 0.05 (Fisher exact-test, two-sided) 
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Abstract 
 
 
DNA fingerprinting has demonstrated predominance of the ‘Beijing’ genotype among 
Mycobacterium tuberculosis strains isolated in South East Asia. We prospectively 
examined the occurrence of Beijing genotype strains in tuberculosis patients in 
Indonesia. Of the 93 M. tuberculosis isolates, 32 (34%) were of the Beijing genotype. 
Beijing strains were more often resistant to INH (36% vs. 20%) and streptomycin 
(15% vs. 5%), but the rate of multi-drug resistance was low. No significant 
associations were found between the M. tuberculosis genotype and patient’s age, 
BCG vaccination status or clinical presentation. However, within the first weeks of 
treatment, patients infected with Beijing genotype strains more often (48% vs. 21%; P  
= .02) developed a febrile response, which was not related to disease severity, 
toxicity or drug resistance. This finding indicates that Beijing genotype strains may 
have specific pathogenic properties, possibly contributing to their spread. 
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Introduction 
 
In 1995 DNA fingerprinting has shown that the vast majority (over 80%) of a 
collection of Mycobacterium tuberculosis isolates from China belonged to a 
genetically closely related group of bacteria, designated the “Beijing genotype family” 
[1]. Strains of this genotype family were also found to dominate in neighboring 
countries in South East Asia, whereas a lower prevalence was found on other 
continents [1]. Recently, it was shown that 50% of the 563 isolates from Vietnam 
belonged to the Beijing genotype and, moreover, that the occurrence of these strains 
correlated significantly with young age and, hence, with active transmission of 
tuberculosis [2]. It was speculated that strains of the Beijing family recently expanded 
from an evolutionary lineage with an unknown selective advantage over other M. 
tuberculosis genotypes [1]. ‘Strain W’, a highly drug-resistant strain which caused 
large nosocomial outbreaks in New York City in the early 90’s [3,4], is an evolutionary 
branch of the Beijing genotype family [5]. 
 
Worldwide, Indonesia has the third highest number of tuberculosis patients with an 
estimated 591.000 cases in 1998 [6]. No data have been published from Indonesia 
on the distribution of M. tuberculosis genotypes. We prospectively collected 
demographic and clinical data and performed DNA fingerprinting of M. tuberculosis 
isolates from a cohort of Indonesian patients in Jakarta. This enabled us to assess 
the prevalence of the Beijing genotype strains, and to compare drug-resistance and 
clinical course of patients infected with Beijing- and other genotype strains of M. 
tuberculosis. 
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Methods 
 
Patient inclusion and follow-up 
From December 1998 through March 1999, 121 consecutive patients were included 
at the Perkumpulan Pembertasan Tuberkulosa Indonesia (PPTI), an outpatient 
tuberculosis clinic in a densely populated area in Jakarta. Demographic data, 
symptoms and signs, risk factors for tuberculosis, and details about previous 
antituberculous therapy were recorded. From three large volume sputum samples, 
microscopy for acid-fast bacilli (AFB) and culture for M. tuberculosis were performed. 
Chest X-rays were made before start of treatment and evaluated by two experienced 
pulmonologists. HIV-seroprevalence was determined. Informed consent for the 
investigations was obtained from all patients. When tuberculosis was bacteriologically 
confirmed, a standard four-drug regimen (INH, rifampicin, pyrazinamide and 
ethambutol) was prescribed [7]. During follow-up, physical complaints, body 
temperature and weight were recorded.  
 
Culture of mycobacteria and drug susceptibility testing  
After standard processing of sputum samples, culture was performed in 3% Ogawa`s 
medium. Twice weekly, slants were examined for the appearance of colonies. At the 
National Institute of Public health and the Environment (RIVM), Bilthoven, the 
Netherlands, susceptibility testing of patient isolates was done using serial dilutions 
of five antituberculous drugs on Middlebrook’s medium [8]. The minimal inhibitory 
concentration used to define drug-resistance were: INH 0,2 mg/l, rifampicin 1 mg/l, 
ethambutol 5 mg/l, streptomycin 5 mg/l, and pyrazinamide 50 mg/l. 
  
DNA fingerprinting and spoligotyping 
Genotyping of mycobacterial isolates was done using restriction fragment length 
polymorphism (RFLP) typing. Extraction of DNA from M. tuberculosis strains and 
Southern blotting with labeled IS6110 DNA as a probe were done by standard DNA 
fingerprinting method [9]. Spacer oligonucleotide typing (spoligotyping) of M. 
tuberculosis DNA from patient isolates was done as previously described [10]. From 
culture-negative patients, M. tuberculosis DNA for spoligotyping was directly isolated 
from sputum smears [11]. Isolates were classified as Beijing genotypes when a 
hybridization reaction was found on the last nine spacers (35-43) in spoligotyping [1]. 
The computer-assisted analysis of the IS6110 fingerprints was done with the 
Windows version of Gelcompar (Applied Maths, Kortrijk, Belgium). 
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Statistics 
Descriptive results for continuous variables are reported as median (range), and for 
categorical data as percentages. Mann-Whitney U test was used for comparison of 
continuous variables, and Pearson chi-squared test for proportions. All reported P 
values are two-sided, and the level of significance was set at P < .05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
 
Genotyping and susceptibility testing of M. tuberculosis strains  
In 121 consecutive patients with a clinical diagnosis of tuberculosis, direct 
examination of at least one sputum smear was positive for AFB in 89 patients (73%), 
and M. tuberculosis was cultured from 84  of 113 single cultures performed (75%). 
Figure 1 represents the IS6110 restriction fragment patterns of these samples. The 
vast majority (85%) of strains demonstrated a fingerprint pattern not found in other 
strains included in this study. Twenty-eight strains exhibited a high number of 
IS6110-containing restriction fragments and a very high degree of similarity (> 66%). 
This homogenous group of isolates represented the Beijing family of genotypes, as 
was confirmed by spoligotyping (Figure 1). Direct spoligotyping on sputum smears of 
culture-negative patients added another four patients with Beijing strain infections. All 
together, from a total number of 93 M. tuberculosis strains analyzed (84 cultured 
isolates, using IS6110 RFLP and spoligotyping; and 9 stained sputum smears, using 
spoligotyping only), 32 strains (34%) were Beijing genotypes.  
Cultures became positive for M. tuberculosis after 4.7 weeks for Beijing strains 
compared with 5.2 weeks for non-Beijing strains (NS). Drug susceptibility testing 
revealed a trend towards a higher prevalence of resistance to INH (36% vs. 20%; p = 
.09) and streptomycin (15% vs. 5%; p = .16) in Beijing strains compared with non-
Beijing strains (Table 1). There was no significant difference between the two groups 
in the prevalence of multidrug resistance (7% vs. 4%). Both for Beijing and non-
Beijing strains, drug resistance was equally found among different age groups (data 
not shown). 
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Figure 1. 
Dendrogram showing similarity of the 84 IS6110 RFLP patterns of M. tuberculosis  isolates 
from Jakarta, in combination with the respective spoligo patterns.  
The branch in the dendrogram representing Beijing genotype isolates is indicated with an 
asterix (*).
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Comparison of patients according to M. tuberculosis genotype 
The characteristics of patients infected with Beijing genotypes (n=32) were compared 
to the ones of patients infected with other strains (n=61) (Table 1). The age 
distribution in the two groups was similar, although no patients under the age of 16 
were evaluated. No relation was found between genotype and BCG vaccination 
status either (Table 1). Of the patients infected with Beijing strains, 7 (22%) had been 
using one or more antituberculous drugs before, compared to 18 (29%) of patients 
infected with non-Beijing strains. Only two patients (one in either group) had been 
prescribed a standard regimen for 6 months. At time of presentation, there were no 
significant differences in the presence of fever, dyspnea or hemoptysis, or the 
duration of symptoms (data not shown). The nutritional status in both groups of 
patients was similar as judged by body mass index (17 vs. 16.9 kg/m2). The smear-
positivity was equally high in both groups, and the density of acid-fast bacilli in 
sputum smears was similar (data not shown). Radiographic evaluation of patients did 
not reveal significant differences either; the number of lungfields involved was similar 
and an equal percentage in both groups presented with pulmonary cavities (Table 1). 
Only one patient in this cohort, presenting with cavitary tuberculosis, appeared HIV-
positive; this patient was infected with a Beijing strain. 
Patients were evaluated at weekly intervals. The majority of patients 
demonstrated an early and beneficial response to treatment. In both groups, 20 % 
continued to lose weight during the first two months. Body weight increased a median 
of 2 kg (range: 0 – 8 kg) in the remaining patients in both groups. No relation was 
found between drug resistance and changes in body weight. At six months patients in 
both groups had equally gained weight (median: 5 kg). No active disease was 
established at this point, but treatment was extended in patients with multiple drug 
resistance.  
Thirty two percent of the patients developed fever (> 380 C, maximum 39.30 C) 
during the first weeks of treatment. No patient reported shaking chills during this 
period. Interestingly, this transient febrile response, which lasted 2 to 3 weeks, was 
found in 15 out of 31 patients (48%) infected with Beijing strains compared with 13 
out of 61 patients (21%) with non-Beijing strains (p = .02). Drug resistance could not 
explain this finding: 46% of patients infected with a fully susceptible Beijing strain 
compared with 19% of patients infected with susceptible non-Beijing strains showed 
a febrile response (p = .06). Disease severity did not account for this difference either 
as there was no association between the febrile response and the nutritional status, 
or between fever and the presence of pulmonary cavities (data not shown). Drug-
toxicity, which may also induce fever, was not established. 
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Table 1. 
Drug resistance and patient characteristics according to M. tuberculosis genotype. 
 
  
Beijing (n=32) 
 
 
non-Beijing (n=61) 
 
Male 
 
19 (59%) 
 
35 (57%) 
Age (years) 31 (19-68) 29 (17-70) 
BCG-scar 8 (25%) 14 (23%) 
Chest X-ray 1 
Cavities 
Bilateral disease 
 
16 (50%) 
25 (78%) 
 
29/55 (53%) 
40/55 (73%) 
Patient strain resistant to 2 
INH 
Rifampicin 
Pyrazinamide 
Ethambutol 
Streptomycin 
Any prescribed drug  
 
10 / 28 (36%) 
2 / 28 (7%) 
0 
1 / 28 (4%) 
4 / 28 (14%) 
11 / 28 (39%) 
 
11 / 54 (20%) 
2 / 54 (4%) 
3 / 54 (5%) 
3 / 54 (5%) 
3 / 54 (5%) 
14 / 54 (26%) 
Febrile response to treatment * 15 / 31 (48%) 
 
13 / 61 (21%) 
 
 
1 Six chest X-rays in the non-Beijing group were only evaluated by a single pulmonologist. 
2 In both groups, 88% of patients was culture-positive, providing 28 respectively 54 
isolates for susceptibility testing. * Significant difference between groups (Mann-Whitney-
U test; P  = .02). 
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Discussion 
 
Worldwide, DNA fingerprinting has revealed extensive heterogeneity of M. 
tuberculosis genotypes [12]. However, a distinct and predominant group of M. 
tuberculosis genotypes, termed Beijing, has been found in the People’s Republic of 
China and neighboring countries [1,13]. The present study indicates that Beijing 
strains are also present in the Indonesian archipelago.  
 
The prevalence of Beijing strains found in China (85%), Mongolia (50%), South 
Korea (43%), Thailand (37%), Vietnam (50%) and Indonesia (34%) suggests that this 
clone spreads in South East Asia, where tuberculosis is endemic. However, also in 
former USSR republics Azerbaijan and Estonia [14,15], and in Cuba [16], the Beijing 
genotype strains account for a significant part of tuberculosis cases involving 
(multidrug) resistance. Strain W, which also represents the Beijing genotype family 
[5], caused outbreaks of MDR-TB during the past decade in the United States [3,4] 
and in South Africa [17]. In summary, all reports on the occurrence of Beijing 
genotypes show a clear correlation with drug resistance. In our study, 36% of the 
Beijing strains was resistant to INH. However, multi-drug resistance was limited, 
which makes it unlikely that drug resistance is the single explanation for the 
predominance of Beijing strains in this population.  
 
Different transmission rates may also account for an unequal distribution of 
genotypes. In a tuberculosis outbreak in the United States, a particular M. 
tuberculosis genotype caused extensive transmission, as evaluated by skin test 
conversion [18]. In Indonesia, outbreak investigations like these seem impossible in 
light of the high prevalence of tuberculosis, and standard BCG vaccination that 
hampers the interpretation of tuberculin skin tests. However, indirect evidence 
supporting an increased transmission of Beijing strains comes from a recent study in 
Vietnam, which demonstrated that Beijing strains were more prevalent among young 
patients [2]. We could not confirm this in the Indonesian patients, but we did not 
investigate patients under 16 years of age. In agreement with the study in Vietnam, 
we did not find a correlation between vaccination status and genotypes. 
 
Disease severity in patients infected with Beijing or non-Beijing genotypes seemed 
similar. However, our prospective evaluation revealed a different response to 
treatment. In 48% of the patients infected with Beijing strains and 21% of the other 
patients a transient febrile response was found shortly after start of antituberculous 
treatment. Neither disease severity nor drug toxicity or drug resistance accounted for 
this difference. The increased febrile response in patients with Beijing strains is 
remarkable and suggests that Beijing strains elicit a different host response. Although 
the number of isolates limits the power of this study, it is tempting to speculate that 
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this is relevant to the distribution of Beijing genotypes. There may be an interesting 
parallel with the outbreak in the United States, as mentioned above [18], since the 
causative strain in that outbreak, designated CDC1551, induced a more rapid and 
robust in-vitro production of pyrogenic cytokines like interleukin-6 and tumor necrosis 
factor-α [19]. It remains to be determined whether Beijing strains also elicit a different 
cytokine response in animal models or patients. 
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Abstract 
 
 
Rifampicin is a key drug in tuberculosis treatment, yet little is known about its quality 
and bioavailability in countries endemic for tuberculosis. High drug levels may lead to 
increased toxicity, while low drug levels may predispose for treatment failure and 
relapse. We measured plasma concentrations of rifampicin among 62 nonselected 
tuberculosis patients in Jakarta, Indonesia and tested the rifampicin content of the 
drug formulations in use. Plasma concentrations were related to patient 
characteristics, drug manufacturer, toxicity, treatment outcome and in vitro 
susceptibility of patient M. tuberculosis isolates. The plasma concentrations of 
rifampin were generally low: 70% of patients had two-hour plasma concentrations 
(Cmax) below 4 mg/L. No toxic plasma concentrations of rifampicin (> 20 mg/L) were 
found. The strongest predictive factor for the magnitude of rifampicin concentrations 
was the drug manufacturer. The rifampicin content of the different drug preparations 
used was between 90.5 and 103.6% of the reference standard. The median ratio 
Cmax / MIC was 9.8 (range: 0 - 46.8). No association was found between low plasma 
rifampicin concentrations and delayed sputum conversion or treatment failure. The 
unexpectedly low plasma concentrations of rifampicin, which were found in this 
setting, are most likely due to reduced bioavailability of local drug preparations, as 
rifampicin content of the drug preparations was normal.  
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Introduction 
 
Because of its strong antimycobacterial capacity, rifampicin is necessary for 
successful first-line antituberculous treatment [1]. Little is known about its 
bioavailability and pharmacokinetics in resource-poor countries where more than 
95% of the world’s tuberculosis patients reside [2]. On the one hand, the low body 
weight of tuberculosis patients may be associated with higher drug levels and 
increased drug-toxicity [3]. On the other hand, if absorption of these drugs is impaired 
[4], or quality of locally produced antituberculous drugs is uncertain [5,6], one may 
find low drug concentrations. Such low drug concentrations, especially of rifampicin, 
may predispose to treatment failure or relapse [7,8]. We investigated possible 
variation of the bioavailability of rifampicin in Indonesia, a country with a high 
tuberculosis case-load [9], which is strongly associated with malnutrition [10].  
 
 
 
 
Methods 
  
patients 
Between September and December 2000, 62 consecutive patients with 
microbiologically proven pulmonary tuberculosis were investigated in an outpatient 
tuberculosis clinic in Jakarta, Indonesia. In accordance with the Indonesian national 
guidelines, treatment consisted of isoniazide (INH) 300 mg, rifampicin 450 mg, 
pyrazinamide (PZA) 1500 mg and ethambutol 750 mg daily for two months, followed 
by INH 600 mg and rifampicin 450 mg three times weekly for four months [11]. 
Treatment was not adjusted for body weight. For every patient, a single box with all 
medication for six months was kept at the clinic throughout the period of treatment. 
All patients visited the clinic at weekly intervals, when drug intake was observed by 
health personnel and medication was provided for the remaining days of the week. 
Patients received all drugs free of charge. The outcome of treatment was monitored 
using standard criteria [12]. This study was conducted with informed consent from all 
patients and with permission from the University of Indonesia.  
 
microbiology 
At least two sputum samples were collected for microscopy and culture before 
treatment, and after two and six months. Culture of M. tuberculosis was performed in 
3% Ogawa’s medium. Drug susceptitbility testing of isolates was done using serial 
dilutions of antituberculous drugs on Middlebrook’s medium [13]. Minimal inhibitory 
drug-concentrations (MIC) to define antimicrobial resistance were: 0.2 mg/L for INH, 
1 mg/L for Rif, 5 mg/L for ethambutol and streptomycin, and 50 mg/L for PZA.  
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measurement of rifampicin in plasma samples and drug preparations 
Patients were evaluated after 4 and 8 weeks of treatment, when stable drug levels 
were expected. Apart from analgetics and antitussives, no other co-medication was 
allowed. Patients were asked not to have breakfast on the morning of blood 
sampling. Witnessed intake of all four antituberculous drugs took place in the clinic 
between 8.00 and 10.00 a.m., at least 24 hours after previous drug intake. Two hours 
after drug intake, corresponding with the estimated time to maximum plasma 
concentrations of rifampicin [14], 10 ml of venous blood was collected. Following 
immediate centrifugation, plasma was separated and frozen at –200 C in 
polypropylene tubes containing 20 mg/mL ascorbic acid. All samples were stored at 
–800 C within 4 hours. Measurement of rifampicin in plasma samples was done by 
high performance liquid chromatography [15]. For measurement of rifampicin in drug 
formulations, two blisters were collected from every individual patient, each 
containing medication for a single day of intensive treatment. Manufacturer, batch-
number and expiration date of medication were recorded. Medication was kept in 
closed plastic bags at room temperature and protected from sunlight until analysis. 
For chromatographic measurement of rifampicin content, single tablets were 
dissolved by addition of MeOH, followed by ultrasonic centrifugation and 
homogenization.  
 
data analysis  
In patients with plasma concentrations of rifampicin available at weeks 4 and 8, the 
mean value was used for further analysis, unless one value was below 1 mg/L and 
less than 25% of the second value, in which case the lower value was excluded. 
Two-hour plasma concentrations (Cmax) of rifampicin > 20 mg/L were considered 
toxic, values between 8 and 20 mg/L therapeutic, between 4 and 8 mg/L “low”, and < 
4 mg/L subtherapeutic (“very low”)[16]. Plasma concentrations of rifampicin were 
correlated with gender, body weight, presence or absence of diarrhea, drug 
manufacturer and HIV-infection. Collected drug preparations of rifampicin were 
defined as substandard if they contained less than 85% or more than 115% of the 
reference standard [5]. The possible significance of low plasma concentrations was 
investigated by calculating the ratio of Cmax / MIC for rifampicin [17], and by 
comparing clinical and bacteriological outcome in patients with rifampicin 
concentrations below and above 4 mg/L.  
 
statistics 
Variables are represented as mean (SD) when normally distributed and as median 
(range) in all other cases. Pearson χ2-test, Student’s t-test, Mann-Whitney test and 
univariate regression analysis were used as appropriate. Statistical analysis was 
performed using SPSS version 9.0 for Windows (SPS Inc., Chicago, IL.). All reported 
P - values are two-sided, and the level of significance was set at P < 0.05.  
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Results 
 
Plasma concentrations of rifampicin 
Tuberculosis patients included in this study were mostly young adults and more often 
of male origin (Table 1). Moderate or severe malnutrition (body mass index < 17 
kg/m2) was present in 45%.  
 
 
 
Table 1. 
Patient characteristics 
 
Male gender 43 (69%) 
Age (yrs)* 34 (16 - 62) 
Sputum microscopy  
             +  18 
             ++ 32 
             +++ 12 
Ever treated for TB before 15 (24%) 
HIV-positive 1 (1.6%) 
Body weight (kg)* 45 (29 – 63) 
            < 33 kg 6 (10%) 
            33-50 kg 39 (63%) 
            > 50 kg 17 (27%) 
Medication (mg/kg body weight)*  
            INH  7.31 (4.76 – 10.34) 
            rifampicin    11.97 (7.14 – 15.52) 
            pyrazinamide 36.58 (23.81 – 51.72) 
            ethambutol   18.29 (11.90 – 25.86) 
  
* median (range)  
 
 
 
 
From 62 patients, 97 samples were available for measurement of rifampicin. The 
mean time recorded between witnessed drug-intake and blood sampling was 2 hours 
(+/- 5 min). From 35 patients, values of two separate measurements were available. 
In these patients, the coefficient of variation (SD/n) of plasma rifampicin 
concentrations four, respectively eight weeks after start of treatment was 36%. Toxic 
concentrations (> 20 mg/L) of rifampicin were not detected in any of the 97 samples. 
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Two-hour plasma concentrations of rifampicin were within the therapeutic range in 
two patients (3%), low (4-8 mg/L) in 17 patients (27%), and very low (< 4 mg/L) in 43 
patients (70%) (Figure 1). Three patients had undetectable rifampicin oncentrations. 
Rifampicin concentrations were significantly lower in male patients than in female 
patients (median 2.67 vs. 4.62 mg/L; P = 0.04; Figure 1). Fifty-three patients (85%) 
had been treated with drug formulations produced by manufacturer “A”, while 9 
patients (15%) had been treated with drugs from manufacturer “B” (both are leading 
manufacurers in Indonesia). Plasma rifampicin concentrations were 2.35-fold higher 
(95% CI: 1.45 – 3.26; P = 0.001) in patients treated with drugs from manufacturer “B” 
than in patients treated with drugs from manufacturer “A”. No significant correlation 
was found between body weight and plasma concentrations of rifampicin (R2 = 0.06). 
Diarrea (n=6) was not associated with lower plasma rifampicin concentrations. HIV-
infection was established in one patient, whose two-hour plasma rifampicin 
concentrations were < 1 mg/L on two separate occasions. 
Figure 1. 
Two-hour plasma rifampicin concentrations in 62 nonselected tuberculosis patients. Each 
dot represents one individual. Horizontal solid bars are the median for all patients, females 
and males respectively. Rifampicin concentrations > 8 mg/L were considered therapeutic, 4-
8 mg/L low, and < 4 mg/L subtherapeutic. 
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rifampicin content of drug formulations. 
From 59 patients, medication was available for analysis: 51 produced by 
manufacturer “A”, and eight by manufacturer “B”. Drug preparations from “A” were 
from three different batches. No medication was expired at time of treatment. The 
weight of tablets was 625 +/- 4.9 mg for “A”, and 901 +/- 18.9 mg for “B”. Rifampicin 
content was 93.6 +/- 1.3 % of the standard reference for tablets from “A”, and 100.1 
+/- 2.4 % for tablets from “B”. No single preparation had a content > 15% from the 
reference standard (range: 90.5 – 103.6%).  
 
clinical and bacteriological significance of plasma rifampicin concentrations 
During treatment, one patient died (1.6%) and 6 defaulted (9.7%). After six months 
treatment, 50 patients were cured (80.6%), two patients (3.2%) showed a 
bacteriological failure, and three patients (4.8%) were still on treatment because of 
delayed sputum conversion. The cure rate was higher in patients with rifampicin 
concentrations > 4 mg/L than in patients with concentrations < 4 mg/L (94.7% vs 
74.4%), but this was mainly caused by a higher default rate in the latter group. 
Weight gain and resolution of symptoms were similar in both groups (data not 
shown). No jaundice or symptomatic hepatitis occurred during treatment. Three 
patients (4.8%) developed a mild elevation of plasma transaminases (twice the upper 
limit of normal); no patient had transaminases greater than three times the upper limit 
of normal. Plasma concentrations of rifampicin in these patients were 3.31, 3.76 and 
7.38 mg/L respectively. After four weeks of treatment, concentrations of plasma 
rifampicin showed a weak correlation with plasma transaminases (R2 = 0.10; P = 
0.017).  
 
The bacteriological response was similar in patients with therapeutic and 
subtherapeutic concentrations of rifampicin: after two months of treatment, sputum 
culture was positive for M. tuberculosis in 25% and 20% of patients with plasma 
rifampicin concentrations < 4mg/L and > 4 mg/L respectively. Minimal inhibitory 
concentrations (MIC’s) for rifampicin were available for 43 M. tuberculosis isolates. 
The MIC for rifampicin was > 1 mg/L in 2 patients (resistant; 4.6%), between 0,5 and 
1 mg/L in 20 patients (intermediate; 46.5%), and < 0,5 mg/L in 21 patients (sensitive; 
48.8%). The median ratio Cmax/MIC for rifampicin was 9.7 (range 0 – 48.8). In 64% of 
patients with rifampicin concentrations < 4 mg/L, and in 16% of patients with 
concentrations > 4 mg/L, The Cmax/MIC was < 10 (P = 0.018). 
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Discussion 
 
In this Indonesian tuberculosis control clinic, 70% of patients had very low two-hour 
rifampicin plasma concentrations (< 4 mg/L), and no toxic concentrations of 
rifampicin were found. The absence of more than two-fold elevated serum 
transaminases during treatment, which normally occurs in 10-20% of cases, is in line 
with low exposure to antituberculous medication in this population.  
 
Our study is not the first to report low plasma concentrations of rifampicin in 
tuberculosis patients. In HIV-infected patients, low or absent 2-hour plasma 
concentrations of rifampicin and reduced total drug exposure have been reported 
[7,18-20]. In 22 non-HIV-infected tuberculosis patients, selected for a slow clinical 
response, treatment failure or relapse, 14 (64%) had plasma concentrations of 
rifampicin below the two-hour target range of 8 mg/L [21]. HIV-infection (1.6% in this 
patient group), diabetes and gastric surgery, which may all result in delayed 
absorption of rifampicin [4], cannot explain our results. Since rifampicin is rather 
unstable, patient studies are vulnerable to artefacts. However, by using a cold-chain 
and stabilization by ascorbic acid we have circumvented breakdown of rifampicin. 
The distribution of the rifampicin concentrations found also argues against decay. To 
increase precision, the majority of patients was evaluated twice on two separate 
days. In light of biological variability, the variation between the two measurements is 
relatively low. Although drug dosages were not adjusted to body weight (in line with 
the national TB-program in Indonesia), this did not account for variation of rifampicin 
concentrations. In accordance with a previous study, rifampicin concentrations were 
significantly lower in male than in female patients [22].  
 
Several recent reports have shown that drug content of antituberculous drugs may be 
insufficient [5,6]. Trade of “fake drugs” is widespread in some parts of the world [23]. 
Indonesia has had serious problems related to drug supply in recent years. We and 
others have occasionally found degraded and expired medication in Indonesia. 
However, no reduced rifampicin content was found in the tablets that had been 
prescribed to the patients in this study. Apart from drug content, other factors such as 
particle size, excipients and manufacturing process may affect bioavailability of 
rifampicin [24]. For example, major problems have been encountered in the 
manufacture of combined formulations of rifampicin plus INH and pyrazinamide [25]. 
In this study, more than a two-fold difference was found in plasma concentrations 
from patients treated with formulations from two different drug companies. Drug 
content of the respective formulations was only slightly different, which indicates that 
the problem must lie in reduced bioavailability. This finding reemphasizes the need 
for pharmacokinetic studies to ensure the quality of marketed formulations of a 
crucial drug like rifampicin [26]. 
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The clinical significance of finding low plasma concentrations of antituberculous 
drugs remains unclear because of the size of this study, which was only designed to 
test for bioavailability. To evaluate therapeutic efficacy would require a much larger 
study, since under supervised treatment, the bacteriological failure rate is in the order 
of 1-2% [27,28]. However, several case reports suggest that treatment failure and 
acquisition of drug resistance occurs with low drug levels [7,18,21,29,30].  
 
It is clear from the literature that the microbicidal effect of rifampicin is concentration 
dependent. The peak concentration after oral administration, which occurs around 2 
hours after ingestion [14] should be between 8 and 20 mg/L. Rifampicin 
concentrations between 4 and 8 mg/L are in a gray zone, and concentrations below 4 
mg/L are considered subtherapeutic. Such insights are derived from studies like the 
US Public Health Service trial in which a significantly higher percentage of 
bacteriological failures occurred in patients treated with 450 mg rifampicin than with 
600 or 750 mg [8]. Patients in this trial treated with < 9 mg rifampicin per kg per day 
had a higher failure rate than those treated with > 9 mg / kg. In another study, a dose 
reduction of rifampicin from 600 mg to 300 mg significantly decreased bactericidal 
acitivity [31]. In line with a concentration dependent effect, less frequent 
administration of rifampicin has no detrimental effects [32]. Rifampicin requires a high 
ratio between maximum plasma concentrations in relation to MIC (high Cmax / MIC) 
for optimal activity [17]. With a Cmax > 8 mg/L and a normal MIC of 0.25 mg/L, the 
estimated Cmax / MIC will be > 32. In our study, Cmax / MIC was less than 10 in 50% of 
cases.  
 
In summary, very low two-hour plasma rifampicin concentrations were found in the 
majority of a group of non-selected tuberculosis patients in Indonesia. The clinical 
significance of this finding is still unclear, but reduced bioavailability of rifampicin, and 
possibly other antituberculous drugs, may contribute to the low cure rates and 
frequent recurrence of tuberculosis in Indonesia [9]. Additional investigations are 
needed to evaluate the bioavailability of antituberculous medication and the 
pharmacokinetic properties of patients in this setting. 
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After Robert Koch discovered Mycobacterium tuberculosis as the cause of TB in 
1882, it would take more than 60 years until the first effective antituberculous drugs 
were developed. In 1948, in the first randomized controlled trial ever conducted [1], 
streptomycin showed remarkable results for treatment of TB. Soon thereafter it was 
discovered that mycobacteria readily become resistant to streptomycin alone. 
However, combination therapy with PAS, INH, and later rifampicin and pyrazinamide 
set the stage for eradication of TB. Now, another 60 years later, TB is more rampant 
than ever. Worldwide, millions of people, mostly in their productive age, suffer from 
active TB. Many of them die or become chronically ill. In large parts of the world, TB 
is as much the death sentence it was a hundred years ago.  
 
TB is an intriguing disease. How does one explain the highly variable disease 
presentation and localisation ? What are the mechanisms behind latent TB and 
reactivation ? What is the pathophysiology of tissue necrosis in TB patients ? What is 
the nature of a protective host defense against TB ? Questions like these have been 
addressed for decades and are still relevant today. From a pathophysiological point 
of view, better understanding of susceptibility and protective immunity may contribute 
to development of more effective vaccines and new therapeutic strategies.  
The operational approach has a very different starting point. Management of TB 
is complicated by problems of diagnosis and treatment. Late, false or missed 
diagnosis contribute to progression of TB and ongoing disease transmission. 
Inadequate or incomplete treatment and non-compliance of patients fuels drug 
resistance. Some of these issues are universal, but many problems are specific for 
particular geographic areas or health settings. Clinical, bacteriological and other (e.g. 
logistic) aspects of operational research may help to solve such problems. This will 
improve patient care and reduce the burden of tuberculosis.  
 
The first half of this thesis contains studies dealing with pathophysiological 
issues related to host defense in TB. Cytokine studies in TB-patients raised 
questions about clinical and bacteriological aspects of TB, leading to investigations of 
operational problems. These studies constitute the second half of this thesis. Below 
is a summary of the content of this thesis. 
Traditionally, acquired T-cell mediated immunity is thought responsible for 
protection in TB. Recently, attention has also focussed on natural, innate host 
defense mechanisms against Mycobacterium tuberculosis. Chapter 2 is a review of 
such innate host defense mechanisms in TB. Our natural response to M. tuberculosis 
can be divided in phagocytosis, immune recognition, the inflammatory response, 
effector mechanisms, and initiation of the adaptive T-cell response. At each level, 
inter-individual differences may account for variable disease susceptibility and 
outcome. Several genetic polymorphisms that may code for these differences have 
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been identified. It is expected that growing understanding of disease pathogenesis 
will ultimately help design of adjunctive treatment, especially in drug- resistant TB.  
Both innate and acquired immune responses are regulated by cytokines, the 
subject of study in chapters 3-5. The study of cytokine profiles in TB patients and 
control subjects may help to understand host defense in TB. Cytokine production in 
humans can be studied in vivo, in the circulation and at the tissue level, and ex vivo 
by stimulation of isolated cells. For ex-vivo cytokine production, whole blood assays 
have theoretical and practical advantages. In chapter 3, whole blood cultures were 
evaluated for non-specific and specific production of monocyte- and lymphocyte-
derived cytokines. Dose-response, kinetics and variability of production of five pro- 
and anti-inflammatory cytokines were compared in undiluted and diluted whole blood. 
Stimulation and incubation of undiluted heparinized blood in closed vacutainer tubes 
has major advantages: simplicity, low contamination risk and minimal in-vitro 
manipulation. The addition of culture medium provides a more sensitive test using 
very small volumes of blood. PPD and MTB culture filtrate selectively induced 
production of interferon (IFN)-γ in skin-test positive individuals, and may therefore be 
used for diagnostic purposes and for identification and exploration of T-cell 
unresponsiveness in TB patients. The characteristics of whole blood determine both 
its advantages and drawbacks for cytokine assays: with optimal standardization, 
whole blood remains a ‘black box’ with many possible confounders. Still, this assay 
has been used successfully in several field studies, especially in Indonesia [2-4]. 
With slight adjustments, it is now employed in an immunogenetic study of TB in 
Indonesia [5]. 
In TB, cellular immunity is considered responsible for eradication of infection but 
also for damage of host tissues. In animal models, the balance between Th1-type 
cytokines, especially IFNγ, and Th2-type cytokines, primarily interleukin (IL)-4, seems 
crucial for these effects. There are conflicting reports on Th1-type and Th2-type 
cytokines in human tuberculosis, and little is known about their role in tissue damage. 
In chapter 4, flowcytometric assessment of cytokine responses in TB-patients and 
healthy controls in Indonesia revealed a similar production of IFNγ. In contrast, IL-4 
production capacity of circulating T-lymphocytes from TB patients was markedly 
increased. Production of IL-4 was established in CD4+ T-cells, the primary cytokine-
producing cell in the Th1-Th2 concept, but also in CD8+ T-cells. Interestingly, the 
expression of IL-4 was especially elevated in patients with cavitary tuberculosis. 
Therefore, as was previously shown in animal studies, these results suggest a role 
for IL-4 in the development of host tissue damage in human TB. 
Tumor necrosis factor (TNF)-α is essential for defense against M. tuberculosis, 
but excessive production of TNFα or other proinflammatory cytokines may be 
responsible for deleterious effects in TB like fever, tissue necrosis and cachexia. 
Pentoxifylline and thalidomide, two drugs which inhibit TNFα production have shown 
some beneficial effects in mycobacterial infections in terms of decreased weight loss 
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and inflammation. Since these drugs have different mechanisms of action, combined 
therapy may lead to synergy, and thus may be advantageous in terms of toxicity and 
effectiveness. Conflicting reports have been published on the effects of these drugs 
on antiinflammatory cytokines. Chapter 5 investigates in-vitro modulation of pro- and 
anti-inflammatory cytokines by either drug alone or in combination. Pentoxifylline 
more strongly inhibited in-vitro production of TNFα, while thalidomide more strongly 
inhibited IL-1β production. Both agents diminished release of IFNγ. No significant 
modulation of antiinflammatory cytokines IL-10 and IL-1Ra was achieved. When 
used together, pentoxifylline and thalidomide had additive, but no synergistic effects 
on the inhibition of TNFα and IFNγ. In vivo studies are needed to assess the possible 
role of combined use of these drugs in TB.  
TB often leads to severe weight loss (wasting), probably through the production 
of inflammatory mediators. Wasting in turn, affects the inflammatory response, 
suppresses cellular immunity and aggravates disease outcome of TB. In these 
complex relations between TB, nutritional status and the host immune response, the 
adipocyte product leptin is a possible mediator. In chapter 6 it is shown that plasma 
leptin concentrations were significantly suppressed in TB patients, more than could 
be explained by loss of body fat. Unexpectedly, leptin was inversely associated with 
C-reactive protein and TNFα production. These results argue against a causal role 
for leptin in TB-associated wasting. Rather, loss of body fat leads to low leptin 
concentrations, and prolonged inflammation may further suppress leptin production. 
As leptin is important for cell-mediated immunity, it may be concluded that low 
plasma leptin production during TB may contribute to increased disease severity, 
especially in cachectic patients.  
 
 
The second half of this thesis consists of operational research and includes clinical 
and bacteriological studies. Under a microscope, Mycobacterium tuberculosis, which 
causes TB, cannot be distinguished from nontuberculous (atypical) mycobacteria, 
many of which are harmless. In clinical specimens, nontuberculous mycobacteria 
may represent true infection, colonization or contamination. In a Dutch TB clinic, 
diagnostic problems related to the presence of nontuberculous mycobacteria in some 
patients called for a retrospective analysis in this setting (chapter 7). It was shown 
that in this population, with a low HIV-prevalence, nontuberculous mycobacteria, 
although highly prevalent, poorly reflected true disease and often led to diagnostic 
and therapeutic errors. Although it is common knowledge that the presence of acid-
fast bacilli is not specific for TB, it may be concluded that a higher index of suspicion 
is needed to circumvent this diagnostic pitfall. Close collaboration of microbiologists 
and clinicians and implementation of rapid DNA-based techniques for detection and 
typing of mycobacteria may improve clinical management.  
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Chapters 8-11 describe studies which were performed in Indonesia. The first 
cytokine study in TB in Indonesia in 1998 raised many clinical and bacteriological 
questions. Six months afterwards, in an urban TB clinic in Jakarta, a prospective 
clinical and bacteriological characterization of a cohort of patients was started 
(chapter 8). Patients in this setting presented with longstanding and severe disease. 
HIV-infection was uncommon. Malnutrition was highly prevalent and strongly related 
to mortality. Irrespective of previous treatment, resistance to antibiotics was 
commonly found among patient isolates. Unexpectedly, liver damage was completely 
absent during treatment. These observations generated new questions prompting 
further patient studies in Indonesia. 
The yield of sputum microscopy in the Indonesian setting is addressed in 
chapter 9. In the first observational study in Jakarta, efforts had been made to 
increase the diagnostic rate. Introduction of larger sputum containers, and education 
of health personnel and patients resulted in more sputum samples of good quality. A 
sustainable two-fold rise of the smear-positive rate in this clinic was achieved. To 
further explore the role of education, a randomized study was conducted in another 
urban clinic. Compared with patients with suspected TB who underwent the routine 
procedure, those who received special instruction were smear-positive more often. 
Interestingly, education had a much larger effect in females. Simple and cheap 
interventions like these may help to increase the low case detection rate for TB in 
Indonesia. This may improve the outcome for the individual patient and may help to 
reduce transmission of TB.  
Worldwide, DNA fingerprinting has revealed an extensive heterogeneity of  
M. tuberculosis genotypes. However, a distinct and predominant genotype, termed 
‘Beijing’ has been found in recent years. Previous reports have shown that ‘Beijing’ 
strains are associated with (multi)-drug resistance. In chapter 10 it is shown that 
strains of the ‘Beijing’-genotype are also present in the Indonesian archipelago. 
‘Beijing’ strains examined showed a tendency towards higher drug resistance. Early 
in treatment, patients infected with ‘Beijing’ strains more often developed fever, 
unrelated to disease severity, toxicity or drug resistence. This suggests that specific 
pathogenic properties of ‘Beijing’ strains induce a different host response. Further 
study is needed to find out if this explains the high prevalence of this genotype.  
Chapter 11 deals with treatment of TB in Indonesia. Two-hour plasma 
concentrations of rifampicin, a key drug for treatment of TB, were measured in TB 
patients. The large majority of patients showed sub-therapeutic concentrations. No 
toxic concentrations were found and liver damage, a common finding during TB 
treatment, was completely absent. A large difference was found in rifampicin 
concentrations from patients treated with drugs from two different manufacturers. 
Because the rifampicin content of the drug preparations in use was within the normal 
range, it can be concluded that bioavailability of locally produced drugs is 
substandard. This is currently examined in pharmacokinetic studies in Indonesia.  
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The link between pathophysiological and operational research in TB is a central 
aspect of this thesis. Pathophysiological (e.g genetic or immunological) patient 
studies very much depend on the quality of the clinical and bacteriological 
infrastructure. Operational projects not only improve research quality, but also 
generate study questions. For example, a first study describing the clinical and 
bacteriological status of a patient cohort in Jakarta led to hypotheses about BCG-
vaccination, TB-associated wasting and lipid metabolism, and immunogenecits of 
different M. tuberculosis genotypes. Some of these hypotheses have now been 
tested.  
In Indonesia, as in any country endemic for TB, there is yet another reason to 
conduct operational (i.e. quality) projects. First, TB research in high-endemic settings 
should address questions, which are relevant to that particular setting. In Indonesia, 
bacteriological, clinical and logistical projects will undoubtedly have more impact on 
TB-control than immunology and genetics. In large parts of the world, the situation is 
similar to that in Indonesia: limited resources to manage a large number of patients 
and questions related to the TB-program or to clinical management rather than to the 
pathogenesis of TB.  
By themselves however, operational projects will not eradicate TB. Improved 
diagnosis and treatment will surely contribute to TB-control. But antibiotics are not 
the final answer, especially in light of growing drug resistance of M. tuberculosis 
isolates. A better understanding of the pathogenesis of TB is a first step towards the 
development of new strategies to fight TB. In recent years, basic science has 
produced exciting insights into TB, related to the mycobacterium as well as to the 
human host. However, many issues that troubled Robert Koch and other scientists a 
century ago, continue to trouble us today. Why are some individuals susceptible to 
TB, while others seem naturally protected ? What determines disease localization in 
TB ? What are the mechanisms behind latency and reactivation of TB ? What is the 
cause of TB-associated weight loss and tissue necrosis ? Renewed interest in TB 
provides the momentum, and modern technology the methods to tackle these issues. 
For TB as for any other health problem, the impact of scientific breakthroughs 
depends on the organization of the health system and quality of patient management. 
This reaffirms the need to combine a pathophysiological and operational approach.  
 
This thesis and that of Elvina Karyadi [6] present the first TB studies we 
performed in Indonesia. In the past few years, a strong multidisciplinary team has 
been established concentrating on four different lines of patient-oriented research: 
two dealing with pathophysiological issues, and two with quality of care. The topics 
are (1) immunogenetic determinants of host defense in TB, (2) nutrition and 
metabolism in TB, (3) TB-diagnostics and (4) treatment of TB. First, immunogenetic 
markers of susceptibility and manifestations of tuberculosis are currently investigated 
in a large case-control study in Indonesia. Second, the mechanisms of wasting and 
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TB-associated changes in lipid- and carbohydrate metabolism will be examined. This 
may contribute to the design of nutritional and other interventions, which may benefit 
TB-patients in this setting. Our third focus is diagnostics. We are currently 
implementing a quality-controlled and optimized method for conventional drug 
susceptibility testing in Jakarta and Bandung. In addition, the feasibility of rapid 
(DNA-based) methods, e.g. for diagnosis of extrapulmonary TB will be examined in 
this setting. Fourth, we continue to evaluate and improve the quality and outcome of 
antibiotic treatment. Many contribute to this work, in Indonesia and the Netherlands.  
We hope that the various projects will add to increased understanding of the 
pathogenesis of TB, and will help to reduce the burden of TB in Indonesia and 
elsewhere.  
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Nadat Robert Koch in 1882 had aangetoond dat Mycobacterium tuberculosis de 
verwekker was van tuberculose (TB), zou het nog meer dan 60 jaar duren tot er 
effectieve medicijnen tegen TB waren ontwikkeld. In 1948, in de eerste 
gecontroleerde klinische trial uit de medische geschiedenis, toonde streptomycine 
een uitgesproken effect bij de behandeling van TB. M. tuberculosis werd al snel 
resistent tegen monotherapie met streptomycine, maar combinatiebehandeling met 
PAS, INH en later rifampicine en pyrazinamide schiep de belofte voor eradicatie van 
TB. Nu, nog eens 60 jaar later, is TB nog altijd niet bedwongen. Wereldwijd lijden 
miljoenen, jong en oud, aan TB. Veel van hen komen te sterven of worden chronisch 
ziek. In grote delen van de wereld is TB dezelfde doodstijding als 100 jaar geleden. 
 
TB is een intrigerende ziekte. Hoe verklaart men de zo diverse presentatie en 
localisatie van de ziekte ? Wat is het mechanisme achter latente TB en reactivatie ? 
Wat is de pathofysiologie van weefselnecrose in TB ? Waaruit bestaat een 
beschermende immuun- of gastheerrespons tegen TB ? Vragen zoals deze zijn nog 
even relevant als een eeuw geleden. Vanuit een pathofysiologische invalshoek zou 
een beter begrip van de vatbaarheid voor, en beschermende afweer tegen TB 
kunnen bijdragen tot ontwikkeling van effectievere vaccins en nieuwe therapeutische 
strategieën.  
Tegenover de pathofysiologische staat een operationele benadering, welke zich 
richt op diagnostische en therapeutische problemen in de TB-zorg. Zo kan een late, 
incorrecte of gemiste diagnose leiden tot verergering van ziekte of onnodige 
verspreiding van TB. En zo voeden inadequate of incomplete behandeling het 
onstaan van antibioticaresistentie. Sommige van zulke operationele problemen zijn 
universeel, maar vaak zijn knelpunten specifiek voor een bepaald gebied of een 
bepaalde gezondheidsinstelling. Klinisch, bacteriologisch en ander (bijv. logistiek) 
gericht operationeel onderzoek  kan helpen zulke problemen het hoofd te bieden. Dit 
zou de zorg voor TB-patiënten ten goede komen en verspreiding van TB remmen. 
 
De eerste helft van dit proefschrift beschrijft pathofysiologisch onderzoek m.b.t. 
de gastheerrespons bij TB. Dit immunologisch onderzoek bij TB-patiënten riep 
klinische, bacteriologische en epidemiologische vragen op, welke leidden tot 
operationeel onderzoek. Het operationele onderzoek wordt beschreven in de tweede 
helft. Hieronder volgt een samenvatting van de inhoud van dit proefschrift. 
Van oudsher wordt verworven cellulaire (T-cel) immuniteit verantwoordelijk 
geacht voor bescherming tegen TB. Recent bestaat er meer aandacht voor onze 
aangeboren afweer tegen M. tuberculosis (MTB). Hoofdstuk 2 bevat een overzicht 
van zulke aangeboren afweermechanismen tegen TB. Onze aangeboren, natuurlijke, 
afweer tegen TB kan worden onderverdeeld in fagocytose, immuun herkenning, 
ontstekings-reacties, effector mechanismen en activering van de verworven cellulaire 
immuniteit. Op elk niveau kunnen interindividuele verschillen de variatie in 
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vatbaarheid en beloop van TB verklaren. Er zijn op DNA-niveau inmiddels een aantal 
subtiele afwijkingen (polymorfismen) gevonden welke zulke verschillen bij bepaalde 
patiënten kunnen verklaren. Het mag verwacht worden dat een groter begrip van de 
pathogenese uiteindelijk zal bijdragen tot ontwikkelen van adjuvante therapie, m.n. in 
multiresistente TB.  
Zowel de aangeboren als de verworven immuniteit worden gereguleerd door 
kleine boodschappereiwitten, zgn. cytokines. Cytokineproductie kan bij patiënten in 
vivo worden gemeten, in de bloedsomloop en op weefselniveau, en ex vivo door 
stimulatie van geisoleerde ontstekingscellen. Voor het meten van de ex-vivo 
cytokineproductie heeft de ‘volbloed-assay’ theoretische en praktische voordelen. In 
hoofdstuk 3 werden dosis-respons, kinetiek en variabiliteit van productie van vijf 
pro- en antiinflammatoire cytokines vergeleken in verdund en onverdund vol bloed. 
Stimulatie en incubatie van onverdund bloed in afgesloten heparinebuisjes heeft 
belangrijke voordelen in termen van eenvoud, risico op contaminatie en minimale in-
vitro manipulatie. Toevoeging van kweekmedium levert een meer gevoelige assay 
met gebruik van minimale hoeveelheden bloed. Stimulatie van volbloed met 
eiwitbestanddelen van de mycobacterie geeft in volbloed-assays een selectieve 
inductie van interferon (IFN)-γ bij individuen met een positieve Mantoux-reactie en 
kan daarom gebruikt worden voor diagnostische doeleinden en voor het meten van 
specifieke T-celresponsiviteit bij TB-patienten. De kenmerken van volbloedassays 
bepalen zowel de voor- als de nadelen voor cytokine onderzoek. De volbloed assay 
leent zich bij uitstek voor veldstudies en is als zodanig met succes toegepast [2-5], 
maar ook met optimale standaardisatie blijft volbloed een ‘black box’ met veel 
mogelijke ‘confounders’. 
In TB wordt cel-gemediëerde immuniteit verantwoordelijk geacht voor eradicatie 
van infectie, maar ook voor de voor TB zo karakteristieke weefselschade. In deze lijkt 
in diermodellen de balans tussen zogenaamde Th1-type cytokines, m.n. IFNγ, en 
Th2-type cytokines, m.n. interleukin (IL)-4, van groot belang voor de uitkomst van 
mycobacteriële infecties. Tegenstrijdige bevindingen zijn gerapporteerd t.a.v. Th1-
type en Th2-type cytokines bij patiënten met TB, en er is weinig bekend over hun rol 
bij weefselschade. In hoofdstuk 4 werd m.b.v. flowcytometrie de cel-specifieke 
cytokinerespons vergeleken van TB-patiënten en gezonde controles: productie van 
IFNγ was gelijk, maar de capaciteit tot productie van IL-4 bleek sterk verhoogd bij TB-
patiënten. Dit gold zowel voor CD4+ T-cellen, het primaire celtype van het Th1-Th2 
concept, als voor CD8+ T-cellen. Interessant genoeg was de expressie van IL-4 met 
name verhoogd in patiënten met cavitaire (holtevormende) TB. Deze bevinding 
suggereert dat IL-4, in analogie met diermodellen, een rol speelt bij het ontstaan van 
weefselschade bij TB.  
Tumor necrosis factor (TNF)-α is essentieel voor bescherming tegen TB, maar 
verhoogde productie van TNFα en andere proïnflammatoire cytokines lijkt 
verantwoordelijk voor schadelijke effecten in TB als koorts, weefselnecrose en 
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cachexie. Gebruik van pentoxifylline and thalidomide, twee medicamenten die de 
productie van TNFα remmen, hebben bij mycobacteriële infecties geleid tot afname 
van gewichtsverlies en ontsteking. Daar deze stoffen een verschillend 
aangrijpingspunt hebben, zou gecombineerde behandeling synergistisch kunnen 
werken, en zo meer effectief of minder toxisch kunnen zijn. Er bestaat in de literatuur 
geen eenduidigheid wat betreft het effect van pentoxifylline and thalidomide op 
antiinflammatoire cytokines. Hoofdstuk 5 beschrijft de in-vitro modulatie van pro-en 
antiinflammatoire cytokines van pentoxifylline and thalidomide apart en tezamen. 
TNFα werd krachtiger geremd door pentoxifylline, en IL-1β door thalidomide. Beide 
stoffen remden de in-vitro productie van IFNγ. Er werd geen significante modulatie 
gevonden van productie van antiinflammatoire cytokines IL-10 en IL-1Ra. Tezamen 
hadden pentoxifylline and thalidomide een additief maar geen synergistisch effect op 
remming van TNFα en IFNγ. In vivo studies zijn noodzakelijk om de eventele plaats 
van deze middelen nader te bepalen voor de behandeling van TB. 
Zoals boven opgemerkt gaat TB regelmatig gepaard met ernstig 
gewichtsverlies. Omgekeerd onderdrukt ondervoeding de menselijke afweer tegen 
TB en leidt zij tot een ongunstiger ziektebeloop. Leptine, een door vetcellen 
geproduceerd eiwit, is een mogelijke mediator in deze complexe interactie tussen 
TB, voedingsstatus en de gastheerrespons. In hoofdstuk 6 wordt beschreven hoe 
plasma leptine concentraties substantieel verlaagd bleken bij TB-patiënten in 
Indonesië, meer dan op grond van verlies van vetmassa kon worden verklaard. 
Onverwachts toonde leptine een omgekeerd verband met twee 
ontstekingsmediatoren: C-reactive protein en TNFα. Deze resultaten pleiten tegen 
een oorzakelijke rol voor leptine in TB-geassocieerd gewichtsverlies. Het lijkt 
waarschijnlijker dat verlies van vetmassa bij TB-patiënten leidt tot verlaagde leptine-
waarden, en dat ontsteking de leptineproductie verder onderdrukt. Leptine is 
belangrijk voor T-cel-immuniteit. Mogelijk dragen lage leptine-spiegels bij tot een 
slechte afloop van TB, vooral bij sterk vermagerde patiënten. 
 
De tweede helft van dit proefschrift beschrijft operationeel onderzoek en omvat 
klinische en bacteriologische studies. Onder de microscoop is Mycobacterium 
tuberculosis, de verwekker van TB, als zuur-vaste staaf niet te onderscheiden van 
nontuberculeuze (atypische) mycobacteriën, waarvan vele onschuldig zijn. In 
patiëntenmateriaal kunnen nontuberculeuze mycobacteriën wijzen op echte infectie, 
maar ook op kolonisatie of contaminatie. In een Nederlandse TB-kliniek hadden 
diagnostische problemen gerelateerd aan het voorkomen van nontuberculeuze 
mycobacteriën bij enkele patiënten geleid tot het doen van een retrospectief 
onderzoek (hoofdstuk 7). Het bleek dat nontuberculeuze mycobacteriën in de 
bewuste populatie weliswaar vaak werden aangetroffen, maar slechts zelden 
duidden op werkelijke infectie. E.e.a. had regelmatig geleid tot diagnostische en 
therapeutische fouten. Alhoewel het algemeen bekend is dat de aanwezigheid van 
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zuur-vaste staven in patiëntenmateriaal niet specifiek is voor TB, kan geconcludeerd 
worden dat een grotere alertheid gewenst is om deze diagnostische valkuil te 
ontwijken. Nauwe samenwerking tussen microbiologen en klinici en toepassing van 
betrouwbare moleculair-biologische methoden voor het opsporen en typeren van 
mycobacteriën zullen het klinische beleid doen verbeteren.  
Hoofdstukken 8-11 beschrijven onderzoek verricht in Indonesië. Het eerste 
onderzoek (over cytokines) in Indonesië in 1998, beschreven in hoofdstuk 4, riep 
veel vragen op over de diagnostiek en behandeling van TB aldaar. Zes maanden 
later ging in een kliniek in een arme wijk in centraal Jakarta een prospectief klinisch-
bacteriologisch, observationeel onderzoek van start (hoofdstuk 8). Patiënten in deze 
setting presenteren zich met langbestaande en ernstige longtuberculose. HIV-infectie 
was zeldzaam, maar ondervoeding was frequent aanwezig en sterk geassocieerd 
met sterfte. Onafhankelijk van eerdere behandeling bleek een belangrijk deel van de 
patiënten besmet met resistente TB-bacillen. Deze waarnemingen leidden tot nieuwe 
vragen en meer patiëntgebonden onderzoek in Indonesië. 
De opbrengst van sputum microscopie voor TB in de Indonesische setting werd 
geëvalueerd in hoofdstuk 9. Tijdens de eerste observationele studie in Jakarta was 
getracht de diagnostische opbrengst van sputumonderzoek te vergroten. Grotere 
sputumpotten en voorlichting voor medewerkers en patiënten in de kliniek leidden tot 
meer sputum monsters van goede kwaliteit. Een blijvende verdubbeling van ZN-
positiviteit werd bereikt. Om de rol van instructie verder te onderzoeken werd in een 
andere kliniek een gerandomiseerd onderzoek uitgevoerd. Vergeleken met patiënten 
verdacht voor TB die de routine procedure ondergingen, waren diegenen die extra 
voorlichting over belang van sputumonderzoek en techniek van ophoesten hadden 
gekregen, vaker positief. Opvallend genoeg was het effect veel groter bij vrouwelijke 
patiënten. Simpele en goedkope interventies zoals deze kunnen helpen de lage 
case-detection rate voor TB in Indonesië te verhogen. Dit komt de uitkomst voor de 
individuele patiënt ten goede en zal bijdragen om verspreiding van TB terug te 
dringen.  
Genotypering (‘DNA-fingerprinting’) van tuberculose-stammen laat werldwijd 
een enorme genetische diversiteit zien, maar recent is een predominant genotype 
gevonden, genaamd “Beijing”. Stammen van het Beijing-genotype bleken veelal 
geassocieerd met antibioticaresistentie. In hoofdstuk 10  wordt aangetoond dat 
stammen van het Beijing-genotype ook in Indonesië voorkomen, en inderdaad vaker 
drug-resistent zijn. Opvallend genoeg bleek dat patiënten geïnfecteerd met Beijing 
stammen tijdens behandeling veel vaker koorts ontwikkelden, onafhankelijk van ernst 
van ziekte, drug-resistentie of toxiciteit. Dit suggereert dat Beijing-stammen bepaalde 
eigenschappen hebben welke een andere gastheerrespons induceren. Inmiddels 
bestaat hiervoor ook bewijs in verschillende diermodellen.  
Hoofdstuk 11 behandelt een aspect van de behandeling van TB in Indonesië. 
Plasma-concentraties van rifampicine, één van de belangrijkste anti-TB middelen, 
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werden gemeten twee uur na inname van de dagelijkse medicatie. Ruim 70% van de 
TB-patiënten had sterk verlaagde rifampicine concentraties. Schadelijke rifampicine 
spiegels werden niet gevonden, net zo min als (asymptomatische) hepatotoxiciteit. Er 
was een twee-voudig verschil in rifampicineconcentratie tussen patiënten behandeld 
met antibiotica van twee verschillende lokale fabrikanten. Het rifampicinegehalte van 
verzamelde tabletten was normaal en derhalve lijkt de biobeschikbaarheid van lokaal 
geproduceerde medicatie onvoldoende. Op dit moment wordt de farmacokinetiek van 
antibiotica van vier fabrikanten vergeleken in gezonde Indonesische vrijwilligers.  
  
De link tussen pathofysiologisch en operationeel  onderzoek in TB vormt de 
rode draad van dit proefschrift. Pathofysiologisch (bijv. genetisch of immunologisch) 
onderzoek bij TB-patiënten valt en staat met de kwaliteit van de klinische en 
bacteriologische infrastructuur. Operationele projecten verbeteren zo de kwaliteit van 
onderzoeksgegevens, maar leveren ook nieuwe vragen voor pathofysiologisch 
onderzoek. Zo leidde de eerste beschrijving van de klinisch-bacteriologische status 
van een groep patiënten tot hypothesen over BCG-vaccinatie, gewichtsverlies en 
vetmetabolisme bij TB, en pathofysiologische eigenschappen van verschillende      
M. tuberculosis genotypen. Sommige van deze hypothesen zijn inmiddels getoetst in 
nieuwe projecten. 
In Indonesië, zoals in de elk land waar TB een groot probleem is, bestaat er nòg 
een reden om operationele (lees: kwaliteits-) projekten uit te voeren. In dergelijke 
landen hebben bacteriologische, klinische en logistieke projekten nameliijk zonder 
twijfel meer effect op TB-controle dan immunologie en genetica. In grote delen van 
de wereld is de situatie niet anders. Met beperkte middelen moet voor enorme 
aantallen TB-patiënten worden gezorgd. TB-onderzoek in die landen zou zich primair 
moeten bezig houden met (voor daar) relevante onderzoeksvragen betreffende 
organisatie en kwaliteit van zorg. 
Het is echter onwaarschijnlijk dat operationeel onderzoek alléén tot eradicatie 
van TB zal leiden. Verbetering van diagnose en behandeling zullen ongetwijfeld 
bijdragen aan bestrijding van TB. Maar antibiotica vormen niet het uiteindelijke 
antwoord, vooral in het licht van toenemende antibiotica-resistentie van TB-bacillen. 
Een beter begrip van de pathogenese van TB is een eerste stap op weg naar het 
ontwikkelen van nieuwe strategieën om TB te bestrijden. Recent basaal onderzoek 
heeft nieuwe inzichten verschaft, zowel met betrekking tot de tuberkelbacil als tot de 
TB-patiënt. Toch zijn veel vragen die Robert Koch en andere wetenschapers zichzelf 
een eeuw geleden stelden vandaag nog steeds niet goed opgelost. Waarom zijn 
sommige individuen vatbaar voor TB, terwijl anderen van nature beschermd lijken ? 
Wat bepaalt dat de plaats van de TB-infectie in het lichaam ? Wat is het mechanisme 
van latente infectie en reactivatie van TB ? Wat is de oorzaak van het gewichtsverlies 
en de necrose (weefselschade) bij TB ? Hernieuwde interesse in TB levert het 
momentum, en moderne technologie de methoden om deze problemen te 
doorgronden. Voor TB, zoals voor elk gezondheidsprobleem, hangt de impact van 
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wetenschappelijke doorbraken op de dagelijkse praktijk af van de organisatie van het 
gezondheidssyteem en de kwaliteit van patiëntenzorg. Dit onderstreept nogmaals het 
belang om pathopfysiologisch en operationeel onderzoek te blijven combineren.  
 
Dit proefschrift en dat van Elvina Karyadi [6] presenteren het begin van een 
onderzoekslijn op het gebied van TB in Indonesië. In de afgelopen jaren heeft zich 
inmiddels een sterk multidisciplinair team gevormd dat zich concentreert op vier 
verschillende lijnen van patiënt-gebonden onderzoek: twee over de pathofysiologie 
van TB, en twee over kwaliteit van zorg. De onderwerpen zijn: (1) immunogenetische 
determinanten van de afweer tegen TB, (2) voeding en metabolisme in TB, (3) 
bacteriologische diagnostiek van TB en (4) behandeling van TB. Allereerst worden 
markers van gevoeligheid voor infectie en presentatie van TB op dit moment 
onderzocht in een grote case-controle studie in Indonesië. Ten tweede worden de 
mechanismen van gewichtsverlies en veranderingen van koolhydraat en vet-
metabolisme bij TB onderzocht. Dit kan mogelijk bijdragen tot het ontwikkelen van 
voedingssupplementen of andere interventies welke de TB-patiënten in deze setting 
ten goede kunnen komen. Ons derde aandachtspunt is de diagnostiek. Op dit 
moment wordt een simpele doch uiterst preciese methode voor conventionele 
bepaling van antibioticaresistentie in Jakarta en Bandung geïmplementeerd. 
Daarnaast wordt de haalbaarheid en de waarde van snelle (moleculair-biologische) 
methoden nagegaan, o.a. voor het opsporen van TB buiten de longen. Ten vierde 
evalueren en verbeteren we continu de kwaliteit en uitkomst van antibiotische 
behandleling. Velen dragen bij aan dit werk, in Indonesië en in Nederland. Wij hopen 
dat de uiteenlopende projecten het begrip van de pathogenese van TB zullen 
vergroten, en zullen helpen om de omvang en de ernst van TB te verminderen in 
Indonesië en daarbuiten. 
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